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    Abstract 
 
 
 
Abstract 
Platelet-expressed C-type lectin-like receptor-2 (CLEC-2) and glycoprotein (GP)VI play 
important roles in inflammation, in particular inflammatory haemostasis in the skin. The 
CLEC-2-ligand, podoplanin, is upregulated in the inflamed and wounded skin, but the 
role of the CLEC-2-podoplanin interaction and the signalling downstream of podoplanin 
in the repair process is unclear. I have addressed these questions by investigating skin 
wound healing in wild-type (WT) mice, transgenic mice that lack platelet GPVI or CLEC-
2 or both receptors (double knockout; DKO), and podoplanin cytoplasmic tail-deficient 
(PdpnCyto) mice. Deletion of both CLEC-2 and GPVI impairs vascular integrity in the 
skin resulting in accelerated wound healing. The beneficial effect was due to increased 
plasma leakage in the tissue that promoted fibrin generation, enhanced re-epithelialisation 
and angiogenesis, and decreased immune cell infiltration. Accelerated wound healing also 
led to smaller scar formation. This healing phenotype is not due to developmental defects 
in DKO animals as similar results were obtained in podoplanin-blocking antibody-
injected GPVI-deficient mice. Wound healing is independent of the signalling 
downstream of podoplanin as PdpnCyto mice had similar healing kinetics compared to 
WT mice. PdpnCyto mice were however capable of upregulating podoplanin during 
wound healing, suggesting further application of this model in inflammatory settings. 
Alongside wound repair, the PdpnCyto mice were characterised. I have shown that the 
cytoplasmic tail is dispensable for the separation of blood and lymphatic vessels. In 
addition, I have used a metabolomics approach to reveal an increase in M1 pro-
inflammatory metabolites, i.e. glycolysis and inducible nitric oxide synthase (iNOS)-
mediated arginine pathway, in bone marrow-derived podoplanin-deficient macrophages, 
which possibly support the anti-inflammatory activity of podoplanin in macrophages.
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Chapter 1 Introduction 
1.1 An overview of platelet biogenesis  
Platelets are small anucleate cells derived from megakaryocytes in bone marrow and in 
the lung vasculature. Platelets primarily circulate in blood vessels and senescent platelets 
are removed from blood by phagocytes in the reticuloendothelial system, mainly in the 
spleen (Semple et al., 2011, Yeung et al., 2018, Lefrancais et al., 2017, Li et al., 2017). A 
circulating lifespan of individual platelet in human is 7-10 days, thereby, leading to daily 
production of approximately 100 billion platelets to maintain normal platelet counts (150-
400 x 109 cells per litre of blood). In mice, platelets live shorter (3-5 days) in blood 
circulation and the platelet counts (900-1,600 x 109 cells per litre of blood) are higher 
than in human (Semple et al., 2011). Platelets express numerous surface proteins, 
including receptors and adhesion molecules. In addition, platelets contain α-granules and 
dense granules (Figure 1.1), which collectively release over 300 molecules upon platelet 
stimulation, including secondary mediators of platelet activation, coagulation factors, 
growth factors, cytokines, and chemokines (Semple et al., 2011, Nurden, 2011, Yeung et 
al., 2018). 
1.2 Platelet function in haemostasis and thrombosis 
Platelets play a major physiological role in haemostasis, a process that stops bleeding 
(Lievens and von Hundelshausen, 2011, Yeung et al., 2018). Based on their size, platelets 
are marginated to the endothelial wall, which allows immediate detection and response to 
vascular damage (Xu et al., 2016). Initially after vessel injury, platelets tether at the vessel 
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wall via the binding of platelet-expressed GPIb-IX-V complex to immobilised von 
Willebrand factor (VWF) on exposed collagen (Jennings, 2009), leading to GPVI 
activation by collagen (Jennings, 2009). Thrombin generated through tissue factor-
mediated initiation of the extrinsic pathway of coagulation also activates its receptors on 
platelets (Monroe et al., 2002). These subsequently result in the activation of integrin 
αIIbβ3 (GPIIb/IIIa) and integrin α2β1 (GPIa/IIa) which bind to VWF/fibrinogen and 
collagen, respectively (Figure 1.1), leading to firm adhesion. Activated platelets also 
release secondary mediators, e.g. thromboxane A2 (TxA2), and adenosine diphosphate 
(ADP), which stimulate their G protein-coupled receptors to further amplify platelet 
activation. The activation of integrin αIIbβ3 on platelets enables binding of fibrinogen 
that bridges platelet-platelet interaction, resulting in platelet aggregation (Jennings, 2009, 
Gale, 2011, Montalescot, 2011). In addition to primary haemostasis, platelets promote the 
coagulation cascade. Upon activation, platelets expose phosphatidylserine, a negatively 
charged molecule, on their outer layer of plasma membrane, which recruits coagulation 
factors (Xase and prothrombinase complexes), contributing to the propagation of 
thrombin generation. Thrombin then converts fibrinogen into fibrin, forming an insoluble 
stable haemostatic plug at the site of injury (i.e. secondary haemostasis) (Gale, 2011, Xu 
et al., 2016). 
In contrast to normal haemostasis, excessive platelet activation/aggregation leads to a 
detrimental occlusion of blood vessels, which contributes to the pathogenesis of arterial 
thrombosis (Rivera et al., 2009, Yeung et al., 2018). Arterial thrombosis, including 
coronary artery disease, cerebrovascular artery disease, and peripheral arterial disease, 
occurs at sites of medium to high shear flow (500-1500 s-1) and is associated with the 
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Figure 1. 1. Simplified mechanism of platelet activation and aggregation. After initial 
adhesion to endothelium during vascular injury, platelets via GPVI and integrins (α2β1 
and αIIbβ3) mediate platelet activation and adhesion. Thrombin, generated by the 
extrinsic pathway of coagulation (tissue factor-dependent), also activates platelets. The 
activated platelets release secondary mediators, such as thromboxane A2 (TxA2), 
adenosine diphosphate (ADP), adenosine triphosphate (ATP), which subsequently 
amplify platelet activation. Integrin αIIbβ3 allows fibrinogen binding, resulting in 
platelet-platelet interaction and the formation of stable platelet aggregates. Thick arrow = 
potent effect. PAR = protease-activated (thrombin) receptor, P2X = purinergic 2X (ATP) 
receptor, P2Y = purinergic 2Y (ADP) receptor, TP = TxA2 receptor. Adapted from 
(Wallentin, 2009, Xu et al., 2016). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
α2β1 
P2Y1 
P2Y12 
TPβ 
TPα 
ADP 
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formation of platelet-rich thrombi (also called a white clot) (Ouriel, 2001, Xu et al., 2016, 
Yeung et al., 2018). The rupture of atherosclerotic plaque is the most common cause of 
acute arterial thrombosis, such as acute coronary syndrome and ischaemic stroke. In 
atherosclerosis, activated platelets not only support clot formation but also recruit 
neutrophils and monocytes to the site of vascular damage, which also promote the growth 
of thrombi. Accordingly, anti-platelet drugs, such as aspirin and P2Y12 receptor 
antagonists, are recommended for prophylactic prevention and treatment of acute arterial 
thrombotic events (Xu et al., 2016, Yeung et al., 2018).  
Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary 
embolism, arises under low shear flow (10 - 500 s-1) and represent as fibrin-rich thrombi 
(also called red clots), indicating an over-activation of blood coagulation. Therefore, 
anticoagulants, such as unfractionated and low-molecular-weight heparins, are mainly 
used for prophylaxis of occurrence, the treatment of acute episodes, and the prevention 
of recurrence in VTE (Yeung et al., 2018, Xu et al., 2016, Mackman, 2012). However, 
emerging evidence has demonstrated a crucial contribution of platelets in the 
pathogenesis of VTE. For example, a reduction in blood flow can cause hypoxia, which 
activates endothelial cells leading to exposure of P-selectin and VWF (Brill et al., 2011). 
Platelets adhere to the activated endothelium via GPIbα-VWF. In addition, platelets 
recruit leucocytes, which express tissue factor on activation, triggering the extrinsic 
pathway of coagulation cascade (Mackman, 2012, Xu et al., 2016). As mentioned, 
phosphatidylserine exposure on the surface of activated platelets also promotes 
coagulation (Xu et al., 2016). Polyphosphate released from activated platelets stimulates 
factor XII activation to XIIa which regulates an intrinsic pathway of blood coagulation, 
although the significance of this is unknown (Mackman, 2012). In mice, genetic ablation 
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of P2Y1 (Bird et al., 2012) or CLEC-2 on platelets (Payne et al., 2017) has been shown 
to decrease the occurrence of VTE. In addition, anti-platelet drugs, such as aspirin and 
clopidogrel reduce VTE in rats, rabbits, and dogs (Yeung et al., 2018). Clinical studies 
also support a role for platelets in VTE by demonstrating that aspirin lowers the rate of 
VTE recurrence in patients who are currently using anticoagulants (Yeung et al., 2018, 
Xu et al., 2016).  
1.3 The role of platelets in maintaining vascular integrity  
Vascular endothelium controls the homeostatic function of blood vessels, including the 
prevention of leakage and the regulation of blood flow, which is termed “vascular 
integrity” (Nachman and Rafii, 2008, Ho-Tin-Noe et al., 2018). Breakage of endothelial 
barrier leads to a loss of vascular integrity. Unlike classical haemostasis, platelets have 
been reported to support vascular integrity by stabilising the intercellular junctions of 
endothelial cells. Sphingosine-1-phosphate (S1P), angiopoietin-1, platelet-activating 
factor, vascular endothelial growth factor (VEGF)-A, brain-derived neurotrophic factor, 
and epidermal growth factor are examples of barrier-strengthening mediators secreted by 
platelets, contributing to this process (Nachman and Rafii, 2008, Rodrigues and Granger, 
2015).  
Petechiae, pinpoint red spots in skin due to the extravasation of red blood cells (Rbcs), in 
patients with thrombocytopenia is one of clinical examples pointing to the 
vasculoprotective role of platelets during steady-state condition (Nachman and Rafii, 
2008). Moreover, sunburn (Carbo et al., 2009) and ultraviolet B (UVB) irradiation 
(Hillgruber et al., 2015) trigger petechiae in patients with thrombocytopenia whereas anti-
inflammatory agents (e.g. glucocorticoids) prevent this reaction (Kitchens and 
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Pendergast, 1986), demonstrating that inflammation increases the risk of vascular leakage 
in the presence of low platelet counts (Ho-Tin-Noe et al., 2018).  
Several experimental models also demonstrate intra-tissue haemorrhage during 
inflammation, especially in the skin and the lungs of platelet-depleted animals (Table 1.1) 
(Ho-Tin-Noe et al., 2018, Gros et al., 2015, Boulaftali et al., 2018, Rayes et al., 2018). 
Microscopic observation during inflammation reveals that at the site of increased vascular 
permeability, mainly post-capillary venules, platelets adhere to the vessel wall and 
prevent inflammatory bleeding by sealing small holes between endothelial junctions 
following leucocyte extravasation in a G protein-coupled receptor-independent 
mechanism (Ho-Tin-Noe et al., 2018, Gros et al., 2015). At least, four characteristic 
features for the contribution of platelets in safeguarding vascular integrity during 
inflammation have been described. Firstly, intra-tissue bleeding occurs only when the 
circulating platelets are substantially low (< 2-15 % of normal platelet counts in mice), 
suggesting that small numbers of platelets are required to prevent inflammatory bleeding. 
Secondly, single platelets (rather than aggregates) appear to seal an open gap at 
endothelial junctions in inflamed vasculature. Thirdly, this process may not need full 
activation of platelets as electron microscopy has shown residual granules in adhered 
cells. Fourthly, platelets protect vascular integrity during inflammation in an organ- 
and/or stimulus-dependent manner since there is no abnormal bleeding in 
thrombocytopenic mice with rheumatoid arthritis, peritonitis, and endotoxaemia (Ho-Tin-
Noe et al., 2018). 
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Table 1. 1. Evidence of intra-tissue bleeding due to the impairment of vascular 
integrity during inflammation in thrombocytopenic mice 
Skin:  
 
reverse passive Arthus reaction (rpA; also called immune complex-induced 
dermatitis), irritant contact dermatitis, UVB-induced dermatitis 
Lung: LPS-induced lung inflammation, Klebsiella-induced pneumonia 
Kidney: immune complex-induced glomerulonephritis 
Brain: cerebral ischemia reperfusion injury, lymphocytic choriomeningitis viral 
infection 
Cancer: breast tumour (4T1), melanoma (B16F10), Lewis lung carcinoma (LLC) 
Other: ovalbumin and complete Freund’s adjuvant-induced immunisation 
Adapted from (Ho-Tin-Noe et al., 2018, Gros et al., 2015, Rayes et al., 2018, Boulaftali 
et al., 2013). 
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1.4 The role of platelets in other pathways 
1.4.1 Platelets as immune cells 
Platelets are now considered as immune cells, regulating both innate and adaptive 
responses. Platelets express toll-like receptors (TLRs) that recognise invading 
microorganisms. In the acute phase response, lipopolysaccharide (LPS) on the outer 
membrane of gram-negative bacteria has been reported to activate platelets via TLR4, 
which induces secretion of antimicrobial peptides and promotes platelet-neutrophil 
interaction, subsequently stimulating the release of neutrophil extracellular traps (NETs) 
for bacterial killing (Clark et al., 2007), although this has not been seen by other groups 
including the Watson laboratory (personal communication). This LPS-TLR4 interaction 
also contributes to sepsis-associated thrombocytopenia caused by platelet consumption 
(microthrombi) within end organs, such as in the lung (Xu et al., 2016, Morrell et al., 
2014, Thomas and Storey, 2015). Moreover, platelets demonstrate host defense against 
parasitic infection by binding to Plasmodium spp.-infected Rbcs and releasing platelet 
factor 4 (PF4) to kill this parasite (Kho et al., 2018, Xu et al., 2016). In contrast, platelets 
directly interact dengue (Simon et al., 2015) and human immunodeficiency virus (HIV)-
1 (Chaipan et al., 2006), which support dengue infection and HIV-1 transmission, 
respectively.  
Activated platelets expose P-selectin on their cell surface, which binds P-selectin 
glycoprotein ligand 1 on leucocytes (Rinder et al., 1991). In addition, platelet GPIbα 
directly interacts with integrin αMβ2 (or macrophage-1 antigen; Mac-1) on leucocytes 
and indirectly through binding to fibrinogen (Wang et al., 2017). These interactions 
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facilitate leucocyte trafficking to the site of inflammation (Xu et al., 2016, Morrell et al., 
2014, Thomas and Storey, 2015). 
The interplay between platelets and the adaptive response has also been described. 
Platelets bind circulating lymphocytes to facilitate lymphocyte entry into lymph nodes in 
a P-selectin-dependent fashion (Diacovo et al., 1996). In addition, platelet-derived PF4 
inhibits Th17 cell differentiation, reducing the inflammatory reaction (Shi et al., 2014, 
Guo et al., 2015). Moreover, a cluster of differentiation (CD) 40 ligand (CD40L) on 
platelets promote inflammatory responses of B- and T-lymphocytes. For example, 
CD40L mediates switching of immunoglobulin (Ig) production by B-cells (i.e. the 
increase in IgG relative to IgM). In addition, it enhances interferon (IFN)-γ secretion by 
T-cells (Elzey et al., 2003). 
1.4.2 Platelets in lymphangiogenesis and angiogenesis 
During embryonic development, platelets play a key role in prevention of mixing of blood 
and lymphatic vasculatures. The interaction of platelets with podoplanin, an endogenous 
CLEC-2 ligand, on lymphatic endothelial cells (LECs), has been shown to regulate this 
process (Xu et al., 2016, Schacht et al., 2003, Bertozzi et al., 2010, Finney et al., 2012).  
Platelets also secrete growth factors to facilitate angiogenesis (i.e. the formation of new 
blood vessels from the existing ones), which is important for embryonic development, 
tissue repair, and tumour growth. Platelet-derived growth factor (PDGF), VEGF, insulin-
like growth factor, and angiopoietin-1 are examples of pro-angiogenic factors released by 
activated platelets. In addition to these proteins, platelet-derived cytokines and 
chemokines promote the recruitment of leucocytes, fibroblasts, and endothelial cells 
during wound healing (Xu et al., 2016, Yang et al., 2011). 
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1.4.3 Platelets in cancer metastasis 
Several lines of evidence suggest the role of platelets in tumour metastasis, a process of 
tumour cell migration from primary site to the distant tissues (Xu et al., 2016). For 
example, tumour spreading is limited in thrombocytopenia whereas it is reversed by 
transfusion of platelet-rich plasma (Gasic et al., 1968). Platelet-derived P-selectin and 
GPIIb/IIIa mediate aggregate formation between platelets and tumour cells within blood 
circulation. In addition, podoplanin on tumour cells has been shown to activate platelet 
CLEC-2 in the bloodstream (Leblanc and Peyruchaud, 2016, Lowe et al., 2012, Shirai et 
al., 2017). Intravascular platelet-tumour aggregate promotes survival of cancer cells by 
protecting against shear rate-induced damage and natural killer (NK) cell-mediated 
cytolysis. In addition, this aggregate activates endothelium to express adhesion molecules 
for cancer cell arrest at the vessel wall, facilitating extravasation of cancer cells to the 
target tissues (Xu et al., 2016, Leblanc and Peyruchaud, 2016). 
1.5 Platelet (hemi)immunoreceptor tyrosine-based activation 
motif (ITAM) receptors 
ITAMs are defined by the presence of two YxxL sequences separated by six to twelve 
amino acids, whereas the hemi-ITAM bears a single YxxL (Watson et al., 2010). In 
human platelets, three (hemi)ITAM-associated platelet activation receptors have been 
described, including FcγRIIA, GPVI, and CLEC-2 (Watson et al., 2010, Stegner et al., 
2014). FcγRIIA is a receptor for the fragment constant (Fc) portion of IgG, which 
contributes to immune complexes-mediated thrombosis and thrombocytopenia, such as 
in heparin-induced thrombocytopenia in human (Kelton et al., 2013, Gitz et al., 2014, 
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Qiao et al., 2015). However, this receptor is not expressed on mouse platelets or indeed 
in the rodent genome (McKenzie et al., 1999). 
1.5.1 Structure and function of GPVI  
GPVI belongs to the Ig superfamily of receptors, and is only expressed on surface of 
megakaryocyte/platelet lineage (Dutting et al., 2012, Stegner et al., 2014). GPVI receptor 
density is approximately 5,586 ± 1155 copy numbers per mouse platelet (unpublished 
data from Watson laboratory) whereas the range of 3,730 ± 453 copy numbers is observed 
per human platelet (Best et al., 2003). On resting platelets, GPVI is present in both 
monomeric (Dutting et al., 2012) and dimeric forms (Jung et al., 2009). Monomeric GPVI 
is unable to bind collagen whereas dimerisation of GPVI has high affinity to this ligand 
(Dutting et al., 2012). To mediate its function, GPVI forms a complex structure with a 
homodimer of γ-chain of Fc receptor (FcRγ-chain) (Figure 1.2). The intracellular 
structure of GPVI itself consists of proline-rich region, which constitutively binds Src 
family kinases (SFKs), including Fyn and Lyn (Dutting et al., 2012, Watson et al., 2010) 
whereas the ITAM domain is located in cytoplasmic region of FcRγ-chain. Upon collagen 
ligation, GPVI dimer triggers tyrosine phosphorylation of ITAMs on FcRγ-chain by the 
SFK, which in turn recruits and activates spleen tyrosine kinase (Syk). This results in 
subsequent activation of downstream signalling molecules, adaptor proteins (e.g. SLP-
76), and effector molecules, including phospholipase C (PLC)-γ2 that mediates platelet 
activation (Stegner et al., 2014, Dutting et al., 2012, Watson et al., 2010).  
In addition to collagen, endogenous ligands of GPVI include fibrin (Alshehri et al., 2015), 
fibrinogen (Induruwa et al., 2018, Mangin et al., 2018), fibronectin (Bultmann et al., 
2010), and laminin (Inoue et al., 2006). Convulxin, a snake venom toxin, can also activate 
Chapter 1: Introduction 
12 
 
platelets via GPVI binding (Jandrot-Perrus et al., 1997). Furthermore, it has recently been 
demonstrated in vitro that GPVI dimers can form clusters (multimers) following platelet 
adhesion to collagen fibres or related substrates, which may potentiate platelet activation 
(Poulter et al., 2017).  
The upregulation of surface GPVI has been reported in patients with acute coronary 
syndrome (Bigalke et al., 2010a, Bigalke et al., 2010c) and stroke (Bigalke et al., 2010b), 
which is associated with poor prognosis. On the other hand, the ectodomain of GPVI is  
rapidly cleaved from activated platelets by A disintegrin and metalloproteinases (ADAM) 
family sheddases, i.e. ADAM-10 and ADAM-17 (Dutting et al., 2012). Although the 
physiological function of GPVI shedding is unclear, a soluble form of GPVI is increased 
in the circulation of patients with thrombotic and thrombo-inflammatory diseases, 
including acute ischaemic stroke (Al-Tamimi et al., 2011), thrombotic microangiopathy 
(Yamashita et al., 2014), rheumatoid arthritis (Stack et al., 2017), gout (Conway et al., 
2017), cirrhosis (Egan et al., 2017), and sepsis (Montague et al., 2018). Therefore, soluble 
GPVI is a marker of platelet activation in various pathological settings.  
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Figure 1. 2. Structure and signalling of platelet GPVI and CLEC-2. The binding of 
collagen to GPVI dimer allows tyrosine phosphorylation of ITAMs on FcRγ-chain by Src 
family kinases (SFKs), which subsequently recruit spleen tyrosine kinase (Syk). The 
phosphorylated Syk further stimulates downstream molecules, including adaptor protein 
SLP-76 and phospholipase C (PLC)-γ2, resulting in platelet activation. Upon podoplanin 
interaction, CLEC-2 dimer recruits Syk to the hemi-ITAMs, which leads to Syk-mediated 
autophosphorylation and the phosphorylation of hemi-ITAMs. SFKs mediate activation 
of Syk. The downstream events of CLEC-2-mediated platelet activation are similar to that 
of GPVI. Podoplanin signals through ezrin (E)/radixin (R)/moesin (M) phosphorylation, 
which modulates actin cytoskeleton and cell migration. “Y” represents the tyrosine 
residue in YxxL sequence on (hemi)ITAMs. “P” denotes phosphorylated state of proteins. 
LAT = membrane adaptor protein called “linker for activated T-cells”. Adapted from 
(Watson et al., 2010, Dutting et al., 2012, Astarita et al., 2012). 
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1.5.2 Structure and function of platelet CLEC-2  
CLEC-2 is a type II transmembrane protein, which is abundantly expressed on 
megakaryocytes and platelets (Watson et al., 2010, Suzuki-Inoue et al., 2011). Murine 
platelets contain approximately 41,652 ± 7,760 copy numbers of CLEC-2 (Zeiler et al., 
2014) whereas 2,016 ± 239 copy numbers are present per human platelet (Gitz et al., 
2014). A low level of CLEC-2 is also detected on Kupffer cells and sinusoidal 
endothelium within the liver (Chaipan et al., 2006, Tang et al., 2010). In mice, CLEC-2 
has been reported on circulating B-lymphocytes and CD11bhiGr-1hi leucocytes (i.e. 
granulocytes, monocytes, and NK cells), although the presence on lymphocytes is in the 
form of microvesicles which are presumed to be platelet in origin (Lowe et al., 2015b). 
Reports of expression of CLEC-2 on neutrophils are due to off-target binding of the 
monoclonal antibody (mAb 17D9) (Kerrigan et al., 2009). CLEC-2 is also present on 
dendritic cells (DCs), especially within lymph node, and it is upregulated during LPS 
stimulation (Lowe et al., 2015b). DC-expressed CLEC-2 facilitates draining of DCs into 
lymph nodes (Acton et al., 2014), promotes DC motility within lymph nodes where it can 
present antigen to T-cells (Acton et al., 2014, Fletcher et al., 2015), and mediates lymph 
node expansion, which supports leucocyte migration and proliferation during immune 
responses (Acton et al., 2014, Astarita et al., 2015). 
Unlike GPVI/FcRγ-chain complex, the cytoplasmic region of CLEC-2 has a hemi-ITAM, 
which does not directly bind to SFKs (Figure 1.2). CLEC-2 is constitutively expressed as 
homodimer. Following ligand engagement, Syk is recruited to the hemi-ITAMs of CLEC-
2. Subsequently, SFKs activate Syk, which mediate phosphorylation of hemi-ITAMs.  
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Activated phosphorylated Syk triggers the similar downstream molecules to that of GPVI 
to mediate platelet activation (Watson et al., 2010, Suzuki-Inoue et al., 2011) 
Currently, the only known endogenous CLEC-2 ligand is podoplanin (also known as 
aggrus, gp36, gp38, T1α, D2-40, OST-8, PA2.26, RANDAM-2, and transmembrane 
glycoprotein E11), which is expressed on LECs and a wide variety of cells outside of 
blood vessels, including type I lung epithelial cells and the choroid plexus (Table 1.2). 
The extracellular part of podoplanin is extensively O-glycosylated, and has platelet 
aggregation-stimulating domains (PLAGs), which interact with CLEC-2 (Pan and Xia, 
2015, Astarita et al., 2012, Krishnan et al., 2018). Podoplanin has a short cytoplasmic tail 
that binds ezrin/radixin/moesin (ERM) family proteins (Figure 1.2). The cellular function 
of podoplanin remains inconclusive. However, the increase in podoplanin expression, 
including in cancer cells, has been demonstrated in vitro to enhance ERM 
phosphorylation and RhoA activation, which allows binding of other intracellular 
proteins, including actin, contributing to cell migration and function (Martin-Villar et al., 
2006, Suchanski et al., 2017, Takemoto et al., 2017, Krishnan et al., 2018). In contrast, 
lymph node-derived fibroblastic reticular cells (FRCs) deficient in cytoplasmic tail of 
podoplanin show a defect in cell elongation despite an intact ERM phosphorylation  
(Astarita et al., 2015), suggesting ERM-independent regulatory downstream of 
podoplanin cytoplasmic tail in FRC elongation. 
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Table 1. 2. Distribution of podoplanin expression in various organs 
Kidney:  podocytes, parietal epithelial cells of Bowman’s capsule 
Lung: type I alveolar epithelial cells, pleura 
Liver: bile ducts, peritoneum 
Skin, oesophagus, cervix: basal keratinocytes 
Salivary gland: myoepithelial cells 
Intestine: peritoneum 
Lymphoid organs: fibroblastic reticular cells, follicular dendritic cells 
Central nervous system: choroid plexus, ependyma, meninges, neuro-epithelium 
Bone: osteocytes, periosteum 
Bone marrow: fibroblastic reticular-like cells 
Heart: epicardium, pericardium 
Breast: myoepithelial cells 
Ovary: follicular granulosa cells, germinal epithelium 
Prostate: myofibroblast 
Testis: fibromyocytes 
Data was combined from human and murine tissues. Adapted from (Astarita et al., 2012, 
Hou et al., 2010, Hur et al., 2014, Kerrigan et al., 2012, Lowe et al., 2015a, Mahtab et al., 
2008, Schacht et al., 2005, Tamura et al., 2016). 
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Podoplanin is also upregulated during inflammation, such as on macrophages following 
LPS stimulation (Kerrigan et al., 2012). Furthermore, skin keratinocytes show elevated 
levels of podoplanin in response to transforming growth factor (TGF)-β, interleukin (IL)-
6, IL-22, and IFN-γ (Honma et al., 2012). In a similar fashion, synoviocytes express high 
levels of podoplanin after treating with IL-1β, tumour necrosis factor (TNF)-α, and TGF-
β1 (Ekwall et al., 2011). Therefore, podoplanin is a marker of inflammation and tumour 
growth (Krishnan et al., 2018), although its function requires further investigation. 
Exogenous ligands of CLEC-2 have also been introduced, including a snake venom toxin 
called ‘rhodocytin’ and brown seaweed-derived sulphated polysaccharide called 
‘fucoidan’, both of which mediate platelet aggregation (Astarita et al., 2012, Pan and Xia, 
2015). Historically, the discovery of CLEC-2 on platelets is based on studies identifying 
the receptor for rhodocytin-induced platelet aggregation (Suzuki-Inoue et al., 2011, 
Watson et al., 2010, Suzuki-Inoue et al., 2006). Moreover, HIV-1 is able to bind CLEC-
2, despite platelet activation being unlikely to be involved in CLEC-2-mediated HIV-1 
transmission (Chaipan et al., 2006).  
1.6 Physiological functions of platelet ITAM receptors  
Although GPVI mediates stable platelet adhesion and platelet activation, mice deficient 
in GPVI show no haemostatic defect (Bender et al., 2013). In human, the prevalence of 
GPVI defects are very rare and it is unclear to what extent loss of GPVI gives rise to 
bleeding as most cases are caused by autoimmune thrombocytopenia (Arthur et al., 2007). 
Several unrelated patients homozygous for a truncation mutant prior to the membrane 
domain in GPVI have been described in Chile and have a mild bleeding diathesis (Matus 
et al., 2013). Similar to that of GPVI, CLEC-2 deficient animals exhibit normal 
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haemostasis (Bender et al., 2013). However, combined deficiency of GPVI and CLEC-2 
leads to prolonged bleeding time in mice although this is also associated with a reduction 
in platelet counts (Bender et al., 2013). Based on the observation in genetic ablation 
studies, GPVI-null mice demonstrate normal viability, fertility, and baseline 
haematological parameters (Kato et al., 2003), suggesting that GPVI deficiency may not 
affect developmental and physiological processes. However, it has recently been revealed 
that GPVI on megakaryocytes controls proplatelet formation in bone marrow (Semeniak 
et al., 2016) making it difficult to reconcile these observations. In addition, GPVI has 
been reported to contribute to postnatal closure of ductus arteriosus (Echtler et al., 2010). 
1.6.1 CLEC-2-podoplanin in the separation of blood and lymphatic vasculatures 
During embryonic day (E) 8.5-9.5 in mice, a subset of venous endothelial cells in cardinal 
veins are committed to change their fate by expressing prospero-related homeobox 
domain 1 (Prox-1) transcription factor and lymphatic vascular endothelial hyaluronan 
receptor-1 (LYVE-1), the markers of lymphatic endothelial cells (LECs) (Bautch and 
Caron, 2015). These lymphatic endothelial precursors migrate away from the vein and 
coalesce into primary lymph sac, the earliest form of lymphatic vessel, at E11.5-13.5 
(Bautch and Caron, 2015, Pan and Xia, 2015). Podoplanin is expressed on LECs at E11.5-
12.5 (Schacht et al., 2003). Platelets via CLEC-2 have been shown to interact with 
podoplanin-positive LECs and play a role in the separation of lymphatic and venous 
vasculatures during E11.5-14.5 (Bautch and Caron, 2015, Pan and Xia, 2015, Bertozzi et 
al., 2010). Mice deficient in podoplanin (Schacht et al., 2003, Bertozzi et al., 2010, Uhrin 
et al., 2010) or platelet CLEC-2 (Finney et al., 2012, Bertozzi et al., 2010) or downstream 
molecules following CLEC-2 activation, including Syk (Finney et al., 2012, Abtahian et 
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al., 2003) and adaptor protein SLP-76 (Abtahian et al., 2003, Bertozzi et al., 2010), exhibit 
blood-lymphatic mixing (also called blood-filled lymphatics) and commonly die in utero.  
Although it remains inconclusive, at least five mechanisms of how CLEC-2-podoplanin 
mediates blood-lymphatic separation have been described:  
1. Initially, it is demonstrated that CLEC-2-podoplanin interaction results in 
accumulation of platelet plug, which terminates blood and lymphatic connections 
(Bertozzi et al., 2010). However, mice deficient in GPIIb/IIIa have no evidence of 
blood-filled lymphatics (Hodivala-Dilke et al., 1999, Hess et al., 2014). In 
addition, blocking GPIIb/IIIa on platelets has no impact on proliferation, 
migration and tube formation of LECs in vitro (Osada et al., 2012), arguing against 
the role of platelet aggregation.  
2. Moreover, the supernatant of activated platelets inhibits this blood-lymph 
connection (Osada et al., 2012), suggesting a GPIIb/IIIa-independent mechanism 
participating in platelet activation for the separation of blood and lymphatic 
vessels that involves platelet granule secretion.  
3. Third, it has been proposed that binding of platelet CLEC-2 to podoplanin leads 
to clustering of both molecules. This stable interaction between platelets and LECs 
activates signalling downstream of podoplanin to inhibit LEC migration during 
contact with blood endothelium (Pollitt et al., 2014). However, transgenic mice 
lacking the cytoplasmic tail of podoplanin show no blood-filled lymphatics 
(Astarita et al., 2015).  
4. Furthermore, once the mature lymphatic capillary has been generated (in late-
gestation), platelets mediate thrombus formation at the bicuspid valve 
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(podoplanin-positive) in lymphovenous junction, where lymph is drained from 
thoracic duct (a main lymphatic vessel) to the vein, to prevent a reflux of blood 
into lymphatic vessel. CLEC-2 deficient embryos (E17.5) and adult mice, which 
lack platelet-containing thrombi at lymphovenous valve, display filling of Rbcs in 
thoracic duct and subsequent lymphatic network (Hess et al., 2014).  
5. More recently, this blood-filled lymphatic phenotype has been linked to the 
impairment of vascular integrity during development. At E14, the murine 
mesenteric vein is temporarily leaky, defined by the presence of gaps between 
adjacent endothelial cells, associated with extravasation of Rbcs, which interact 
with LECs. Platelets are observed at the intercellular gaps of venous endothelium. 
Perivascular podoplanin is also detected on mural cells, including the fibroblasts, 
at E14, suggesting the role of CLEC-2-podoplanin interaction for the maintenance 
of mesenteric venous integrity during embryogenesis. The intercellular gaps 
disappear at E15 when the lymphatic vessel is formed. During this stage, Rbcs are 
transiently presence in developing lymphatic vessels whereas platelets are only 
observed in blood vasculature. At E16, Rbcs are no longer detected in lymphatic 
vessel, indicating the beginning of lymphatic drainage (Zhang et al., 2018). In 
CLEC-2 knockout embryos, there is extravascular localisation of both platelets 
and Rbcs, which interact with LECs at E14. A more pronounced blood-filled 
lymphatic vessel is observed at E15 of CLEC-2 deficient embryos. At E16, Rbcs 
remained in the lymphatic vasculature, suggesting a lack of lymph flow in CLEC-
2 knockout embryos (Zhang et al., 2018). 
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1.6.2 Regulation of high endothelial venule (HEV) integrity by CLEC-2 and 
podoplanin 
In the perivascular zone of lymph nodes (Figure 1.3 A), it has been shown that circulating 
lymphocytes generally enter into lymph nodes through HEV, a specialised blood vessel, 
for immune surveillance and this process is substantially increased during immune 
responses. Following leucocyte transmigration, platelet CLEC-2 binds podoplanin on 
fibroblastic reticular cells (FRCs) surrounding HEV, resulting in the secretion of platelet-
derived S1P. Subsequently, S1P promotes the expression of vascular endothelial (VE)-
cadherin to seal HEV cell-cell junctions, maintaining HEV barrier function (integrity) 
(Herzog et al., 2013). The spontaneous leakage of Rbcs into the extravascular space is 
observed in lymph nodes of FRC-specific podoplanin-knockout, platelet CLEC-2 
deficient, and S1P-deficient mice, which is increased upon immunisation (Herzog et al., 
2013). Moreover, histological analysis in mice bearing podoplanin-negative FRCs or 
CLEC-2-deficient platelets show Rbcs within lymphatic vessels (Herzog et al., 2013), 
suggesting that the impairment of HEV integrity may also contribute to blood-filled 
lymphatic phenotype in the absence of CLEC-2-podoplanin interaction (Zhang et al., 
2018). 
1.6.3 CLEC-2 and podoplanin regulate development and integrity of cerebral 
blood vessels 
It has been reported that CLEC-2 deficient and neuroepithelium-specific podoplanin-
knockout embryos exhibit cerebral haemorrhage, in association with a tortuous and 
discontinuous vascular structure, in the developing brain between E10.5 and E11.5. The 
evidence of bleeding is more apparent, especially in the ventricle, at E12.5. In addition, 
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histological examination reveals a decrease numbers of mural cells, including pericytes, 
around the developing vessel in these embryos, suggesting the defects in vascular 
development. Cerebral haemorrhage is also present at E12.5 of embryos deficient in 
integrin αIIb or platelet α- and dense-granules but not in platelet-specific S1P-knockout 
littermates. Collectively, it is proposed that the early-developed blood vessel is leaky, 
which allows transient extravasation of Rbcs and platelets into the perivascular area. The 
interaction of platelet CLEC-2 to podoplanin-expressing neuro-epithelium leads to 
platelet activation, subsequently releasing non-S1P pro-angiogenic factors to recruit 
mural cells for a full development of blood vessel (Figure 1.3 B). In addition, the activated 
platelets (via CLEC-2 stimulation) may form small platelet plugs at the vascular wall in 
a GPIIb/IIIa-dependent manner to prevent bleeding (maintain vascular integrity) during 
the development of cerebral blood vessels (Lowe et al., 2015a). This CLEC-2-podoplanin 
interaction may explain a role of platelets for the prevention of intraventricular 
haemorrhage in preterm infants (Lowe et al., 2015a).  
1.6.4 CLEC-2-podoplanin interaction aids platelet formation in bone marrow 
A low platelet count observed in megakaryocyte/platelet-specific CLEC-2 knockout mice 
raises the research question whether CLEC-2-podoplanin axis contributes to platelet 
biogenesis. In bone marrow, podoplanin is detected on stromal cells at the periarteriolar 
interface, defined as ‘bone marrow FRC-like cells’. Megakaryocytes are observed in 
proximity to these perivascular podoplanin-positive cells. CLEC-2 knockout mice had a 
reduction in total numbers and the association of megakaryocytes with bone marrow 
FRC-like cells. The in vitro experiments have revealed that either recombinant 
podoplanin or bone marrow FRC-like cells increases megakaryocyte expansion whereas  
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Figure 1. 3. Physiological functions of platelet CLEC-2 and podoplanin interaction. 
(A) Regulation of high endothelial venule integrity within lymph nodes (Herzog et al., 
2013). (B) Cerebrovascular development and integrity (Lowe et al., 2015a). (C) 
Megakaryocyte expansion and proplatelet formation in bone marrow (Tamura et al., 
2016). (D) Lung development (Tsukiji et al., 2018a). FRC = fibroblastic reticular cell, 
HEV = high endothelial venule, PDPN = podoplanin, S1P = sphingosine-1-phosphate, 
S1PR1 = sphingosine-1-phosphate receptor 1, VEGF = vascular endothelial growth 
factor, PDGF-β = platelet-derived growth factor-β, Ang-1 = angiogenin-1, TGF-β = 
transforming growth factor-β, ECM = extracellular matrix, MK = megakaryocytes, LEC 
= lymphatic endothelial cell, LMC = lung mesothelial cell, MF = myofibroblast. See text 
for details. 
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anti-podoplanin antibody inhibits this effect. These parameters are decreased using 
CLEC-2 knockout megakaryocytes. In addition, recombinant CLEC-2 enhances secretion 
of the chemokine (C-C motif) ligand 5 (CCL5) from bone marrow FRC-like cells in vitro, 
which is accompanied by an increase in proplatelet formation, supporting the significance 
of periarteriolar CELC-2-podoplanin interaction in megakaryocyte/platelet production 
(Figure 1.3 C) (Tamura et al., 2016). However, postnatal depletion of CLEC-2 in mice 
has no impact on platelet counts (Lowe et al., 2015b), which contradicts these data. 
1.6.5 CLEC-2-podoplanin in lung development 
As mentioned, constitutive deletion of CLEC-2 or podoplanin in mice commonly leads 
to death during development. Lung abnormalities are one of the suspected causes of 
embryonic or perinatal lethality (Ramirez et al., 2003, Finney et al., 2012). Recently, a 
detailed mechanism involving CLEC-2-podoplanin interactions in lung development has 
been proposed. Although podoplanin is expressed in alveolar type I cells, the interaction 
of platelet CLEC-2 and podoplanin on lymphatic endothelial cells (LECs) is likely to 
regulate this process by inducing transforming growth factor (TGF)-β1 secretion from 
activated platelets. Subsequently, TGF-β1 stimulates differentiation of lung mesothelial 
cells into alveolar duct myofibroblasts, which synthesise extracellular matrix (ECM) to 
support the normal lung structure and function (Figure 1.3 D). In mice, global CLEC-2 
knockout and LEC-specific podoplanin knockout neonates show a similar lung 
malformation, including a smaller alveolar space, a thickening of alveolar septum, and a 
minimal extent of elastic fibres. This is in association with an increase in lung mesothelial 
cells but a decrease in alveolar duct myofibroblasts. In addition, CLEC-2 null mice 
demonstrate a reduction of TGF-β in the developing lung. However, a milder form of 
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lung malformation is observed in platelet-specific CLEC-2 deficient mice, which is 
possibly due to the 2% remaining of CLEC-2 on platelets in this model (Tsukiji et al., 
2018a). Further treatment of the platelet-specific CLEC-2 deficient pregnant mice with 
anti-CLEC-2 or anti-TGF-β antibody shows lung malformation in neonates, which is 
identical to that of global CLEC-2 knockout littermates, suggesting that platelet CLEC-2 
regulates normal lung development in part through TGF-β secretion (Tsukiji et al., 
2018a). Moreover, in vitro and ex vivo incubation of platelet supernatant plus 
hydrochloric acid (to convert TGF-β into active form) promote differentiation of lung 
mesothelial cells into myofibroblasts, supporting the role of platelet-derived TGF-β in 
lung development (Tsukiji et al., 2018a). 
1.7 Platelet ITAM receptors in pathological conditions 
In addition to the regulation of normal physiological function, GPVI and CLEC-2 have 
been reported to participate in various pathological conditions, including in thrombosis 
and inflammation. These two ITAM receptors show additive or synergistic effect in 
certain circumstances whereas they may provide opposing activity in others. Moreover, 
even GPVI or CLEC-2 itself plays different role depending on the related pathological 
context, which is possibly because of the distribution and the specific function of their 
ligands. 
1.7.1 The role of GPVI and CLEC-2 in thrombosis 
It has been elucidated ex vivo that GPVI predominantly binds collagen at the core of 
human carotid atherosclerotic plaque. In addition, anti-human GPVI antibody (5C4) 
inhibits plaque-induced platelet aggregation in vitro (Schulz et al., 2008). In 
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apolipoprotein E knockout (Apoe-/-) animals, the major mouse model of atherosclerosis, 
GPVI is also detected in atherosclerotic lesion on arterial wall, including at carotid artery 
and aortic arch (Schulz et al., 2008). Anti-mouse GPVI antibody (JAQ1) has been 
reported to reduce the size of thrombus following either ultrasound- or needle-induced 
acute plaque rupture in carotid artery of Apoe-/- mice (Kuijpers et al., 2009, Hechler and 
Gachet, 2011). Moreover, GPVI fusion protein (GPVI-Fc), which competitively binds 
collagen, has been shown to inhibit platelet adhesion and aggregation in vitro 
(Schonberger et al., 2012), attenuates the progression of atherosclerosis in Apoe-/- mice 
(Schulz et al., 2008), reduces infarct size and improves left-ventricular systolic function 
in a mouse model of myocardial infarction (temporary ligation of the left anterior 
descending artery) (Schonberger et al., 2012). In murine model of ischemic stroke 
(transient middle cerebral artery occlusion), JAQ1 has been demonstrated to reduce 
infarct volume in the absence of bleeding complication (Kleinschnitz et al., 2007). The 
association of GPVI in these thrombotic events is suggested in part by the regulation of 
inflammatory responses (Schonberger et al., 2012, Nieswandt et al., 2011). Moreover, a 
Syk inhibitor given orally shows a promising effect by prolonging time to arterial 
occlusion and reducing infract size in animal model of acute stroke (van Eeuwijk et al., 
2016). GPVI-null mice are also protected against VTE by showing the increase in survival 
rate following pulmonary embolism compared to control (Lockyer et al., 2006).  
CLEC-2 has also been investigated in thrombosis. In a mouse model of ferric chloride 
(FeCl3)-induced thrombus formation at mesenteric arterioles, either JAQ1 or anti-CLEC-
2 antibody (INU1) alone does not affect thrombosis and haemostasis (tail bleeding time). 
However, combined administration of both antibodies significantly reduces thrombus 
formation but prolongs bleeding time, suggesting that GPVI and CLEC-2 cooperate in 
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thrombosis whereas these two ITAM receptors play a redundant role in haemostasis 
(Bender et al., 2013). Moreover, CLEC-2-podoplanin axis protects against DVT in mice. 
Either CLEC-2 knockout or anti-podoplanin antibody-treated mice show a reduction in 
platelet recruitment and thrombus formation following partial ligation of inferior vena 
cava-induced DVT (Payne et al., 2017). A recent study, finding drug candidates for 
CLEC-2 inhibition, demonstrates that cobalt haematoporphyrin is able to inhibit 
rhodocytin- and podoplanin-induced platelet aggregation in a dose-dependent manner. 
Moreover, this compound shows a promising effect by reducing thrombus formation in 
murine models of arterial thrombosis and DVT (Tsukiji et al., 2018b). 
1.7.2 GPVI and CLEC-2 mediate inflammatory haemostasis 
Initially, the function of GPVI and CLEC-2 in maintaining vascular integrity during 
inflammation has been introduced in a murine model of cutaneous rpA (Boulaftali et al., 
2013); bovine serum albumin (BSA) is intravenously injected into mice followed by 
intradermal injection of anti-BSA antibody to generate immune complex-mediated skin 
inflammation. Mice lacking the extracellular domain of GPIbα do not exhibit intra-skin 
haemorrhage following rpA unless they are thrombocytopenic, suggesting GPIbα-
independent platelet function in rescuing vascular damage during skin inflammation. 
Adoptive transfusion of either normal platelets plus JAQ1 injection or CLEC-2 deficient 
platelets into these thrombocytopenic GPIbα deficient mice also results in rpA-mediated 
bleeding. Moreover, transfusion of CLEC-2 deficient platelets accompanied with JAQ1 
treatment increases bleeding phenotype, which is identical to a reconstitution of SLP-76 
knockout platelets, indicating the important role of these two ITAM-associated receptors 
and their signal transduction in preventing inflammatory bleeding (Boulaftali et al., 
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2013). Subsequently, it has been revealed that neutrophil transmigration is a cause of 
vascular breaches during cutaneous and peritoneal rpA (Gros et al., 2015). GPVI 
contributes to neutrophil-mediated cytotoxic activity in both conditions whilst it has been 
shown to simultaneously seal vascular damage only in cutaneous but not peritoneal rpA. 
Intravital microscopy reveals that single platelets, rather than platelet aggregates, regulate 
this inflammatory haemostasis, which is unlike classical haemostasis (Gros et al., 2015). 
A more recent study elucidates that GPVI deficient mice show bleeding during cutaneous 
rpA whereas platelet-specific CLEC-2 knockout mice do not (Rayes et al., 2018). 
However, the degree of bleeding is increased in GPVI and CLEC-2 double deficient mice. 
Administration of anti-podoplanin antibody also increases vascular leakage in GPVI 
knockout mice but does not cause bleeding in GPVI-expressing controls (Rayes et al., 
2018). These data suggest that GPVI has a primary role and that CLEC-2-podoplanin 
functions as a back-up in safeguarding vascular integrity during skin rpA. Binding of 
GPVI to its ligands (e.g. collagen) in subendothelial matrix, and CLEC-2 to podoplanin-
expressing cells in proximity to blood vessel (proposed as fibroblasts and macrophages), 
mediate this vasculoprotective function during inflammation by sealing the gap following 
leucocyte extravasation (Figure 1.4) (Ho-Tin-Noe et al., 2018, Boulaftali et al., 2018, 
Rayes et al., 2018).  
The role of GPVI and CLEC-2 in preventing vascular leakage during a model of 
intranasal Pseudomonas aeruginosa LPS-induced lung inflammation is controversial. 
Following LPS (7 µg) inhalation in adoptive transfusion experiment in mice lacking 
extracellular domain of GPIbα, intra-pulmonary haemorrhage is observed in all similar 
settings to that of cutaneous rpA, which supports the contribution of platelet GPVI and 
CLEC-2 in this inflammatory condition (Boulaftali et al., 2013). In contrast, a recent work 
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reveals that higher dose of LPS (20 µg) does not cause bleeding into bronchoalveolar 
space in GPVI-null mice (with or without anti-podolanin antibody) or platelet-specific 
CLEC-2 knockout mice, whereas GPIbα-ectodomain deficient mice present bleeding in 
the inflamed lung (Rayes et al., 2018), indicating that GPIbα-IX-V complex may play a 
role in maintaining vascular integrity during lung inflammation. Moreover, intra-
bronchoalveolar bleeding during lung rpA model (intranasal anti-BSA antibody + BSA 
i.v.) only occurs in thrombocytopenic mice but not in mice deficient in GPVI or GPIbα-
ectodomain, pointing to stimulus-dependent mechanism for the prevention of 
inflammatory bleeding (Rayes et al., 2018). 
Dasatinib, an anti-cancer drug that inhibits tyrosine kinases (e.g. Src), has been reported 
to increase risk of bleeding in leukaemia patients, including in skin (petechiae) and the 
gastrointestinal tract (Kreutzman et al., 2017, Apperley et al., 2009). Dasatinib also 
inhibits in vitro ITAM-mediated platelet adhesion (Pollitt et al., 2014, Induruwa et al., 
2018) and aggregation (Lorenz et al., 2015, Induruwa et al., 2018). Moreover, mice 
treated with this drug exhibits significant bleeding in the small intestine. Dasatinib shows 
no direct cytotoxicity, but reversibly disrupts cell-cell junctions between endothelial cells 
in vitro, supporting the mechanism of dasatinib-induced loss of vascular integrity 
(Kreutzman et al., 2017). 
Although a loss of vascular integrity is suggested to cause detrimental consequences, 
including intra-tissue bleeding during inflammation, it may provide a beneficial effect in 
wound healing (Shaterian et al., 2009) and cancer chemotherapy (Demers et al., 2011). 
During skin wound healing model, extensive vascular leakage is observed at the initial 
phase of repair, in association with a progression of angiogenesis in later phases. The 
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increase in vascular permeability allows the release of growth factors, matrix proteins, 
and cells into the wound to facilitate healing process. Moreover, vascular leakage may 
aid in drug delivery to the wound site that would accelerate wound healing (Shaterian et 
al., 2009, Mendonca et al., 2010). There is no evidence of dasatinib-associated impaired 
wound healing relative to other tyrosine kinase inhibitors (Shah et al., 2014). On the other 
hand, dasatinib may facilitate the entry of other chemotherapeutic drugs into a solid 
tumour, which potentially enables effective cancer treatment (Kreutzman et al., 2017). 
The direct role of platelet GPVI and CLEC-2 has never been investigated in these settings. 
1.7.3 Regulation of inflammatory responses by GPVI and CLEC-2 
During recent years, GPVI and CLEC-2 have been shown to regulate inflammatory 
responses in various conditions. In addition, these two ITAM receptors can play an 
opposite role in inflammation. For example, GPVI promotes a pro-inflammatory 
phenotype during glomerulonephritis by increasing platelet and neutrophil recruitment to 
the inflamed glomeruli (Devi et al., 2010). Microparticles, which are released upon GPVI-
mediated platelet activation, promote an inflammatory activity of synovial fibroblasts and 
exacerbate the progression of arthritic diseases (Boilard et al., 2010). As mentioned 
previously, GPVI contributes to neutrophil-mediated tissue damage in cutaneous rpA 
(Gros et al., 2015). More recently, it has been reported that GPVI ablation promotes 
switching of macrophages from a M1 pro-inflammatory to M2 anti-inflammatory 
phenotype, which reduces inflammation and pain in an inflamed paw skin model (Pierre 
et al., 2017). However, this pro-inflammatory activity of GPVI supports innate immunity, 
which is beneficial for bacterial killing during gram-negative bacterial pneumonia-
induced sepsis (Claushuis et al., 2018).  
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CLEC-2-podoplanin interaction has been demonstrated to protect against organ damage 
and reduce inflammation during lung injury (Lax et al., 2017b) and sepsis (Rayes et al., 
2017). In addition, in vitro ligation of CLEC-2 with podoplanin-positive T cells inhibits 
the inflammatory response in Th17 cells (Nylander et al., 2017). However, CLEC-2 
promotes M1 macrophage migration to the site of infection, resulting in efficient 
pathogen clearance during bacterial peritonitis (Rayes et al., 2017). On the other hand, 
the upregulation of podoplanin is also associated with the degree of inflammation in 
arthritis (Croft et al., 2016, Takakubo et al., 2017). Moreover, CLEC-2-podoplanin 
involves in infection-induced thrombosis, which occludes liver microvessels, despite the 
unaltered degree of inflammation (Hitchcock et al., 2015). 
Dasatinib also produces anti-inflammatory activity, at least by reducing neutrophil 
recruitment (da Silva et al., 2016) and neutrophil-derived respiratory burst (Futosi et al., 
2012) as well as enhancing M2 macrophage population (Ozanne et al., 2015, Cruz et al., 
2016). However, these activities are suggested as a direct effect of dasatinib on 
leucocytes. There is no evidence demonstrating the cooperation of platelet GPVI and 
CLEC-2 in mediating inflammatory responses. 
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Figure 1. 4. Role of platelet GPVI and CLEC-2 in safeguarding vascular integrity 
during inflammation. (A) Platelets, primarily via GPVI (green), seal the small hole 
between endothelium following neutrophil extravasation. GPVI binds collagen in 
subendothelial matrix, leading to platelet activation and secretion of barrier-strengthening 
mediators, such as sphingosine-1-phosphate (S1P), to restore endothelial integrity. 
Platelet CLEC-2 (yellow) acts as backup pathway of vasculoprotective function during 
inflammation in the absence of GPVI, via binding to podoplanin on perivascular cells 
(e.g. fibroblasts and macrophages). (B) A lack of both ITAM receptors results in intra-
tissue bleeding during inflammation. Adapted from (Ho-Tin-Noe et al., 2018, Boulaftali 
et al., 2018). 
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1.8 Potential role of platelet ITAM receptors in skin wound 
healing 
1.8.1 An overview of skin structure 
The integumentary system, made up of skin and its appendages, is the largest organ 
system in the body that function as a protective barrier against external environment 
(McLafferty et al., 2012). Skin comprises of two layers, including the epidermis (the 
uppermost part) and the dermis (Figure 1.5 A). Skin epidermis lacks blood vessels. 
Moreover, it is subdivided into five layers from the deepest to the uppermost layer, 
including stratum basale, stratum spinosum, stratum granulosum (granular layer), stratum 
lucidum (only found in the area of thick skin, such as the palms and soles), and stratum 
corneum, respectively (McLafferty et al., 2012). In mouse skin (Figure 1.5 B, left), the 
epidermis is thinner than in human (Figure 1.5 B, right) (Wagner et al., 2010, Pasparakis 
et al., 2014). 
Keratinocytes are the most abundant cell population within the skin epidermis. Stratum 
basale is a basal layer adjacent to dermis, containing columnar keratinocytes, which are 
capable of dividing (Figure 1.5 A). During homeostasis, keratinocytes regularly multiply 
and migrate to the upper layers, accompanied by keratin accumulation (keratinised). 
While moving upward, keratinocytes change their morphology from rounded to flattened 
shape and finally undergo apoptosis, which become flattened (stratified squamous) dead 
cells at stratum corneum and are sloughed off overtime (McLafferty et al., 2012). 
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                                                                                                                                    (Wagner et al., 2010) 
 
Figure 1. 5. Structure of murine skin. (A) Schematic illustration of skin structure. 
Epidermis is the uppermost layer of skin, containing skin epithelium called keratinocytes. 
Dermis comprises of various structures (e.g. blood and lymphatic vessels), cell types (e.g. 
fibroblasts and immune cells), and molecules (e.g. collagen and elastic fibres). (B) 
haematoxylin and eosin (H&E) staining of normal mouse skin (left) and human skin 
(right). AD = adipocytes, BV = blood vessel, HF = hair follicle, PC = panniculus carnosus 
muscle. KC = keratinocytes. Arrow points to KC. 
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Dermis contains blood vessels, lymphatic vessels, nerve endings, hair follicles and 
glands. In addition, fibroblasts in this layer synthesise the collagen and elastic fibres, 
which constitute a strong connective tissue to mediate tensile strength of skin (Figure 1.5 
A). Immune cells, including macrophages, dendritic cells, T-cells, mast cells, mainly 
reside in dermis, although some of T-cells and Langerhans cells (specific type of dendritic 
cells) are located in epidermis (Wagner et al., 2010, Pasparakis et al., 2014, McLafferty 
et al., 2012). In mice, there is a fast-twitch muscle called “panniculus carnosus” that lies 
under the dermis (Figure 1.5 B). This specialised muscle helps twitching a loose skin and 
regulates body temperature in rodent (Naldaiz-Gastesi et al., 2016, Driskell et al., 2014). 
1.8.2 Pathophysiology of skin wound healing 
Skin wound repair is a multifactorial process, which comprises of four interdependent 
phases, including haemostasis, inflammation, proliferation, and remodelling (Figure 1.6) 
(Shaw and Martin, 2009). Immediately following tissue injury, platelet aggregation and 
fibrin clot play a haemostatic function to stop bleeding. Circulating neutrophils are the 
first immune cells recruited into the wound site to eliminate invading microorganisms 
and cellular debris during the initial inflammatory phase. Monocytes enter shortly after 
and differentiate into tissue macrophages. By exposing to the inflammatory stimuli in 
injured tissue, macrophages are directed to M1 pro-inflammatory characteristics, which 
further contribute to the inflammatory response. In the late inflammatory phase, 
macrophages switch to a M2 reparative phenotype and initiate the resolution of 
inflammation (Fadok et al., 1998, Sindrilaru and Scharffetter-Kochanek, 2013). The 
proliferative phase begins in an overlapping period, where keratinocytes start migration 
and proliferation to recover skin epithelium; this process is called “re-epithelialisation” 
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(Shaw and Martin, 2009). In addition, angiogenesis during this stage forms a granular 
structure, which is termed “granulation tissue” (Flanagan, 1998) in wound area and 
provides nutrients and oxygen to the tissue. Simultaneously, skin fibroblasts are recruited 
into the granulation tissue to synthesise extracellular matrix, including collagen, which 
allows cell migration. Moreover, lymphangiogenesis is stimulated to facilitate draining 
of inflammatory component. Fibroblasts further differentiate into myofibroblasts and 
mediate wound contraction in the remodelling (or maturation) phase. The wound turns 
into healed state during this final phase, represented by the resolution of inflammation, in 
conjunction with the completion of wound closure and the re-organisation of collagen 
fibres to restore skin integrity (Shaw and Martin, 2009, Pence and Woods, 2014, Brown 
et al., 2014, Hur et al., 2014). 
1.8.3 Platelets in wound healing 
Platelets play additional roles alongside haemostasis during wound healing. Activated 
platelets secrete growth factors and cytokines/chemokines, which support vessel repair 
and regulate immune cell recruitment (Shaw and Martin, 2009, Yang et al., 2011). In an 
animal model of superficial wound, thrombocytopenic and P-selectin-deficient mice 
show delayed wound healing, in association with a reduction in leucocyte infiltration, 
following corneal epithelial abrasion (Li et al., 2006). In addition, platelet-rich plasma, 
which contains growth factors, including PDGF, VEGF, and TGF-β, facilitates skin 
wound healing in mice (Yang et al., 2011). Moreover, platelet-rich fibrin promotes wound 
healing in diabetic mice at least by enhancing angiogenesis (Ding et al., 2017). 
Surprisingly, one report has demonstrated that skin wound healing is not impaired in 
thrombocytopenic mice (Szpaderska et al., 2003). Although the numbers of macrophages 
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Figure 1. 6. Simplified scheme of skin wound healing phases. Haemostasis (1) 
immediately begins after injury to terminate blood loss. The influx of leucocytes, 
particularly neutrophils and macrophages at day 1-5 post-injury drives the inflammatory 
phase (2). Proliferative phase (3) takes place during day 3-9 post-injury. Re-
epithelialisation, a process of keratinocyte migration and proliferation, promotes recovery 
of skin epidermis. Angiogenesis within the granulation tissue of the wound supplies 
nutrients and oxygen for cell function. Fibroblasts synthesises extracellular matrix to 
support cell migration. Lymphangiogenesis aids in draining the inflammatory component. 
Finally, the remodelling phase (4) occurs approximately at day 7 onwards. Fibroblasts 
differentiate into myofibroblasts and mediate wound contraction. Complete wound 
closure and re-organisation of collagen fibres turn the wound into healed state. In each 
phase, the important events and cellular/molecular contributions are listed. The scheme 
is depicted based on (Shaw and Martin, 2009, Brown et al., 2014, Pence and Woods, 
2014, Hur et al., 2014).  
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and T-cells are increased in the inflammatory and proliferative phases, respectively, the 
wound closure, re-epithelialisation, angiogenesis, and collagen synthesis, are unaffected 
in thrombocytopenic mice (Szpaderska et al., 2003), disclaiming the essential 
contribution of platelets in wound healing, including in haemotasis. In addition to this 
controversy, it is unclear which platelet-expressed receptor(s) are required to facilitate 
wound healing. 
1.8.4 Fibrinogen, fibrin, and coagulation cascade in wound healing 
During the initial inflammatory phase of wound healing, the increased vascular 
permeability allows extravasation of plasma proteins, including fibrinogen, coagulation 
factors, growth factors, cytokines, and chemokines into the site of injury. Tissue factor, 
expressed on keratinocytes, pericytes, and leucocytes within the wound (Hoffman and 
Monroe, 2012), can activate clotting factor (F)VII, which mediates thrombin generation. 
Subsequently, thrombin cleaves fibrinogen into fibrin strands, which stabilise the blood 
clot. Fibrinogen and fibrin not only initiate haemostatic plug formation but also facilitate 
wound healing by various mechanisms. Firstly, fibrinogen and fibrin provide a 
provisional matrix for local cell migration, including endothelial cells, fibroblasts, and 
keratinocytes (Drew et al., 2001, Brown et al., 1992). Once endothelial cells are recruited 
from tissue near the wound, they proliferate and migrate over fibrinogen and fibrin matrix, 
then form a capillary tube, contributing to angiogenesis during wound healing 
(Chalupowicz et al., 1995, Laurens et al., 2006, Sahni and Francis, 2000). Fibrin is also 
shown to promote fibroblast proliferation and migration in vitro (Cox et al., 2004). 
Although keratinocytes do not adhere to fibrinogen and fibrin (Kubo et al., 2001), they 
mediate fibrinolysis, a process of fibrin degradation, and form a tunnel-like structure to 
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move along this matrix (Ronfard and Barrandon, 2001). In contrast, fibrinogen and fibrin 
may inhibit the recruitment of neutrophils (Higazi et al., 1994, Hanson and Quinn, 2002) 
and monocytes/macrophages (Lishko et al., 2007) to the site of injury. Secondly, 
fibrinogen and fibrin may act as a reservoir for growth factors and cytokines since they 
bind with high affinity to pro-angiogenic factors, including VEGF and fibroblast growth 
factor 2 (Drew et al., 2001). Thirdly, fibrinogen and fibrin act as natural suture by 
stabilising wound field (Drew et al., 2001). Recently, it has also been demonstrated that 
a fibrin film over surface of the wound protects against bacterial invasion (Macrae et al., 
2018). 
In mice lacking fibrinogen, abnormal proliferation and migration of keratinocytes are 
observed, characterised by epithelial hyperplasia and the projection of epithelial tongues 
away from the centre of the wound. However, the time to complete wound closure is 
unaltered in these mice (Drew et al., 2001). In diabetic mice, fibrin together with 
leucocytes and platelets accelerate skin wound healing by promoting angiogenesis (Ding 
et al., 2017). Moreover, severe impairment in wound healing has been reported in a 
patient with dysfibrinogenaemia (van Vulpen et al., 2018). In clinical practice, fibrin 
sealant is used in several surgical procedures, supporting its role in promoting wound 
healing (Laurens et al., 2006, Alston et al., 2008, Albala, 2003). 
Deficiency in FIX (haemophilia B), FVII, and tissue factor also delays wound healing. In 
haemophilia B mice, an impaired wound healing is associated with the persistent 
subcutaneous bleeding, due to a defect in fibrin generation, leading to haematoma 
formation during the course of wound closure (Hoffman et al., 2006). In addition, mice 
expressing low tissue factor (approximately 1% of normal level) show milder form of 
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bleeding in the granulation tissue during wound healing (Monroe et al., 2010). Moreover, 
a reduction in leucocyte recruitment is a proposed mechanism of delayed wound healing 
in mice with low FVII (less than 1% of normal level), although they display an initial red 
spot at the centre of the wound, and a subsequent darker wound scab along the healing 
process, which may indicate certain degree of bleeding within the wound (Xu et al., 
2010). FXIII, a transglutaminase, is also important in wound healing. Following fibrin 
generation and polymerisation by thrombin, FXIIIa (thrombin-activated FXIII) forms a 
thioester bond with glutamine residue of fibrin. Then, acyl group (R-C=O) in thioester 
intermediate binds with amine group (R-NH2) of lysine residue from another fibrin 
molecule and mediates cross-linking of fibrin, which increases the stability and tensile 
strength of the clot (Ariens et al., 2002). Delayed wound healing is observed in FXIII 
knockout mice (Dickneite et al., 2015). Therefore, fibrin formation and its stability may 
promote wound healing by tightening the clot. Moreover, patients with haemophilia and 
FXIII deficiency demonstrate bleeding, which is related to poor wound healing 
(Rodriguez-Merchan, 2012). These observations collectively point to an important 
function of the coagulation cascade in wound healing. 
1.8.5 The role of leucocytes in wound healing 
During the inflammatory phase, neutrophils are the first inflammatory cells recruited from 
blood circulation into the wound site, which reach peak level at 24-48 hours. Neutrophil 
number is maintained at high level until day 3 after injury, and gradually decrease 
afterwards (Dovi et al., 2003, Kim et al., 2008). Blood monocytes enter the wound later 
and differentiate into tissue macrophages. The increased number of wound monocytes is 
observed at day 3 post-injury, and proceeded during the course of wound healing, in 
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correlation with the number of wound macrophages (Crane et al., 2014). At the early 
inflammatory phase (day 1-4 post-injury) where wound sterilisation is needed, 
macrophages mainly express M1 pro-inflammatory phenotype and function with 
neutrophils to remove invading microorganisms and cellular debris (Sindrilaru and 
Scharffetter-Kochanek, 2013, Eming et al., 2007). In addition, these cells produce pro-
inflammatory cytokines, including TNF-α, IL-1β, and IL-6, which promote inflammation 
(Eming et al., 2007). In contrast, wound macrophages demonstrate M2 reparative 
characteristics during the late inflammatory phase (day 5-7 post-injury), which secrete 
anti-inflammatory cytokines (e.g. IL-10) and growth factors (e.g. TGF-β1), contributing 
to resolution of inflammation and tissue repair (Sindrilaru and Scharffetter-Kochanek, 
2013). The M2 macrophages possibly arise by either a polarisation of M1 macrophages 
or a direct differentiation of non-classical (murine Ly6Clow) monocytes within the wound 
(Crane et al., 2014). In addition, macrophage plasticity is also dependent on its metabolic 
profiles. For example, M1 macrophages use aerobic glycolysis and pentose phosphate 
pathway as major metabolism whereas M2 macrophages primarily rely on tricarboxylic 
acid cycle coupled to oxidative phosphorylation (Van den Bossche et al., 2016, Das et al., 
2015, Geeraerts et al., 2017). 
Although their role in preventing infections is certain, how inflammatory cells facilitate 
wound healing is controversial (Martin and Leibovich, 2005). In a model of skin wound 
healing, neutrophil depletion results in accelerated wound healing, in association with the 
increase in re-epithelialisation at the early phase (Dovi et al., 2003), suggesting a non-
essential function of neutrophils in tissue repair. Moreover, several lines of evidence 
demonstrate a detrimental activity of neutrophils during wound healing, including the 
secretion of proteases (Dovi et al., 2003), the production of inflammatory cytokines and 
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oxidative stress (Wilgus et al., 2013, Slater et al., 2017), and the formation of NETs (e.g. 
in diabetic wounds, which demonstrate chronic inflammation) (Wong et al., 2015), all of 
which cause tissue damage and delay wound healing.  
Macrophages might also be dispensable for wound healing. In mouse embryos (E11.5-
13.5), there is no macrophage recruitment to the wound along the course of repair. In 
addition, these embryos show absence of scar after wound healing (Hopkinson-Woolley 
et al., 1994). However, wound macrophages are observed in older foetus (E14.5), which 
is resemble to adult mice (Hopkinson-Woolley et al., 1994). In PU.1 transcription factor-
knockout mouse neonates that lack neutrophils, macrophages, and lymphocytes, the rate 
of skin wound healing is unaltered and these neonates demonstrate scar-free after healing, 
similar to that of embryos (Martin et al., 2003). Moreover, it has been reported that 
deletion of wound macrophages in the early stage (day 1-5 post-injury) does not 
negatively affect initial wound closure (day 1-4 post-injury) but delays the mid-stage of 
healing, accompanied by a reduction in M2 macrophages and a defect in re-
epithelialisation and granulation tissue formation. However, it leads to a reduction in scar 
formation at the end (Lucas et al., 2010). Macrophage depletion in mid-stage (day 4-10 
post-injury) causes severe haemorrhage within the wound and delays wound closure, 
suggesting the role of macrophages in regulating vascular stability during tissue repair. 
Lack of macrophages after this time point does not influence wound healing (Lucas et al., 
2010). Therefore, it suggests that M2 macrophages, rather than M1 pro-inflammatory, 
may be essential for wound healing, especially during the proliferative-to-maturation 
phases of repair. 
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Mast cells, derived from blood basophils, have also been illustrated to participate in 
wound healing. Histamine secreted from mast cells mediates vascular permeability during 
inflammation and may facilitate wound healing. Mice deficient in mast cells represents a 
delayed wound closure, especially within the first six days, in association with a decrease 
in vascular permeability, and neutrophil recruitment (Weller et al., 2006). In addition, 
histamine promotes wound healing (Numata et al., 2006) whereas anti-histamine 
mediates the opposite effect in mice (Weller et al., 2006), supporting the role of mast cells 
and histamine in repair process. In the recent years, a crosstalk between dendritic 
epithelial T-cells (DETCs) and keratinocytes has been elucidated. In aged mice, a 
reduction in keratinocyte activation, subsequently lowers the number of recruited DETCs 
(day 3-7) and decreases re-epithelialisation process, contributing to delayed wound 
closure compared to young littermates, indicating the role of DETCs in normal wound 
healing (Keyes et al., 2016). 
1.8.6 Other cellular aspects during the wound healing process 
As mentioned, keratinocytes at the basal layer are capable of renewing during 
homeostasis and certainly after skin injury. The activated keratinocytes not only migrate 
and proliferate during wound healing but also mediate other effects. Keratinocytes release 
pro-inflammatory cytokines, including IL-1 and TNF-α, which produce paracrine 
function in fibroblast activation. TGF-β secreted by both keratinocytes and fibroblasts 
induces differentiation of fibroblasts into myofibroblasts. In addition, keratinocytes 
express TLRs, which recognises pathogens, providing host defense mechanism during 
tissue injury. Moreover, stem cell niche within hair follicle has been shown to promote 
re-epithelialisation process by producing the keratinocyte stem cells (Pastar et al., 2014). 
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Fibroblasts are resident cells in skin dermis, which turnover ECM under physiological 
setting. Fibroblasts express vimentin (intermediate filament protein) but not α-smooth 
muscle actin (α-SMA). Upon tissue injury, fibroblasts at adjacent skin area are activated 
and differentiate into myofibroblasts in proliferative phase (Li and Wang, 2011). Bone 
marrow-derived circulating fibrocytes also largely contributes to the source of 
myofibroblasts during wound healing. It has been reported that 30-50% of wound 
myofibroblasts are originated from fibrocyte progenitors (Barisic-Dujmovic et al., 2010). 
Moreover, smooth muscle cells and pericytes are believed as other potential origins of 
myofibroblasts (Li and Wang, 2011). The main function of myofibroblasts is the ECM 
synthesis, including collagen and other elastic fibres. In addition, myofibroblasts express 
α-SMA alongside vimentin, which represent their contractile property to mediate wound 
contraction. Myofibroblasts generally undergo apoptosis at the final stage of wound 
healing. However, excessive numbers or activities of myofibroblasts may lead to 
hypertrophic or keloidal scar formation and a detrimental tissue fibrosis (Li and Wang, 
2011). 
Pericytes, the cells located nearest to vascular endothelium and have long cytoplasmic 
processes encircle blood vessel, also participate in tissue repair. Pericytes generally 
express neuron-glial antigen 2 (NG2) and are further classified into two subsets based on 
the presence of nestin, including Type 1 (nestin-/NG2+) and type 2 (nestin+/NG2+). Type 
1 pericytes express α-SMA and are primarily observed around both arterioles and venules, 
which function in regulating the vessel tone. Type 2 pericytes have mesenchymal stem 
cells/multipotent stromal cells characteristic, which contribute to angiogenesis (Bodnar 
et al., 2016). In addition to angiogenesis, pericytes support wound healing by several 
mechanisms. For example, pericytes enhance vascular permeability and the extravasation 
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of leucocytes during the inflammatory phase. These perivascular cells also control 
keratinocyte migration. Moreover, pericytes differentiate into fibroblasts/myofibroblasts, 
which contribute to late phases of repair (Bodnar et al., 2016, Thomas et al., 2017). 
1.8.7 Podoplanin-CLEC-2 axis during skin wound repair 
In a murine model of skin wound healing, the increased expression of podoplanin, 
including in keratinocytes, is observed on day 1 after injury and is prominent on day 3 to 
day 7 post-injury alongside the progression of re-epithelialisation. At day 10 post-injury, 
when complete wound closure is achieved; podoplanin is substantially decreased (Asai et 
al., 2016). Immunostaining of skin wound reveals that platelets are present in the wound 
and located near podoplanin at day 1 post-injury. In addition, the increase in keratinocyte-
expressed E-cadherin is marginally co-localised with podoplanin at day 3 post-injury, 
suggesting that podoplanin may regulate keratinocyte migration by down-regulating this 
cell adhesion molecule. This observation is supported by in vitro experiments, which 
demonstrate an elevated expression of E-cadherin in podoplanin-knockdown 
keratinocytes, in association with reduced keratinocyte migration. In addition, 
keratinocytes incubated with recombinant human CLEC-2 exhibit complementary results 
(Asai et al., 2016). Collectively, it is proposed that platelets, via CLEC-2-podoplanin 
interaction, inhibit keratinocyte migration at the initial phase of repair until the wound 
bed is completely prepared. During the later phases where platelets do not exist, the 
upregulation of podoplanin promotes re-epithelialisation process (Asai et al., 2016). 
However, mice deficient in keratinocyte podoplanin show no significant differences in 
skin re-epithelialisation and wound closure, compared with controls (Baars et al., 2015). 
Moreover, there are no defects in cell proliferation, migration, and adhesion in podoplanin 
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deficient keratinocytes in vitro, indicating that keratinocyte podoplanin is dispensable for 
wound healing (Baars et al., 2015). 
The potential function of monocyte-derived podoplanin during wound healing has also 
been studied. A single intradermal injection of human podoplanin-positive monocytes in 
combination with platelets around the wound edge significantly accelerates skin wound 
healing in mice, whereas either platelets or podoplanin-positive monocytes alone does 
not (Hur et al., 2014). This platelet-monocyte combination enhances lymphangiogenesis 
in the later phase of wound repair. Anti-podoplanin antibody reverses healing phenotype 
observed in platelet-monocyte-treated mice, including a reduction in lymphangiogenesis. 
Although multiple mechanisms may contribute, these data suggest a transdifferentiation 
of podoplanin-positive monocytes into a lymphatic phenotype, under the interaction with 
platelets (via CLEC-2), to facilitate tissue repair. 
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1.9 Aims 
Platelets play several roles beyond haemostasis during wound healing as discussed above. 
Additionally, platelet (hemi)ITAM receptors regulate vascular integrity and 
inflammatory responses, and this may affect wound repair process. Therefore, the primary 
aims of my thesis is to investigate the role of CLEC-2 and GPVI in a mouse model of 
skin wound injury. This is based on the hypothesis that the regulation of vascular integrity 
and inflammatory responses by GPVI and CLEC-2 may influence wound healing. As part 
of this, I have also characterised a novel podoplanin cytoplasmic tail-deficient mouse 
model. The question is how much of the action of podoplanin is by signalling through its 
tail. Podoplanin is up-regulated on the keratinocytes during wound healing and may 
influence repair process. Thus, the role of podoplanin cytoplasmic tail in skin wound 
healing has been studied. I have also studied the effect of CLEC-2-podoplanin on 
metabolic changes, mainly glycolysis and arginine metabolism, in inflammatory 
macrophages using metabolomics analysis. This is to understand whether CLEC-2-
podoplanin interaction regulates cellular metabolism in inflammatory macrophages.
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Chapter 2 Materials and Methods 
2.1  Materials 
1.2.1 Reagents and antibodies 
The reagents and antibodies used in this thesis are described in Table 2.1 and Table 2.2, 
respectively.  
Table 2. 1. List of reagents and chemicals used 
Reagents Company Cat No. 
Martius scarlet blue stain kit Atom Scientific RRSK2 
Mayer’s Haematoxylin Sigma MHS32 
Eosin Y solution Sigma HT110232 
Normal goat serum Vector Lab S-1000 
Histo-clear Scientific laboratory supplies NAT1330 
Tissue-Tek optimal cutting 
temperature (O.C.T.) compound 
Sakura Finetek 4583 
1% Acid alcohol Atom Scientific RRSP187-G 
DPX mounting medium Sigma 06522 
Rat anti-mouse GPIbα antibody Emfret Analytics R300 
Anti-podoplanin antibody (for 
injection) 
In-house production  
N-Formyl-Methionyl-Leucyl-
Phenylalanine (fMLP) 
Sigma F3506 
Collagen type I Takeda (formerly Nycomed)  
Fibrinogen Enzyme Research Laboratories MFg 
Thrombin Sigma T4648 
Factor XIIIa Zedira T061 
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Table 2.1. List of reagents and chemicals used (continued.) 
Reagents Company Cat No. 
LPS (from Escherichia coli 
055:B5) 
Sigma L2880 
Recombinant dimeric CLEC-2-
Fc (rCLEC-2-Fc) 
In-house production  
Proteinase K Thermo Scientific EO0491 
Buffer E 10X Buffer Promega R005A 
BSA, Acetylated Promega R396E 
HindIII Promega R604A 
Orange G dye Sigma O3756 
Microclean Labgene Scientific 2MCL-5 
BigDye® Terminator v1.1 & 
v3.1 5X Sequencing Buffer 
Life Technologies 4336697 
 
Table 2. 2. List of antibodies used in immunostaining 
Reagents Working dilution Company Cat No. 
Primary antibodies 
Rat anti-mouse Gr-1 
monoclonal antibody 
1:200 eBiosciences 14-5931-82 
Rat anti-mouse F4/80 
monoclonal antibody 
1:200 (IHC) 
1:100 (IF) 
Bio-Rad MCA497GA 
Rabbit anti-mouse CXCL-1 
monoclonal antibody 
1:200 R&D 
systems 
MAB4532 
Syrian hamster anti-mouse 
podoplanin monoclonal 
antibody 
1:500 (IHC) 
1:200 (IF) 
eBiosciences 14-5381-85 
Rat anti-mouse CD41 
monoclonal antibody 
1:100 BD 
Pharmagen 
553847 
IHC = Immunohistochemistry, IF = Immunofluorescence 
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Table 2.2. List of antibodies used in immunostaining (continued.) 
Reagents Working dilution Company Cat No. 
Primary antibodies 
Rabbit anti-CD31 polyclonal 
antibody 
1:100 Abcam ab28364 
Rabbit anti-NG2 polyclonal 
antibody 
1:200 Merk 
Millipore 
AB5320 
Rabbit anti-tissue factor 
monoclonal antibody 
1:400 Abcam ab151748 
Rabbit anti-TNF alpha 
polyclonal antibody 
1:200 Abcam ab9739 
Rat anti-mouse Ly6C 
monoclonal antibody 
1:200 Biolegend 128002 
Rat anti-mouse CXCL4/PF4 
monoclonal antibody 
1:200 R&D 
systems 
MAB595-100 
Goat anti-mouse fibrinogen 
polyclonal antibody 
1:200 Accurate 
Chemical & 
Scientific 
Corp. 
YNGMFBG7S 
Rabbit anti-vimentin 
monoclonal antibody 
1:200 R&D 
systems 
MAB2105 
Rabbit anti-iNOS polyclonal 
antibody  
1:50 Abcam ab15323 
Rabbit anti-RELM alpha (Fizz-
1) polyclonal antibody  
1:50 Abcam ab39626  
Rat anti-mouse Ly6G-
APC/Cy7-conjugated 
monoclonal antibody (clone 
1A8) 
1:100 BD 
Pharmagen 
560600 
Rat anti-mouse CLEC-2 
monoclonal antibody  
1:200 Bio-Rad 
MCA5700 
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Table 2.2. List of antibodies used in immunostaining (continued.) 
Reagents Working dilution Company Cat No. 
IgG controls 
Rat IgG2b control 1:400 Bio-Rad MCA1125 
Rat IgG1,Ƙ control 1:200 Biolegend 400402 
Golden Syrian hamster IgG 
control 
1:500 (IHC) 
1:200 (IF) 
eBiosciences 14-4914-85 
Rabbit IgG control 1: 10,000 Life 
technologies 
10500C 
Secondary antibodies 
Goat anti-rat IgG-HRP 1:200 (Gr-1) 
1:500 (F4/80, 
CLEC-2) 
Santa Cruz sc-2032 
Goat anti-hamster IgG-HRP 1:500 Santa Cruz sc-2905 
Donkey anti-rabbit IgG-HRP 1:200 GE 
Healthcare 
NA934V 
Donkey anti-goat IgG-HRP 1:500 Santa Cruz Sc-2020 
Goat anti-rat IgG-Alexa 568 1:200 Life 
technologies 
A11077 
Goat anti-rat IgG-Alexa 488 1:200 (vimentin) 
1:100 (F4/80) 
Life 
technologies 
A11006 
Goat anti-hamster IgG-Alexa 
488 
1:200 Life 
technologies 
A21110 
Goat anti-rabbit IgG-Alexa 
647 
1:200 
1:100 (iNOS, Fizz-
1) 
Life 
technologies 
A21245 
Hoechst 1:10,000 Life 
technologies 
H3570 
ImpactDAB substrate  As recommended Vector Lab SK-4105 
IHC = Immunohistochemistry, IF = Immunofluorescence 
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2.2  Mice 
All animal procedures were performed under the regulation of UK laws (Animal 
[Scientific Procedures] Act 1986) with approval of local ethics committee and UK Home 
Office under PPL P0E98D513 and P14D42F37. Transgenic mice used during the course 
of this thesis are on a C57BL/6 background, which are listed in Table 2.3.  
Constitutive GPVI knockout (Gp6-/-) mice was generated as described previously (Kato 
et al., 2003). For conditional deletion of CLEC-2, mice that carry the loxP sites flanking 
exons 3 and 4 of the Clec1b gene (Clec1bfl/fl) were generated. Then Clec1bfl/fl mice were 
bred with either Pf4-Cre recombinase-bearing mice (Finney et al., 2012) or Gp1bα-Cre 
mice (Nagy et al., 2019) to delete CLEC-2 on megakaryocyte/platelet lineage. Gp6-/- and 
Clec1bfl/flPf4-Cre strains were cross-bred to produce DKO mice. Clec1bfl/fl mice were also 
crossed with Cd11c-Cre mice to knockout CLEC-2 on dendritic cells (Finney et al., 2012, 
Acton et al., 2014). Mice with insertion of the loxP sites to Pdpn gene was generated 
(Pdpnfl/fl) and bred with Vav1-Cre mice for conditional deletion of podoplanin on 
haematopoietic lineage (Lax et al., 2017b, Rayes et al., 2017). PdpnCyto mice was 
produced by Taconic Biosciences using clustered regularly interspaced palindromic 
repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology. Three stop codons 
were constitutively inserted immediately before the nucleotide sequence encoding lysine-
164 located in exon 5 of Pdpn gene. Clec1bfl/fl or Pdpnfl/fl or WT mice were used as WT 
controls. 
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Table 2. 3. List of transgenic mouse strains 
Mouse strain Description 
Gp6-/- Constitutive GPVI knockout  
Clec1bfl/flPf4-Cre Platelet-specific CLEC-2 knockout  
Clec1bfl/flGp1bα-Cre Platelet-specific CLEC-2 knockout 
Clec1bfl/flPf4-Cre/Gp6-/- (DKO) Platelet CLEC-2 and GPVI double-knockout 
Clec1bfl/flCd11c-Cre Dendritic cell-specific CLEC-2 knockout  
PdpnCyto Podoplanin cytoplasmic tail deficient 
Pdpnfl/flVav1-cre Haematopoietic cell-specific podoplanin knockout 
 
2.3  DNA extraction and genotyping of PdpnCyto colony 
Tissue samples from adult mice (ear clipping) or embryos (hind paw) were digested by 
incubation at 55 ºC overnight in lysis buffer, containing Tris-hydrochloride (100 mM) pH 
8.5, EDTA (5 mM), sodium dodecyl sulphate (0.2%), sodium chloride (200 mM), with 
proteinase K (1.25 mg/ml per sample). Next, tissue samples were vortexed and 
centrifuged at 16000 g at 4 ºC for 10 minutes, followed by supernatant collection. 
Isopropanol (1:1 v/v) was added to supernatant with gently mixed and centrifuged at 
16000 g at 4 ºC for 20 minutes. The supernatant was discarded. The pellets were left to 
dry for 20 minutes to allow alcohol evaporation, followed by adding DNase-free water. 
The DNA samples were incubated at 55 ºC for one hour before adding into the reaction 
mix for polymerase chain reaction (PCR) amplification with the following primers;  
Forwards: GCTTGTGACATGGAATTCAGC  
Reverse: CGTATTTCCTCAGCAGAACAGG 
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Following PCR amplification, the PCR products were added into reaction mix, containing 
HindIII enzyme, acetylated BSA, and buffer E 10X, and incubated at 37 ºC overnight for 
DNA restriction digestion. Finally, orange G dye was added followed by running 
electrophoresis on 1% agarose gel to obtain the bands of digested PCR products for 
genotype identification. 
2.4  DNA Sequencing of PdpnCyto colony 
Beside HindIII digestion and gel electrophoresis, PCR products were identified using 
standard Sanger sequencing method (Zimmermann et al., 1988). In brief, the PCR 
products were cleaned using Microclean, followed by adding into BigDye reaction mix, 
containing primers shown above, and were subsequently amplified. Next, the PCR 
products were washed twice with ethanol and denatured with formamide at 94 ºC for two 
minutes, followed by cooling down to 0 ºC, which were ready to run on an ABI 3730 
automated sequencer. The signals of nucleotide sequence were analysed using Chromas 
2.6.6 software (Technelysium, AU) based on the reference sequence of murine Pdpn 
(GenBank: AK158855.1). 
2.5  Full-thickness excisional skin wound model 
Male and female WT, Clec1bfl/flPf4-Cre, Gp6-/-, DKO, and PdpnCyto-/- mice at the age of 
8-10 weeks were used for skin wound experiments. Analgesic (buprenorphine) was given 
subcutaneously (s.c.) to all mice at least 30 minutes before procedure, followed by twice 
daily for two consecutive days. Under general anesthesia using isoflurane inhalation, the 
flank area of each mouse was shaved and cleaned, followed by a single cut through whole 
layer of skin using a 4 mm-diameter biopsy punch (Kai Industries, Japan) to generate a 
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full-thickness excisional skin wound (Figure 2.1). All mice were s.c. injected with 0.5 ml 
of 5% glucose-saline solution for rehydration after procedure. Wound size was measured 
using calipers (Moreira et al., 2015) and wound appearance was imaged using a Nikon 
COOLPIX B500 digital camera every day for up to nine days post-injury. Wound area 
was calculated as described below (Moreira et al., 2015) and presented as the percentage 
of initial wound size (Yang et al., 2011).  
Wound area = π x (diameter A/2) x (diameter B/2) 
      Where diameter A = larger diameter of the lesion (vertical length), 
      diameter B = minor diameter of the lesion (horizontal length) 
A second set of wound experiments were performed in Gp6-/- mice in the presence of a 
podoplanin-blocking antibody. Two doses of anti-podoplanin antibody (clone 8.1.1, 100 
µg) that blocks CLEC-2-podoplanin interaction in vivo (Rayes et al., 2018, Rayes et al., 
2017, Payne et al., 2017) or Syrian hamster IgG isotype control were intravenously (i.v.) 
injected into Gp6-/- mice at 24 hours prior and after wounding. Wound size was monitored 
for three days post-injury. 
For a pilot wound experiment in platelet depletion model, an anti-GPIbα antibody (1.5 
µg/g) was i.v. injected into WT mice 24 hours before biopsy (Rayes et al., 2017). Wound 
bleeding was monitored every 30 minutes.  
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Figure 2. 1. Full-thickness excisional skin wound model in mice. The animal was 
placed in a lateral position. Then the flank skin was folded. Finally, the punch was gently 
pressed and slowly screwed on the folded skin to cut the whole layer of skin (left). As 
shown, the muscle underneath the skin was exposed after biopsy (right). 
 
2.6  Microscopy 
2.6.1 Tissue processing for histology 
Tissue samples, including wound tissues, multi-organs from adult mice, and whole 
embryos (E14.5), were processed using a standard paraffin embedding protocol (Canene-
Adams, 2013). In brief, wounds were excised and the inner side was firmly pressed onto 
a piece of filter paper to hold the tissue, which prevents curling during processing. All 
tissue samples were fixed in 4% paraformaldehyde for 24 hours. Next, tissues were put 
into tissue cassettes, followed by dehydration with graded ethanol (70% for 30 minutes, 
95% for 30 minutes, two changes in 100% for 30 minutes each) and two changes (one 
hour each) in Histo-clear at room temperature, respectively. After that, tissues were 
immersed into two changes (one hour each) of melted paraffin at 65 ºC to allow paraffin 
infiltration. Finally, tissues were put into the moulds pre-filled with melted paraffin and 
allowed to cool. Once the paraffin was hardened, tissue blocks were removed from the 
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moulds. Paraffin-embedded tissues from adult mice were sectioned at 5 µm by microtome 
(Leica Biosystems, UK) and from embryos at 10 µm. In addition to paraffin-embedding, 
wound tissues were excised, held with filter paper, and directly embedded in optimal 
cutting temperature (O.C.T) compound, and frozen at -80 ºC. These O.C.T-embedded 
tissues were sectioned at 10 µm by Cryostat (Bright instruments, UK). 
2.6.2 Morphometric analysis 
Paraffin-embedded skin samples and other tissues were stained with haematoxylin and 
eosin (H&E) and imaged using a ZEISS AxioScan.Z1 slide scanner for microscopic 
examination. In skin histology (Figure 2.2), the thickening of keratinocytes (hyperplastic 
epidermis; He) appears at the wound edge within a few days after injury. The formation 
of granulation tissue, which comprised of newly formed vasculatures, infiltrating cells, 
and molecules, is also observed. The migration of keratinocytes generates epithelial 
tongues underneath the scab and above the granulation tissue (red dotted line), which 
migrate towards the centre of the wound to resurface skin epithelium (Shaw and Martin, 
2009, Lucas et al., 2010, Yang et al., 2011).  
Morphometric analysis was performed in low power field images of skin histology. All 
parameters were measured manually using a freehand or straight line tool in Fiji (a 
distribution of ImageJ software) (Schindelin et al., 2012), and the terms were defined in 
the following ways; 
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Figure 2. 2. Schematic demonstration for morphometric analysis of skin histology. 
Top: illustration shows morphometric parameters for the assessment of wound healing. 
Red arrow indicates the tips of epithelial tongue. Black arrow points to wound edge. All 
abbreviations are described in the text. Bottom: representative low power field image of 
skin histology at day 3 post-injury. Dotted red line indicates migration of keratinocytes 
from the wound edges toward centre. Dotted black coverage represents the granulation 
tissue area. 
 
 Re-epithelialisation is the re-generation of skin epidermis, which comprises of 
proliferation and migration of keratinocytes (Ben Amar and Wu, 2014, Stavrou et 
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al., 2018). In histology images, the area of thickening of keratinocytes immediately 
adjacent to the normal skin was considered as the wound edge for measuring re-
epithelialisation (Stavrou et al., 2018, Chen et al., 2015, Oda et al., 2017, Sheets et 
al., 2016, Carretero et al., 2008, Schmidt and Horsley, 2013). Percentage of re-
epithelialisation at day 3 post-injury was calculated using the formula (Stavrou et 
al., 2018, Chen et al., 2015); 
% Re-epithelialisation = [(E1+E2)/W0] x 100 
where E1 and E2  = distance of epithelial tongue from each side of wound edge     
W0 = original wound diameter at day 0  
 Unlike human, wound contraction significantly affects wound closure in rodents. 
The specialised muscle panniculus carnosus (PC) in deeper layer of murine skin 
contributes to wound contraction (Davidson et al., 2013). To examine the influence 
of this effect, closure by contraction at day 3 post-injury was calculated using the 
formula (Chen et al., 2015);  
% Wound contraction = [(W0-WT)/W0] x 100 
where WT = distance between the wound edges at indicated time point 
 The area of granulation tissue was also measured at day 3 post-injury (Lucas et al., 
2010, Yang et al., 2011). 
 Scar formation following the complete wound closure was evaluated at day 9 post-
injury. This includes the length of hyperplastic epidermis (the remaining thickened 
keratinocytes) (Yang et al., 2011, Rono et al., 2013) and the distance between intact 
subcutaneous (Sc) edges at both side of the wound (“X” in Figure 2.2) (Yang et al., 
2011), which represents the size of scar at upper and deeper layers, respectively. 
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2.6.3 Measurement of fibrin and collagen contents 
The slides of paraffin-embedded skin sections were dewaxed in two changes of Histo-
clear (five and three minutes, respectively), followed by rehydration with graded ethanol 
(three minutes in 100%, 95%, 70%, 50%, and 30%, respectively) and water (five 
minutes). Then, Martius scarlet blue staining was performed to detect fibrin and collagen 
according to the protocol recommended by manufacturer. Tissue slides were dehydrated 
in graded ethanol (three minutes in 70%, 95%, and 100%) and two steps in Histo-clear 
(five minutes and overnight, respectively). The tissue slides were mounted with DPX 
mounting medium and left dry, followed by imaging. For quantitative analysis, high 
power field (HPF) images were taken from the whole wound area (an example is shown 
in Figure 2.3).  
 
 
Figure 2. 3. An example histology image demonstrates how to obtain high power 
field (HPF) images. Each rectangle represents a single HPF image. For consistency of 
the procedure, HPF images were taken from the bottom (left → right) to the top area of 
all samples, which covered both granulation tissue and scab area.  
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A relative quantification of fibrin and collagen contents was performed using Fiji by the 
following steps; 
1) Image colours were isolated using Colour Deconvolution plugin (Masson 
Trichrome) (Ruifrok and Johnston, 2001) to obtain green, red, and blue 
colour channel, respectively. 
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2) The red colour (for fibrin) or blue colour (for collagen) channel was 
converted to binary image (8 bit). Threshold was set using the Otsu method 
(Luo et al., 2018).  
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3) The measurements, including “integrated density” were selected and 
measured. 
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4) A total intensity (RawIntDen) derived from all HPF images was 
normalised by total measured area (i.e. per HPF), and expressed as fold 
relative to WT. 
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2.6.4 Immunohistochemistry 
Immunohistochemistry staining for podoplanin, CLEC-2, fibrinogen, tissue factor, Gr-1, 
Ly6C, F4/80, TNF-α, CXCL-1, and PF4 were performed on paraffin-embedded tissue 
sections according to a standard protocol (Ramos-Vara, 2017). In brief, the slides of skin 
sections were dewaxed and rehydrated as stated in the previous section. For antigen 
retrieval, tissues were incubated in preheated citrate buffer (10 mM citric acid 
monohydrate+0.5% Tween 20, pH 6.0), and boiled for 15 minutes (skin samples) or 30 
minutes (other tissues). After cooling down at room temperature, tissues were washed 
once (10 minutes) in phosphate buffer saline with 0.1% Tween (PBST) and treated with 
3% hydrogen peroxide solution (10 minutes) to block endogenous peroxidase, followed 
by one hour incubation with blocking buffers, either 5% goat serum + 1% BSA in PBST 
or 5% BSA in PBST. Next, tissue sections were incubated with primary antibodies at 4 
ºC overnight, followed by three washes in PBST (30 minutes each) and one hour 
incubation with horseradish peroxidase (HRP)-conjugated secondary antibodies. After 
three washes in PBST (10 minutes each), ImpactDAB substrate were used for signal 
detection. The tissues were counterstained with haematoxylin (two minutes and wash in 
water), followed by colour differentiation in 1% acid alcohol (two dips and wash in 
water), and bluing with Scott’s tap water (two minutes and wash in water). Finally, tissue 
slides were dehydrated and mounted, followed by imaging as described in the previous 
section. HPF images were taken from the whole wound area for further quantitative 
analysis. 
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Gr-1+, Ly6C+, and F4/80+ cells were counted using Fiji, according to a protocol shown 
below. Then, the total cell count was normalised by total measured area and presented 
per HPF (Qiang et al., 2017). 
1) Brown colour was separated using IHC toolbox in Fiji plugins. H-DAB 
mode, followed by “color” button, was selected. 
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2) Image was converted to binary image (8 bit) and threshold was set using 
“Ostu” mode to obtain a good signal with minimal background. 
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3) Thresholded image was undergone binary process using “fill holes” to fill 
the possible holes that arose from colour separation process, followed by 
“watershed” to separate attached particles/cells. 
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4) The “oval selection tool” was used to select the possible smallest size of 
signal/particle in the image, followed by “Analyze particles” mode with 
no any settings. Then, the “Summarize” box, followed by “OK” button, 
was selected to measure the size of such smallest particle (in a square pixel 
unit). 
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5) The “Analyze particles” mode was used again to set the range of particle 
size in square pixel unit (e.g. 20-infinity). To count all particles within the 
image except on edges, “Summarize” and “Exclude on edges” boxes, 
followed by “OK” button, were selected. 
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To quantify the intensity of tissue factor (Zhou et al., 2009), TNF-α, PF4, podoplanin, 
and CXCL-1 (Smith et al., 2010), HPF images were processed using step 1 and 2 shown 
above, followed by “Measure” mode in “Analyze” menu in Fiji. Then the total intensity 
(RawIntDen) was normalised by total measured area (i.e. per HPF), and expressed as fold 
relative to WT. 
2.6.5 Immunofluorescence 
Immunofluorescence staining for NG2, CD41, podoplanin, vimentin, Ly6C, Ly6G, 
F4/80, iNOS, Fizz-1, and CD31 were processed in O.C.T-embedded frozen skin sections. 
In brief, tissue slides were placed at room temperature for 30 minutes to allow O.C.T. 
melting, and then fixed in iced-cold acetone for 20 minutes, followed by drying at room 
temperature for 30 minutes and wash once in PBST (five minutes). Next, tissues were 
permeabilised in 0.5% Triton X-100 (10 minutes) and wash in PBST (five minutes), 
followed by auto-fluorescence quenching using 20 mM ammonium chloride (15 
minutes). After that, tissue slides were incubated with blocking buffer for one hour at 
room temperature and then primary antibodies at 4 ºC overnight. After three washes in 
PBST (30 minutes each), tissues were incubated with fluorophore-conjugated secondary 
antibodies for one hour in the dark at room temperature and washed again with PBST 
(three times, 30 minutes each). Nuclei were stained with Hoechst (five minutes) and 
washed three times (five minutes each), followed by mounting and imaging. For 
subsequent quantification, HPF images were taken from the whole wound area.  
To measure CD31+ area (Uchiyama et al., 2014), the single-colour (green) fluorescence 
images was converted to binary images as shown in the previous section, followed by 
Otsu thresholding. Then, “Measure” mode from “Analyze” menu was used to measure 
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area fraction (% area covered by positive signal). Finally, the total % area was normalised 
by total measured area (i.e. per HPF), and presented as fold relative to WT. 
The M1 (iNOS+F4/80+ cells) and M2 (Fizz-1+F4/80+ cells) macrophages were counted 
according to the previous protocol (Arqués et al., 2012) with adaptation as presented in 
the following steps; 
1) HPF image was split into a single blue (nuclei), green (F4/80) and red 
(iNOS or Fizz-1) channel, respectively.  
 
2) The threshold of green fluorescence was set using Otsu model.  
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3) Then, the binary images were processed by a “watershed” to separate 
attached particles.  
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4) The red fluorescence was thresholded without a “watershed” process.  
5) To create a merged image of previously processed red and green channels, 
the “image calculator” mode from “process” menu was used, followed by 
choosing the operator “AND”.  
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6) All connected areas larger than 20 square pixels were counted using 
“Analyze particles” mode as shown in the previous section. The total cell 
count was normalised by total measured area and presented per HPF.  
 
 
2.7  In vitro neutrophil migration towards fMLP assay 
Bone marrow-derived neutrophils from WT and DKO mice were isolated as previously 
described (Swamydas and Lionakis, 2013). Neutrophils were suspended in Hank’s 
Balanced Salt Solution + 0.5 % BSA. The µ-slides (Ibidi) were pre-coated with either 
collagen (10 μg/ml) or fibrinogen (100 μg/ml) or cross-linked fibrin (prepared by mixing 
fibrinogen (1 mg/ml), thrombin (1 U/ml), Ca2+ (10 mM), and FXIIIa (7 μg/ml) in PBS 
and incubated for 1 hour at 37 °C). fMLP (5 µM) was added into lower chamber of µ-
slides (Figure 2.4). Next, neutrophils (50,000 cells) were loaded into upper chamber and 
chemotaxis toward fMLP was assessed for 3 hours.  
Merged channel Red channel 
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Figure 2. 4. Schematic demonstration of in vitro neutrophil migration towards fMLP 
assay using µ-slides. fMLP slowly diffuses through matrix-filled platform to the cell-
containing side (chamber), which spontaneously generates fMLP concentration (Conc.) 
gradient. Matrix means either collagen or fibrinogen or cross-linked fibrin. 
 
The cells in the loaded and migrated chambers were fixed with formalin and subsequently 
imaged. The number of cells in five representative areas per sample was quantified using 
Fiji as shown below.  
1) Background was subtracted by setting rolling ball radius at 50 pixels  
 
Load cells 
Load fMLP 
Direction of 
cell migration 
Upper chamber 
Lower chamber 
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Top view Side view 
fMLP Cells 
Matrix 
High Low 
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2) Image was converted to 8 bit and the threshold was set using Ostu model. 
 
3) Cells were counted using “Analyze particles” mode in “Analyze” menu. 
The minimal size was estimated according to the previous section and set 
at 100 square pixels. 
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4) Percentage of migrated cells was calculated using the formula;  
Percent neutrophil migration = [N1/(N1+N2)] x 100 
Where N1 = numbers of migrated cells,  
N2 = numbers of remaining cells in loaded chamber 
 
2.8  Haematological analysis 
Whole blood was collected from the inferior vena cava using ethylenediaminetetraacetic 
acid (EDTA)-filled syringe. Blood counts were analysed on an ABX Pentra 60 (Horbia 
Ltd, UK).  
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2.9  Untargeted metabolomics analysis 
2.9.1 Bone marrow-derived macrophage culture 
Hind legs of adult WT and Pdpnfl/flVav1-cre mice were cut after cervical dislocation. 
Then, femur and tibia were taken. To collect progenitor cells, bone marrow cavity was 
inserted with 25 gauge needle and gently flushed with collection medium (DMEM+10% 
FBS+1% penicillin/streptomycin/L-glutamine) under the control of 10 ml syringe. Cell 
suspension was centrifuged at 400 g for 8 minutes at room temperature. After discarding 
the supernatant, cell pellet was re-suspended in collection medium and filtered through 
cell strainer. Total cells were counted by haemocytometer and adjusted to 2 x 106 cells/ml 
in macrophage complete medium (DMEM + 20% (v/v) L-929 conditioned medium, 
which contains M-CSF). Then, cell concentration was diluted to 2 x 107 cells/10 ml of 
macrophage complete medium and transferred to a sterile plastic non-coated 10 cm Petri 
dish to seed cells in 37 ºC, 5% CO2 incubator (day 1). At day 4, another 5 ml of 
macrophage complete medium was added into each Petri dish. At day 7, the culture 
medium was discarded and replaced by 10 ml of fresh macrophage complete medium 
(Lee and Hu, 2013).  
2.9.2 LPS stimulation 
At day 8, macrophages were counted and 3 x 105 cells were seeded into 6-well plate. WT 
macrophages were incubated in three conditions, including no treatment, LPS (1 µg/ml), 
and LPS plus rCLEC-2-Fc (20 µg/ml) for 24 hours in 37 ºC, 5% CO2 incubator. 
Pdpnfl/flVav1-cre macrophages were divided into no treatment and LPS-treated groups, 
respectively.  
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The rCLEC-2-Fc was kindly provided by Ying Di in Watson laboratory. In brief, this 
recombinant protein was produced using the following method. The extracellular domain 
region of mouse CLEC2 was cloned into pFusion-Rabbit FC expression vector (In 
ViVogen). The construct was used with polyethylenimine to transiently transfect into 
human embryonic kidney (HEK) 293T cells. The stable clones were selected with Zocin 
and high expression of mouse rCLEC-2-Fc clone was screened from the cell culture 
supernatant. Then the recombinant protein was produced from the selected positive stable 
clone. The cell culture supernatant was collected, filtered by 0.22 µm filter, went through 
and purified by Protein G column, and therefore eluted by 0.1M pH3 glycine with 
immediately neutralised by 1M Tris pH 8 buffer. The elutes were pooled and dialysed 
against PBS. The obtained recombinant protein was characterised by SDS-PAGE and 
Western blot. The biological activity was verified by specific binding to mouse 
podoplanin on LPS-stimulated Raw cells via flow cytometry. 
2.9.3 Metabolite extraction for metabolomics analysis 
After LPS challenge, macrophage extraction was performed as previously described (Fei 
et al., 2016). In brief, all cells were washed once with ice cold PBS followed by adding 
500 µl of cold extraction mixture containing methanol/ethanol/water (2:2:1 v/v) and cells 
were detached from 6-well plate using a cell lifter. Then, cell suspension was collected 
into 1.5 ml tube containing two ball bearings (2-mm diameter) (LabTIE B.V., the 
Netherlands) and vigorously vortexed for 2 minutes, followed by centrifugation at 9500 
g for 3 minutes at 4 ºC without bearings. The supernatant was collected. The pellet was 
re-extracted as above with minimal volume (50 µl) of cold extraction mixture. Cell extract 
was dried and re-solubilised according to the previous protocol (Fei et al., 2016). 
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2.9.4 Ultra High Performance Liquid Chromatography-Mass Spectrometry 
In collaboration with the Phenome Centre at the University of Birmingham, untargeted 
metabolomics analysis was performed. In brief, the polar metabolites was examined using 
the hydrophilic interaction liquid chromatography (HILIC)/mass spectrometry (MS) 
method (Fei et al., 2016), which run on a Dionex UltiMate 3000 Rapid Separation LC 
system (Thermo Fisher Scientific, USA) coupled with a heated electrospray Q Exactive 
Focus mass spectrometer (Thermo Fisher Scientific, USA). The LC-MS spectra were 
processed, including the conversion to mass spectrometer output file format (mzML) 
using the open access ProteoWizard software (Kessner et al., 2008) and deconvolution 
using XCMS software (Smith et al., 2006). The putative metabolites were 
identified/annotated by matching the mass-to-charge (m/z) and the retention time, which 
was performed by applying the PUTMEDID-LCMS workflow operating in the Taverna 
workflow environment (Dunn et al., 2013, Brown et al., 2011, Sumner et al., 2007). The 
peak area of individual metabolite was used as arbitrary unit of expression. The 
metabolite of interest from each sample was presented as fold change relative to the mean 
value in unchallenged WT (Di Guida et al., 2016).  
2.10   Statistical analysis 
All data are presented as mean ± standard error of mean (SEM). Kinetics of wound closure 
was compared by two-way ANOVA with Bonferroni’s multiple comparison test. Mean 
differences in other parameters were analysed by either Student’s t-test (two-group 
comparison) or one-way ANOVA with Bonferroni post-hoc test (more than two groups) 
using GraphPad Prism software. p<0.05 was considered as statistically significant. 
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Chapter 3 Skin Wound Healing in Mice: the Role of 
Platelet (hemi)ITAM Receptors 
3.1 Introduction 
Wound healing is a complex mechanism, which involves various cellular and molecular 
interplays with platelets playing a key role at different stages of the healing process. The 
role of platelets in wound repair is not limited to the formation of an aggregate to stop 
bleeding during tissue injury. Several lines of evidence have shown that platelets release 
growth factors and cytokines, which potentially promote tissue repair in multiple ways 
(Etulain, 2018, Scully et al., 2018). For example, platelet-rich plasma containing VEGF, 
PDGF, and fibroblast growth factor 2, facilitates wound closure by enhancing re-
epithelialisation, demal regeneration, and angiogenesis in a murine model of full 
thickness skin wound (Yang et al., 2011). In addition, meta-analysis of animal 
experiments, including eight rodent and ten non-rodent studies, indicates that platelet-rich 
plasma provides positive outcomes in the healing of full thickness skin wound, suggesting 
its use as an adjucntive treatment in veterinary wound care (Tambella et al., 2018). 
Moreover, platelet-rich fibrin enhances angiogenesis and promotes wound healing in 
diabetic mice (Ding et al., 2017).  
Although the potential advantages of platelets in wound healing have been described, 
somewhat surprisingly, the results of one study argue against the contribution of platelets 
in wound healing, including the primary role in haemostasis, by demonstrating that skin 
wound healing is not impaired in thrombocytopenic mice (Szpaderska et al., 2003). In 
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this model, rabbit anti-mouse platelet serum was used to deplete platelets. There is no 
report of uncontrolled bleeding in these thrombocytopenic mice after a full thickness skin 
biopsy, except the evidence of increased haemorrhage within the wound bed. The number 
of inflammatory cells, especially macrophages is increased, which is proposed to clear 
the extravascular red blood cells in thrombocytopenic mice. However, the rate of 
macroscopic wound closure, re-epithelialisation, angiogenesis, and collagen deposition 
are normal in these platelet-depleted mice (Szpaderska et al., 2003).  
Murine platelets express two (hemi)ITAM receptors, including GPVI and CLEC-2, which 
signal through a similar Src/Syk-dependent pathway for platelet activation (Watson et al., 
2010, Suzuki-Inoue et al., 2011). During dermatitis, GPVI null mice demonstrate vascular 
leakage following neutrophil diapedesis in the inflamed skin (Gros et al., 2015) whereas 
the bleeding is not observed in platelet-specific CLEC-2 knockout mice (Rayes et al., 
2018). However, lack of both platelet GPVI and CLEC-2 increases intra-skin bleeding in 
this model (Rayes et al., 2018). In a similar fashion, GPVI-deficient mice treated with 
antibody against podoplanin, the endogenous ligand for CLEC-2, enhances inflammatory 
bleeding phenotype (Rayes et al., 2018), suggesting a role for the CLEC-2-podoplanin 
axis in inflammatory haemostasis in the absence of GPVI. These observations support the 
primary role of GPVI in inflammatory haemostasis whereas CLEC-2-podoplanin 
interaction partially compensates this function in the absence of GPVI. This mechanism 
is independent of classical αIIbβ3-mediated haemostasis (Ho-Tin-Noe et al., 2018). 
GPVI has also been reported to mediate pro-inflammatory activity in several disease 
models, including in skin inflammation. For example, GPVI contributes to neutrophil-
mediated tissue damage in cutaneous rpA, an immune complexes-induced inflammation 
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(Gros et al., 2015). In addition, GPVI knockout mice show an increase in M2 anti-
inflammatory macrophages, which contributes to a reduction in pain during paw skin 
inflammation (Pierre et al., 2017). In contrast, CLEC-2-podoplanin axis demonstrates 
anti-inflammatory activity, which protects from organ damage and attenuates 
inflammation during acute lung injury (Lax et al., 2017b) and sepsis (Rayes et al., 2017). 
In skin wound healing, it is speculated that platelet CLEC-2 also binds podoplanin on 
keratinocytes, which inhibits keratinocyte migration while the wound bed is being 
prepared at the initial phase (Asai et al., 2016). Moreover, intradermal injection of human 
podoplanin-positive monocytes in combination with platelets allows interaction of 
CLEC-2 to podoplanin, which accelerates skin wound healing by promoting 
lymphangiogenesis (Hur et al., 2014). 
Previous evidences have shown that the leakage of blood vessels may produce potential 
benefits in wound healing. At the initial phase of skin wound healing, the increase in 
vascular permeability is generally observed. This extensive vascular leakage allows 
extravasation of repair-associated plasma components, including fibrinogen and growth 
factors, into the wound to facilitate healing process (Shaterian et al., 2009, Mendonca et 
al., 2010). Mast cell-derived histamine, which increases vascular permeability, has also 
shown to promote skin wound healing in mice (Numata et al., 2006, Weller et al., 2006) 
whereas anti-histamine attenuates this effect (Weller et al., 2006).  
According to their effects in the maintenance of vascular integrity and inflammatory 
responses during skin inflammation, it is possible that GPVI and CLEC-2 may also 
influence the wound healing process. The aim of this chapter is to investigate the role of 
CLEC-2 and GPVI in a mouse model of skin wound injury. A single full-thickness 
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excisional skin wound (4 mm-diameter) was generated in male and female WT, 
Clec1bfl/flPf4-Cre, Gp6-/-, as well as DKO mice. Wound size was monitored on a daily 
basis for up to 9 days post-injury. Wound tissue was collected at day 1, 3, and 9 post-
injury for histological and immunohistochemistry/immunofluorescence analyses. 
Clec1bfl/flPf4-cre and DKO mice display blood/lymphatic mixing and moderate 
thrombocytopenia (Bender et al., 2013, Rayes et al., 2018). Therefore, wound healing 
was monitored for 3 days post-injury (the major changes are seen by this time) in Gp6-/- 
mice injected with podoplanin-blocking antibody to recapitulate the DKO setting in the 
absence of these defects. Moreover, to clarify the haemostatic function of platelets in 
wound repair, a pilot experiment of skin wound in thrombocytopenic mice was 
performed. 
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3.2 Results  
3.2.1 The ligands for GPVI and CLEC-2 are present at perivascular area during 
skin wounding 
CLEC-2 and GPVI play a key role in inflammatory haemostasis in the inflamed skin 
(Rayes et al., 2018), thereby, the presence of GPVI and CLEC-2 ligands in the skin before 
and after wounding was assessed. In unchallenged WT murine skin, collagen, a GPVI 
ligand, was highly distributed throughout skin dermis and hypodermis, including the area 
underneath blood vessels (Figure 3.1 A). Podoplanin was mainly detected on lymphatic 
endothelial cells and cells around the blood vessels (Figure 3.1 B). At day 3 post-injury, 
podoplanin was upregulated on migrating keratinocytes, and on stromal and infiltrating 
cells within the granulation tissue in all mouse strains (Figure 3.1 C). Podoplanin 
expression was also observed surrounding blood vessels (NG2+) (Figure 3.2 A). Further 
characterisation of podoplanin-expressing cells at perivascular area in all groups revealed 
the upregulation of podoplanin on many cell types around the blood vessels, including 
pericytes (NG2+) (Figure 3.2 A), fibroblasts (vimentin+), infiltrating monocytes (Ly6C+), 
and macrophages (F4/80+) (Figure 3.2 B). The level of perivascular podoplanin was 
increased in Clec1bfl/flPf4-cre mice compared to WT mice (Figure 3.2 A, B). In DKO 
mice, podoplanin expression was similar to that observed in WT and Gp6-/- mice (Figure 
3.2 A, B).  
Platelets (CD41+) were observed in proximity to the vessel wall (surrounded by NG2+ 
pericytes) in WT, Clec1bfl/flPf4-cre, and Gp6-/- mice (Figure 3.2 A, arrow). There was no 
notable evidence of extravascular localisation of platelets in these mouse strains. In DKO 
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mice, platelets were more widely distributed, including at the vessel wall and in the tissue 
close to blood vessel (Figure 3.2 A, star), supporting the vascular leakage observed in 
these mice. In WT and Gp6-/- mice, the mean platelet count at baseline was 700-800 x 103 
cell/mm3 (Figure 3.2 C). The platelet counts prior to injury in Clec1bfl/flPf4-cre and DKO 
mice were 600 and 500 x 103 cell/mm3, which is 25% and 40% lower than in WT, 
respectively (Figure 3.2 C). However, platelet counts (Figure 3.2 C) and blood 
haemoglobin (Figure 3.2 D) were not significantly altered during wound healing in all 
groups. 
Overall, these results demonstrate that in mouse skin, platelets are observed in proximity 
to the vessel wall during the initial wound healing process where the ligands for GPVI 
and CLEC-2 are also present. Lack of GPVI and CLEC-2 leads to leakage of platelets 
into perivascular tissue. Deletion of platelet CLEC-2 is associated with the increased 
infiltration of podoplanin-expressing cells at the perivascular space during inflammatory 
phase of wound healing while combined deletion with GPVI compromises this 
phenotype. 
3.2.2  Skin wound healing is accelerated in GPVI and CLEC-2 double-deficient 
mice 
The pilot experiment of skin wound generated using 4-mm diameter punch biopsy in WT 
mice shows that the wound was completely closed by nine days post-injury. Therefore, 
wound healing between tested mouse strains was compared during this timeframe. 
Bleeding was mild (not severe) in WT and all transgenic mice after the initial injury 
(Figure 3.3 A). A wound scab was clearly observed at day 1 post-injury. In addition, 
oedema occurred during day 1-4 post-injury in all groups (Figure 3.3 A). The skin wound  
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A                                                                          B 
 
Figure 3. 1. Collagen and podoplanin are present around blood vessels of murine 
skin. (A) Martius scarlet blue staining shows collagen (blue) in dermis and hypodermis 
of unchallenged WT mouse skin (n=5). Red = old fibrin, blue = collagen, yellow = red 
blood cells/fresh fibrin. Scale bar = 100 µm. (B) Immunohistochemistry of podoplanin 
(brown) in unchallenged WT mouse skin (n=5). L = lymphatic vessel, KC = keratinocyte. 
PDPN = podoplanin. BV = blood vessel. Scale bar = 100 µm. (C) Representative image 
of podoplanin immunohistochemistry staining (brown) in all mouse strains at day 3 post-
injury (n=6). S = scab, G = granulation tissue. Arrow points to podoplanin on migrating 
keratinocytes. Scale bar = 500 µm.  
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Figure 3.2. 
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Figure 3. 2. Podoplanin-expressing cells are present at perivascular area in contact 
with platelets during skin wound repair. (A) Immunofluorescence staining of NG2 
(red), podoplanin (green) and CD41 (white) illustrates platelets and podoplanin-
expressing pericytes (NG2+) around blood vessel at day 3 after injury (n=5-7). Hoechst 
counterstains nuclei (blue). BV = blood vessel. Arrow points to platelets at perivascular 
site. Star indicates extravascular localisation of platelets. Scale bar = 20 µm. (B) 
Podoplanin (green) was double-stained with either vimentin (white; top panel) or Ly6C 
(white; middle panel) or F4/80 (white; bottom panel), which are located around blood 
vessel at day 3 after injury (n=4-5). Scale bar = 20 µm. (C) Platelet counts at baseline 
(n=10), day 3 post-injury (n=6-9), and day 9 post-injury (n=10-13). (D) Blood 
haemoglobin at baseline (n=10), day 3 post-injury (n=6-9), and day 9 post-injury (n=10-
13). Data are presented as mean ± SEM and analysed by one-way ANOVA with 
Bonferroni’s multiple comparison test. **p<0.01. 
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of DKO mice showed a dark red-to-black colour on scab and increased redness around 
the wound edge at day 1-3 post-injury compared to other mouse strains (Figure 3.3 A). 
Gp6-/-mice also had a more moderate redness surrounding the wound during this period 
compared to WT mice. However, the macroscopic wound appearance was identical in all 
groups at day 4 post-injury and was sustained to the end of experiment (Figure 3.3 A). 
Although all mouse strains demonstrated full wound closure within nine days post-injury, 
there was an accelerated rate of healing in DKO mice, represented by a significantly 
smaller wound size than in WT controls at day 1-5 post-injury, and then single knockout 
mice at day 2-3 post-injury, respectively (Figure 3.3 B).  
Macroscopic measurement using callipers did not differentiate wound size between WT 
and DKO mice in later phases (day 6-9 post-injury) (Figure 3.3 B). However, histological 
analysis of wound scar at day 9 post-injury illustrated that these ITAM-receptors double-
deficient mice had a faster rate of both epidermal and dermal regeneration than in WT 
mice (Figure 3.3 C). This was indicated by a shorter length of hyperplastic epidermis in 
DKO compared to WT and Clec1bfl/flPf4-cre mice (Figure 3.3 C, D) and a narrower 
distance between subcutaneous edges in the deeper dermis layer of DKO skin compared 
to WT controls (Figure 3.3 C, E). Gp6-/- mice did not exhibit significant differences in 
wound scar at day 9 post-injury compared to DKO mice (Figure 3.3 D, E).  
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Figure 3. 3. Platelet ITAM-receptors deficiency accelerates skin wound healing. (A) 
Macroscopic appearance of the wound at indicated time points is shown. (B) Percentage 
changes in wound size over nine days post-injury (n=10-13). Graphs are presented as 
mean ± SEM. Kinetics of wound closure are analysed by two-way ANOVA with 
Bonferroni’s multiple comparison test. *p<0.05, **p<0.01. *WT vs. DKO, 
+Clec1bfl/flPf4-cre vs DKO, #Gp6-/- vs. DKO. (C) H&E staining of the skin wound tissue 
at day 9 post-injury (n=9-13). Scale bar = 200 µm. a = length of hyperplastic epidermis, 
b = inter-subcutaneous distance. (D) Assessment of the length of hyperplastic epidermis. 
(E) Measurement of inter-subcutaneous distance. Data from females (open symbols) and 
males (closed symbols) are shown in (E) and (D). Data are presented as mean ± SEM and 
analysed by one-way ANOVA with Bonferroni’s multiple comparison test. *p<0.05. 
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3.2.3 Re-epithelialisation and angiogenesis are enhanced at the early phase of 
wound healing in DKO mice 
In order to investigate the mechanisms involved in the accelerated wound healing in DKO 
mice, a three-day wound experiment was performed. When wound closure was 
monitored, there was again a significant reduction in wound size of DKO mice at day 1-
3 post-injury, compared to WT mice (Figure 3.4 A), indicating the reproducibility of this 
model. Histological analysis of skin at day 3 post-injury revealed that re-epithelialisation, 
a process of epidermal regeneration from the wound edge toward the center of the wound, 
was observed in all tested groups (Figure 3.4 B). However, DKO mice exhibited a 
significantly accelerated rate of re-epithelialisation relative to WT and Clec1bfl/flPf4-cre 
mice but not Gp6-/- mice (Figure 3.4 B, C) with no differences in wound contraction 
between all groups (Figure 3.4 B, D). In addition, a greater extent of granulation tissue 
was observed in DKO mice than WT controls (Figure 3.4 E).  
The density of blood vessels (CD31+) (Figure 3.5 A) and lymphatic vessels (podoplanin+) 
(Figure 3.5 B) in unchallenged skin was similar among all groups. During wound healing, 
DKO mice had a wide distribution of CD31+ cells within the wound at day 3 post-injury 
(Figure 3.5 C), which was supported by a significant increase in the CD31-labelled area 
(Figure 3.5 D), compared to all other groups.  
Together, these data suggest that DKO mice have an enhanced rate of wound repair, 
including re-epithelialisation, granulation tissue formation, and angiogenesis, all of which 
begin at the early stage. 
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Figure 3. 4. DKO mice demonstrate a faster rate of wound closure, re-
epithelialisation, and granulation tissue formation. (A) Kinetics of wound closure over 
three days post-injury (n=6-9). (B) H&E staining at day 3 post-injury (n=6-9). Dotted red 
line indicates hyperplastic coverages. Red arrow indicates gap between epithelial tongues. 
Black arrow points to wound edge. S = scab, G = granulation tissue. Scale bar = 500 µm. 
(C) Measurement of re-epithelialisation. (D) Assessment of wound contraction. (E) 
Quantification of granulation tissue area. Data from females (open symbols) and males 
(closed symbols) are shown in (C-E). All graphs are presented as mean ± SEM. Kinetics 
of wound closure (A) are analysed by two-way ANOVA with Bonferroni’s multiple 
comparison test. **p<0.01 in WT vs. DKO. Other parameters (C-E) are analysed by one-
way ANOVA with Bonferroni’s multiple comparison test. *p<0.05. 
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Figure 3. 5. Combined GPVI and CLEC-2 deletion enhances angiogenesis at early 
phase of wound repair. (A) Immunofluorescence staining of CD31 (green), a marker of 
endothelial cells, in unchallenged skin of WT and genetically modified mice (n=5). 
Hoechst counterstains nuclei (blue). (B) Podoplanin staining (brown) on lymphatic 
vessels in unchallenged skin of WT and genetically modified mice (n=5). PDPN = 
podoplanin. (C) Detection of endothelial cells (CD31+; green) in wound area at day 3 
post-injury. (D) Quantification of CD31+ area within the wound at day 3 post-injury (n=5-
6). Data from females (open symbols) and males (closed symbols) are shown in (D). 
Graphs are presented as mean ± SEM and analysed by one-way ANOVA with 
Bonferroni’s multiple comparison test. *p<0.05. Scale bar = 50 µm. 
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3.2.4 DKO mice demonstrate vascular leakage during the inflammatory phase of 
repair process 
Having observed the redness surrounding the wound in DKO mice, which was 
pronounced at day 3 post-injury, the inner side of the wound was examined. In the DKO 
mice, skin wound showed vasodilation and intra-tissue bleeding around the wound area 
at day 3 post-injury compared to other groups (Figure 3.6 A), indicating a loss of vascular 
integrity during this time. Vascular leakage was also observed in Gp6-/- mice but was less 
marked (Figure 3.6 A). H&E staining of wound tissue at day 3 post-injury revealed 
extravasation of Rbcs in skin dermis around the wound edge in DKO mice and to a lesser 
extent in Gp6-/- mice (Figure 3.6 B). This phenotype was not observed in WT and 
Clec1bfl/flPf4-cre mice where Rbcs remained in the skin vasculature (Figure 3.6 B). 
However, the intra-skin bleeding in DKO and Gp6-/- mice did not last throughout the 
course of healing, especially when the inflammation had ceased. Histological analysis 
showed no persistent bleeding or haematoma formation within the wound scar at day 9 
post-injury in DKO and Gp6-/- mice compared to WT and Clec1bfl/flPf4-cre mice (Figure 
3.6 C), suggesting the complete clearance of extravascular Rbcs from the healing wound 
in all groups. Due to blood/lymphatic misconnection in DKO mice, with a lesser extent 
in Clec1bfl/flPf4-cre mice, Rbcs were present in both blood and lymphatic vessels 
(podoplanin+) during this time (Figure 3.6 D).  
These data indicate a loss in the maintenance of vascular integrity during the 
inflammatory phase of wound repair in DKO mice, and a less severe form in Gp6-/- mice, 
which subsequently subsides in later phase. 
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Figure 3. 6. Lack of platelet GPVI and CLEC-2 leads to vascular leakage during 
inflammatory phase of wound repair. (A) Macroscopic images of inner side of skin 
wound at day 3 post-injury (n=4-6). Dotted circle indicates wound area. Arrow points to 
dilated vessel. Arrowhead shows bleeding into surrounding skin. (B) H&E staining of the 
wound at day 3 post-injury (n=6-9). Arrow points to intra-skin bleeding. Scale bar = 50 
µm. (C) H&E staining of wound scar at day 9 post-injury (n=10-13). Arrow indicates red 
blood cells (Rbcs) within the vessel. Scale bar = 20 µm. (D) Immunohistochemistry 
shows podoplanin on lymphatic endothelium (upper panel) and cells around blood vessel 
(lower panel). Cells (dark blue nuclei) presented within lymphatic vessel of Clec1bfl/fl Pf4-
cre are leucocytes. L = lymphatic vessel. BV = blood vessel. Arrow points to Rbcs (pale 
yellow/brown) in both types of vasculature. Scale bar = 20 µm. 
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3.2.5 The vascular leakage results in fibrinogen deposition and fibrin generation 
during the inflammatory phase of wound healing in DKO mice 
It has been previously demonstrated that the increase in vascular permeability allows 
entry of blood composition, including fibrinogen, into the wound (Shaterian et al., 2009, 
Mendonca et al., 2010). Extravascular fibrinogen is subsequently converted to fibrin by 
tissue factor-mediated pathway within the wound (Hoffman et al., 2006), both of which 
promote wound healing (Drew et al., 2001). During wound healing in DKO mice, the 
results of immunohistochemistry showed that wound fibrinogen was identical to that of 
WT at day 1 post-injury (Figure 3.7 A, B). However, fibrinogen deposition was 
significantly increased in the granulation tissue area of DKO mice at day 3 post-injury 
compared to WT (Figure 3.7 C, D). Tissue factor was highly expressed on 
proliferating/migrating keratinocytes (Figure 3.7 E), with a lower level of expression in 
the granulation tissue at this time. There was no significant differences in tissue factor 
level among all strains tested (Figure 3.7 F). 
The fibrin content was measured by Martius scarlet blue staining. At day 1 post-injury, 
fibrin was primarily detected at the wound scab (Figure 3.8 A) and it was similar between 
WT and DKO mice (Figure 3.8 B). Fibrin content was increased in wound scab of DKO 
mice at day 3 post-injury (Figure 3.8 C), which was significantly higher than WT and 
Clec1bfl/flPf4-cre mice (Figure 3.8 D) but not Gp6-/- mice that presented a certain degree 
of vascular leakage. At day 9 post-injury, fibrin was mainly observed on the uppermost 
area of scar in all groups (Figure 3.8 E). The DKO mice had a notably lower level of 
fibrin than WT and Gp6-/- mice (Figure 3.8 F). In addition, Clec1bfl/flPf4-cre mice also 
showed lower levels of fibrin than Gp6-/- mice at this time (Figure 3.8 F). During the 
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course of skin wound healing, DKO mice did not demonstrate significant differences in 
(myo)fibroblasts (Figure 9 A-C) and collagen content (Figure 9 D, E) compared to WT. 
Overall, the loss of vascular integrity may enhance the extravasation of fibrinogen into 
the wound of DKO mice, leading to increased fibrinogen and fibrin deposition to promote 
wound healing. This provisional matrix is then removed from the healing wound. 
3.2.6 Mice deficient in GPVI and CLEC-2 demonstrate a reduction in wound 
neutrophils and M1 macrophages during inflammatory phase 
The infiltration of inflammatory cells, including neutrophils (Gr-1+), monocytes (Ly6C+), 
and macrophages (F4/80+), was examined at days 1, 3, and 9 post-injury. At day 1 post-
injury, neutrophils were primarily observed in scab area (Figure 3.10 A), with a lower 
number observed in the granulation tissue. During this time, wound neutrophils were 
similar between WT and DKO mice (Figure 3.10 B). Monocytes were observed at the 
sides of the granulation tissue (Figure 3.10 C), indicating an initial entry of this 
inflammatory cell. In a similar fashion to neutrophils, DKO mice demonstrated equivalent 
level of wound monocytes compared to WT mice (Figure 3.10 D). Macrophages were 
also detected at the edge of granulation tissue (Figure 3.10 E). Unlike other leucocytes, a 
significant decrease in the number of wound macrophages was observed in DKO mice 
compared to WT mice during this initial phase of wound healing (Figure 3.10 F).  
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Figure 3. 7. Fibrinogen accumulation within the wound of DKO mice during the 
inflammatory phase. (A) Fibrinogen staining (brown) of skin wound at day 1 post-
injury. Scale bar = 500 µm. (B) Quantification of fibrinogen content at day 1 post-injury 
(n=4-5). Data are presented as mean ± SEM and analysed by Student’s t-test. (C) 
Fibrinogen staining (brown) of skin wound at day 3 post-injury. Scale bar = 200 µm. (D) 
Quantification of fibrinogen content at day 3 post-injury (n=6). (E) Staining of tissue 
factor (TF, brown) at day 3 post-injury. Scale bar = 50 µm. (F) Quantification of tissue 
factor at day 3 post-injury (n=5-6). Data from females (open symbols) and males (closed 
symbols) are shown in (B, D, F). Data are presented as mean ± SEM and analysed by 
one-way ANOVA with Bonferroni’s multiple comparison test. *p<0.05.  
 
Fibrinogen 
Day1 
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Figure 3. 8. Fibrin generation is enhanced during the inflammatory phase of wound 
healing in DKO mice. (A) Martius scarlet blue (MSB) staining of skin wound at day 1 
post-injury. Red = old fibrin, blue = collagen, yellow = red blood cells/fresh fibrin. Scale 
bar = 200 µm. (B) Quantification of fibrin content in the wound at day 1 post-injury (n=5). 
Data are presented as mean ± SEM and analysed by Student’s t-test. (C) MSB staining of 
skin wound at day 3 post-injury. Scale bar = 200 µm. (D) Quantification of fibrin content 
in the wound at day 3 post-injury (n=6-9). (E) MSB staining of skin wound at day 9 post-
injury. Scale bar = 200 µm. (F) Quantification of fibrin content in the scar at day 9 post-
injury (n=9-13). Data from females (open symbols) and males (closed symbols) are 
shown in (B, D, F). Graphs are presented as mean ± SEM and analysed by one-way 
ANOVA with Bonferroni’s multiple comparison test. *p<0.05, **p<0.01.  
Day1 
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Figure 3. 9. Normal (myo)fibroblasts, and collagen content in DKO mice during the 
course of skin wound healing. (A) Immunofluorescence staining of (myo)fibroblasts 
(vimentin+ cells; red) in the wound of WT and DKO mice at day 3 (n=4) and day 9 post-
injury (n=3). Hoechst counterstains nuclei (blue). Scale bar = 20 µm. (B) Quantification 
of (myo)fibroblasts (vimentin+ cells) at day 3 post-injury (n=4). (C) Quantification of 
(myo)fibroblasts (vimentin+ cells) at day 9 post-injury (n=3). (D) Quantification of 
collagen content (blue color) in Martius scarlet blue (MSB) staining within the wound at 
day 3 post-injury (n=7-9). (E) Quantification of collagen content in MSB staining within 
the scar at day 9 post-injury (n=9-13). Data from females (open symbols) and males 
(closed symbols) are shown in (B-E). Graphs are presented as mean ± SEM and analysed 
by Student’s t-test. 
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At day 3 post-injury, neutrophil influx was reduced in DKO mice compared to WT and 
Clec1bfl/flPf4-cre mice (Figure 3.11 A, B). Immunofluorescence staining using anti-Ly6G 
antibody (clone 1A8) also confirmed a decrease in wound neutrophils in DKO mice at 
this time (Figure 3.11 C, D). WT mice showed a two-fold increase in neutrophil 
infiltration at day 3 relative to day 1 post-injury (Figure 3.11 E) whereas a steady level 
was observed in DKO mice. At day 9 post-injury, wound neutrophils were significantly 
decreased in both WT and DKO mice relative to the level at initial phase (Figure 3.11 E). 
However, neutrophils in the wound of DKO mice were higher than in WT at this time 
(Figure 3.11 F, G). The number of blood neutrophils was equivalent in unchallenged mice 
in all groups (Figure 3.11 H), and it was significantly decreased only in WT and 
Clec1bfl/flPf4-cre mice at day 3 post-injury (Figure 3.11 H). DKO and Gp6-/- mice did not 
show alteration of blood neutrophils during the time course of wound healing (Figure 
3.11 H).  
In order to assess a possible defect in neutrophil chemotaxis in the wound of DKO mice, 
the expression of chemokine CXCL-1 (also known as keratinocyte-derived chemokine), 
a neutrophil chemoattractant (Devalaraja et al., 2000), was measured. The result 
demonstrated that CXCL-1 was highly expressed in proliferating/migrating keratinocytes 
at day 3 post-injury (Figure 3.12 A), although a very low level of expression was observed 
within the granulation tissue area. There was no alteration in wound CXCL-1 in DKO 
mice compared to other groups (Figure 3.12 B). PF4 released from activated platelets also 
contributes to leucocyte chemotaxis (Deuel et al., 1981). At day 3 post-injury, PF4 was 
detected in the wound in all mouse strains (Figure 3.12 C). However, the lack of platelet 
GPVI and CLEC-2 did not affect PF4 secretion within the wound area (Figure 3.12 D).  
   Chapter 3: Skin Wound Healing: the Role of Platelet (hemi)ITAM Receptors 
 
110 
 
Previous evidences have demonstrated the role of fibrinogen and fibrin in inhibiting 
neutrophil chemotaxis (Hanson and Quinn, 2002, Higazi et al., 1994). Therefore, in vitro 
migration of bone marrow-derived neutrophils towards fMLP was performed. The results 
demonstrated that fibrinogen impeded migration of neutrophils from WT mice compared 
to the migration through collagen matrix (Figure 3.13). Moreover, crosslinked fibrin 
strongly inhibited migration of WT-derived neutrophils (Figure 3.13). Fibrinogen and 
fibrin showed a similar degree of potent inhibition for the migration of DKO-derived 
neutrophils (Figure 3.13). 
A significantly higher number of wound monocytes was observed in DKO mice 
compared to WT and single knockout mice at day 3 post-injury (Figure 3.14 A, B). This 
was supported by a four-fold increase in wound monocytes relative to day 1 post-injury 
(Figure 3.14 C). WT mice had low number of wound monocytes during the course of 
healing (Figure 3.14 C). At day 9 post-injury, a reduction in wound monocytes relative 
to day 3 post-injury was detected in DKO mice (Figure 3.14 C). However, the level 
remained higher than in all other groups (Figure 3.14 D, E). Blood monocytes in 
unchallenged Clec1bfl/flPf4-cre mice were increased compared to WT and DKO mice 
(Figure 3.14 G, left). At day 3 and day 9 post-injury, a significant reduction in circulating 
monocytes was observed in all groups compared to unchallenged controls (Figure 3.14 
F). In DKO mice, however, the level of monocytes in blood was significantly greater than 
Clec1bfl/flPf4-cre mice at day 3 post-injury (Figure 3.14 G, middle) and all other strains 
at day 9 post-injury (Figure 3.14 G, right). 
Wound macrophages in Clec1bfl/flPf4-cre mice were significantly increased at day 3 post-
injury, relative to other groups (Figure 3.15 A, B). In comparison with day 1, a six-fold 
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increase in macrophage infiltration was observed in WT mice at day 3 post-injury (Figure 
3.15 C). Wound macrophages in DKO mice were decreased compared to WT but not 
Gp6-/- mice at this time (Figure 3.15 B, C). At day 9 post-injury, macrophage numbers 
were equivalent among DKO, WT, and Clec1bfl/flPf4-cre mice (Figure 3.15 D, E). A 
lower number of macrophages within the wound was observed in Gp6-/- mice relative to 
Clec1bfl/flPf4-cre mice at this time (Figure 3.15 E).  
To examine whether a reduction of macrophage infiltration in DKO animals affects M1 
or M2 phenotype, double immunofluorescence staining was performed. The results 
showed that iNOS-expressing macrophages (a M1 marker) were decreased (Figure 3.16 
A, B) whereas M2 population (Fizz-1-positive) were unaltered relative to WT at day 3 
post-injury (Figure 3.16 D, E). At day 9 post-injury, there was no difference in M1 (Figure 
3.16 A, C) and M2 macrophages (Figure 3.16 D, F) between WT and DKO mice. During 
the inflammatory phase of wound healing, the inflammatory cytokines, including IL-1β 
and TNF-α, are secreted by the inflammatory cells, leading to wound inflammation 
(Eming et al., 2007). At day 3 post-injury, a significant decrease in TNF-α was observed 
within the wound tissue of DKO mice compared to WT (Figure 3.16 G, H). 
Together, these data suggest that CLEC-2 deficiency promotes leucocyte infiltration to 
the wound during the inflammatory phase, especially macrophages. A lack of both GPVI 
and CLEC-2 results in a significant decrease in inflammatory cells (i.e. neutrophils and 
M1 macrophages) and TNF-α level within the wound at this initial phase.  
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Figure 3. 10. Wound neutrophils, and monocytes (but not macrophages) are 
unaltered in DKO mice at day 1 post-injury. (A) Staining of neutrophils (Gr-1; brown) 
in wound area at day 1 post-injury. (B) Quantification of neutrophils (Gr-1+ cells) in 
wound area at day 1 post-injury (n=5). (C) Staining of monocytes (Ly6C; brown) in 
wound area at day 1 post-injury. (D) Quantification of monocytes (Ly6C+ cells) in wound 
area at day 1 post-injury (n=5). (E) Detection of macrophages (F4/80 staining; brown) in 
wound area at day 1 post-injury. (F) Quantification of macrophages (F4/80+ cells) in 
wound area at day 1 post-injury (n=5). Data from females (open symbols) and males 
(closed symbols) are shown in (B, D, F). Graphs are presented as mean ± SEM and 
analysed by Student’s t-test. *p < 0.05. 
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Figure 3.11. 
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Figure 3. 11. A reduction in neutrophil influx is observed during the inflammatory 
phase of wound healing in DKO animals. (A) Detection of neutrophils (Gr-1 staining; 
brown) in wound at day 3 post-injury. Scale bar = 20 µm. (B) Quantification of 
neutrophils (Gr-1+ cells) in wound at day 3 post-injury. *p<0.05, **p<0.01.  (C) 
Representative images of neutrophil staining in wound at day 3 post-injury using anti-
Ly6G antibody (clone 1A8). Arrow indicates wound edges. Scale bar = 500 µm (upper 
panel) and 20 µm (lower panel). (D) Quantification of Ly6G+ cells at day 3 post-injury 
(n=4). *p<0.05.  (E) Comparison of Gr1+ cells between day 1, day 3, and day 9 post-
injury in WT and DKO mice. The symbols * and § indicate p<0.05 in WT and DKO 
mice, compared to the data at day 1 post-injury, respectively. The bracket shows p<0.05 
for the comparison between day 3 and day 9 post-injury in *WT and §DKO mice, 
respectively. (F) Detection of neutrophils (Gr-1 staining; brown) in wound at day 9 post-
injury. Scale bar = 20 µm.  (G) Quantification of neutrophils (Gr-1+ cells) in wound at 
day 9 post-injury. *p<0.05. (H) Comparison of blood neutrophil counts between baseline, 
day 3, and day 9 post-injury in each mouse strain. The symbols * and + indicate p<0.05 
in WT and Clec1bfl/flPf4-cre mice, compared to their control, respectively. Sample 
numbers in unchallenged control = 10, day 1 = 5, day 3 = 6-9, and day 9 post-injury = 9-
13, respectively. Data from females (open symbols) and males (closed symbols) are 
shown in (B, D, G). Graphs are presented as mean ± SEM and analysed by either Student’s 
t-test (D) or one-way ANOVA with Bonferroni’s multiple comparison test (B, E, G, H).  
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Figure 3. 12. CXCL-1 and PF4 are no  t impaired during inflammatory phase of 
wound repair in DKO mice. (A) Detection of CXCL-1 (brown) in wound area at day 3 
post-injury. (B) Quantification of keratinocyte-expressed CXCL-1 in wound area at day 
3 post-injury (n=6). (C) Detection of PF4 (brown) in wound area at day 3 post-injury. (D) 
Quantification of PF4 within the granulation tissue in wound area at day 3 post-injury 
(n=6). Data from females (open symbols) and males (closed symbols) are shown in (B) 
and (D). Data are presented as mean ± SEM and analysed by one-way ANOVA with 
Bonferroni’s multiple comparison test. 
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Figure 3. 13. Fibrinogen and fibrin inhibit neutrophil migration towards fMLP in 
vitro. Graphs show percentage of neutrophil migration through collagen, fibrinogen, and 
fibrin matrix towards fMLP for 3 hours (n=3). Data are presented as mean ± SEM and 
analysed by one-way ANOVA. *p<0.05, **p<0.01.  
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Figure 3.14. 
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Figure 3. 14. Wound monocytes during the inflammatory phase of repair are 
increased in mice deficient in GPVI and CLEC-2. (A) Detection of monocytes (Ly6C+ 
cells; brown) in wound at day 3 post-injury. (B) Quantification of Ly6C+ cells in wound 
at day 3 post-injury (n=5-7). **p<0.01. (C) Comparison of Ly6C+ cells between day 1, 
day 3, and day 9 post-injury in WT and DKO mice. The symbols * and § indicate p<0.05 
in WT and DKO mice, compared to the data at day 1 post-injury, respectively. The 
bracket shows p<0.05 for the comparison between day 3 and day 9 post-injury in §DKO 
mice. (D) Detection of Ly6C+ cells (brown) in wound at day 9 post-injury. (E) 
Quantification of Ly6C+ cells in wound at day 9 post-injury (n=6). *p<0.05, **p<0.01. 
(F) Comparison of blood monocyte counts between baseline, day 3, and day 9 post-injury 
in each mouse strain. The symbols *, +, #, and § indicate p<0.05 in WT, Clec1bfl/flPf4-
cre, Gp6-/-, and DKO mice, compared to their control, respectively. (G) Comparison of 
blood monocytes between all groups at baseline (left), day 3 (middle), and day 9 post-
injury (right). Sample numbers in unchallenged control = 10, day 1 = 5, day 3 = 6-9, and 
day 9 post-injury = 10-13, respectively. Data from females (open symbols) and males 
(closed symbols) are shown in (B, E, G). Graphs are presented as mean ± SEM and 
analysed by one-way ANOVA with Bonferroni’s multiple comparison test. Scale bar = 
20 µm. 
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Figure 3. 15. Wound Macrophages are reduced during the inflammatory phase of 
wound healing in ITAM receptors-deficient mice. (A) Detection of macrophages 
(F4/80+ cells; brown) in wound at day 3 post-injury. (B) Quantification of F4/80+ cells in 
wound at day 3 post-injury (n=6-8). *p<0.05. (C) Comparison of F4/80+ cells between 
day 1, day 3, and day 9 post-injury in WT and DKO mice. The symbols * and § indicate 
p<0.05 in WT and DKO mice, compared to the data at day 1 post-injury, respectively. 
The bracket shows p<0.05 for the comparison between day 3 and day 9 post-injury in 
§DKO mice. Sample numbers at day 1 = 5, day 3 = 6-9, and day 9 post-injury = 10-13, 
respectively. (D) Detection of macrophages (F4/80+ cells; brown) in wound at day 9 post-
injury. (E) Quantification of F4/80+ cells in wound at day 9 post-injury (n=10-13). 
*p<0.05. Data from females (open symbols) and males (closed symbols) are shown in 
(B) and (E). Graphs are presented as mean ± SEM and analysed by one-way ANOVA 
with Bonferroni’s multiple comparison test. Scale bar = 20 µm. 
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Figure 3.16. 
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Figure 3. 16. M1 pro-inflammatory macrophages and TNF-α level are decreased 
during the inflammatory phase of repair in DKO mice. (A) Immunofluorescence 
double staining of iNOS (red) and F4/80 (green) in the wound of WT and DKO mice at 
day 3 (n=4) and day 9 post-injury (n=4). Hoechst counterstains nuclei (blue). (B) 
Quantification of M1 macrophages (iNOS+F4/80+ cells; yellow) at day 3 post-injury 
(n=4). (C) Quantification of M1 macrophages (iNOS+F4/80+ cells; yellow) at day 9 post-
injury (n=4). (D) Immunofluorescence double staining of Fizz-1 (red) and F4/80 (green) 
in the wound of WT and DKO mice at day 3 (n=4) and day 9 post-injury (n=4). (E) 
Quantification of M2 macrophages (Fizz-1+F4/80+ cells; yellow) at day 3 post-injury 
(n=4). (F) Quantification of M2 macrophages (Fizz-1+F4/80+ cells; yellow) at day 9 post-
injury (n=4).  (G) Immunohistochemistry staining of TNF-α (brown) in the wound at day 
3 post-injury. (H) Quantification of TNF-α level in granulation tissue area at day 3 post-
injury (n=6). Data from females (open symbols) and males (closed symbols) are shown 
in (B, C, E, F, H). Graphs are presented as mean ± SEM and analysed by either Student’s 
t-test (B, C, E, F) or one-way ANOVA with Bonferroni’s multiple comparison test (H). 
*p<0.05. Scale bar = 20 µm. 
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3.2.7 Blocking CLEC-2-podoplanin axis promotes skin wound healing in GPVI 
deficient mice 
Deletion of both CLEC-2 and GPVI accelerated wound healing in a murine model of full-
thickness excisional skin wound, which was associated with inflammatory bleeding (i.e. 
a loss of vascular integrity), fibrinogen and fibrin matrix deposition, a reduction in 
inflammation (i.e. decreased wound neutrophils, M1 macrophages, and TNF-α level), and 
enhanced re-epithelialisation and angiogenesis during the initial phase of repair process. 
However, DKO mice had blood-filled lymphatics and a moderate degree of 
thrombocytopenia, which may influence the repair process. To generate DKO setting in 
the absence of these limitations, Gp6-/- mice, which have a normal platelet count and no 
blood/lymphatic mixing phenotype, were treated with an anti-podoplanin antibody that 
blocks CLEC-2-podoplanin interaction. This antibody has previously been shown to 
increase vascular leakage in Gp6-/- mice during a model of skin inflammation (Rayes et 
al., 2018). 
During the period of wound monitoring for up to 3 days post-injury, Gp6-/- mice treated 
with anti-podoplanin antibody (Gp6-/- + anti-podoplanin) displayed redness around the 
wound edge (Figure 3.17 A), although a mild degree of redness was also observed in IgG 
isotype-treated Gp6-/- mice. However, there was no significant vasodilation in this setting, 
which possibly contributes to a lower extent of redness compared to the transgenic DKO 
mice. Wound closure was significantly accelerated in Gp6-/- + anti-podoplanin at day 2 
and 3 post-injury compared to Gp6-/- controls (Figure 3.17 A, B). Macroscopic 
observation of the inner side of skin wound at day 3 post-injury indicated an increase in 
vascular leakage (Figure 3.17 A, arrow). Histological analysis of wound tissue showed 
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an increase in the extravasation of Rbcs into the skin dermis at the wound edge of Gp6-/- 
+ anti-podoplanin mice relative to Gp6-/- controls (Figure 3.17 C, arrow). 
3.2.8 Co-localisation of anti-podoplanin antibody on podoplanin-positive cells in 
the skin wounding in GPVI deficient mice 
To validate the anti-podoplanin antibody on podoplanin-positive cells in the skin tissue, 
immunofluorescence staining was performed using a secondary antibody against syrian 
hamster IgG. The results showed that the antibody was highly detected at perivascular 
area in Gp6-/- + anti-podoplanin mice whereas it was absent in Gp6-/- + IgG controls 
(Figure 3.18) at day 3 post-injury. In addition, the leakage of platelets into perivascular 
tissue was observed in Gp6-/- + anti-podoplanin mice, confirming the impairment of 
vascular integrity during this time (Figure 3.18).  
In support of previous reports, these data indicate that injection of anti-podoplanin 
antibody blocks the binding of CLEC-2 to its ligand podoplanin in Gp6-/- mice, especially 
at perivascular area, which recapitulates GPVI and CLEC-2 double deficient setting, 
leading to an increase in vascular leakage during the inflammatory phase of wound 
healing. In addition, this experimental setting provides further evidence that the 
accelerated wound healing in DKO mice is not due to developmental defects or 
thrombocytopenia, but it is due to a combined loss of the interaction of platelet CLEC-2 
and GPVI with their respective ligands. 
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Figure 3. 17. Anti-podoplanin antibody injection in Gp6-/- mice (Gp6-/- + anti-PDPN) 
recapitulates the accelerated wound healing observed in DKO mice. (A) Macroscopic 
appearance of wound at indicated time points is shown. Arrow points to intra-skin 
bleeding around the wound at day 3 post-injury. (B) Percentage changes of wound size 
over 3 days post-injury (n=5). (C) H&E staining at day 3 post-injury (n=5). Arrow points 
the bleeding into surrounding skin. Scale bar = 20 µm. Graphs are presented as mean ± 
SEM. Kinetics of wound closure are analysed by two-way ANOVA with Bonferroni’s 
multiple comparison test. *p<0.05. 
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Figure 3. 18. Anti-podoplanin antibody (PDPN-Ab) is detected together with 
extravascular platelets at perivascular area in Gp6-/- mice treated with this antibody. 
Immunofluorescence staining of NG2 (red), PDPN-Ab (green) and CD41 (white) 
illustrates extravasation of platelets and the presence of PDPN-Ab on pericytes (NG2+) 
and other cells around blood vessel at day 3 after injury (n=4-5). Alexa 488-conjugated 
goat anti-hamster IgG secondary antibody was used in immunofluorescence to detect 
PDPN-Ab (clone 8.1.1.). Hoechst counterstains nuclei (blue). BV = blood vessel. Scale 
bar = 20 µm. 
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3.2.9 Treatment of GPVI deficient mice with anti-podoplanin antibody enhances 
re-epithelialisation and angiogenesis during the inflammatory phase of 
wound healing 
In association with the accelerated wound closure, histological analysis of skin wound at 
day 3 post-injury revealed that Gp6-/- treated with anti-podoplanin mice had a longer 
distance of re-epithelialisation arising from the wound edges toward the center of the 
wound (Figure 3.19 A, B) with no alteration in wound contraction (Figure 3.19 C). A 
larger area of granulation tissue was also observed in the antibody-treated mice (Figure 
3.19 A, D).  
Examination of angiogenesis using immunofluorescence staining illustrated that Gp6-/- + 
anti-podoplanin mice had an increased expansion of endothelial cells (CD31+) within the 
wound at day 3 post-injury (Figure 3.19 E), and the quantitative analysis confirmed a 
signigficant increase in CD31+ area (Figure 3.19 F), compared to Gp6-/- controls. 
These data indicate that blocking CLEC-2-podoplanin axis in GPVI deficient mice 
phenocopies the wound repair process observed in DKO mice, including enhanced re-
epithelialisation, granulation tissue formation, and angiogenesis, all of which begin at the 
early stage, rejecting the influence of blood/lymphatic mixing or a low platelet counts in 
wound healing of DKO animals. 
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Figure 3. 19. Enhanced re-epithelialisation, granulation tissue formation, and 
angiogenesis in Gp6-/- mice treated with anti-podoplanin antibody. (A) H&E staining 
at day 3 post-injury. Dotted line indicates hyperplastic coverages. Arrow indicates gap 
between epithelial tongues. Scale bar = 500 µm. (B) Measurement of re-epithelialisation 
(n=5). (C) Assessment of wound contration (n=5). (D) Quantification of granulation 
tissue area (n=5). (E) Immunofluorescence staining of endothelial cells (CD31+ cells; 
green) in wound area at day 3 post-injury. Hoechst counterstains nuclei (blue). Scale bar 
= 50 µm. (F) Quantification of CD31+ area within the wound at day 3 post-injury (n=5). 
Data from females (open symbols) and males (closed symbols) are shown in (B, C, D, F). 
All graphs are presented as mean ± SEM and analysed by Student’s t-test. *p<0.05.  
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3.2.10 Fibrin accumulation during the inflammatory phase of wound healing is 
increased in GPVI deficient mice treated with podoplanin-blocking antibody 
Due to the increase in vascular leakage during the inflammatory phase of repair in Gp6-/- 
+ anti-podoplanin mice, the extravasation of fibrinogen and the formation of fibrin were 
further investigated. Immunohistochemistry staining of fibrinogen showed that 
fibrinogen was accumulated in the granulation tissue area (Figure 3.20 A), although no 
significant increase in Gp6-/- + anti-podoplanin mice was observed at day 3 post-injury 
relative to Gp6-/- controls (Figure 3.20 B). Tissue factor was abundantly expressed on 
proliferating/migrating keratinocytes (Figure 3.20 C), with a lower level was detected in 
the granulation tissue. There was no significant difference in tissue factor expression in 
the tissue between two groups (Figure 3.20 D). However, the fibrin content in the wound 
scab of Gp6-/- + anti-podoplanin mice was significantly higher than IgG-treated Gp6-/- 
mice at day 3 post-injury (Figure 3.20 E, F).  
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Figure 3. 20. Wound fibrin is increased during the inflammatory phase in Gp6-/- mice 
treated with anti-podoplanin antibody. (A) Fibrinogen staining (brown) of skin wound 
at day 3 post-injury. Scale bar = 500 µm. (B) Quantification of fibrinogen content at day 
3 post-injury (n=5). (C) Immunohistochemistry staining of tissue factor (brown) at day 3 
post-injury. TF = tissue factor. Scale bar = 50 µm. (D) Quantification of tissue factor at 
day 3 post-injury (n=5). (E) Martius scarlet blue staining of skin wound at day 3 post-
injury. Red = old fibrin, blue = collagen, yellow = red blood cells/fresh fibrin. Scale bar 
= 200 µm. (F) Quantification of fibrin content in the wound at day 3 post-injury (n=5). 
Data from females (open symbols) and males (closed symbols) are shown in (B, D, F). 
Graphs are presented as mean ± SEM and analysed by Student’s t-test. 
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3.2.11 Injection of podoplanin-blocking antibody in GPVI deficient mice reduced 
neutrophils and macrophages in the wound during the inflammatory phase 
At day 3 post-injury, wound neutrophils was abundantly present at the border between 
the scab and granulation tissue (Figure 3.21 A), which was significantly reduced in the 
Gp6-/- + anti-podoplanin mice compared to Gp6-/- controls (Figure 3.21 B). Monocytes 
and macrophages were primarily localised in the granulation tissue (Figure 3.21 C, E) at 
day 3 post-injury. The number of wound monocytes in Gp6-/- + anti-podoplanin mice was 
significantly higher than IgG-treated Gp6-/- controls (Figure 3.21 D). In contrast, a 
reduction in wound macrophages was observed in Gp6-/- + anti-podoplanin mice (Figure 
3.21 F).  
Moreover, CXCL-1, which highly expressed in proliferating/migrating keratinocytes 
(Figure 3.22 A), was unaltered in Gp6-/- + anti-podoplanin mice relative to controls 
(Figure 3.22 B). There was also no significant reduction in TNF-α level in the granulation 
tissue area in Gp6-/- + anti-podoplanin mice compared to IgG-treated Gp6-/- controls 
(Figure 3.22 C, D) possibly because of the pre-existing pro-inflammatory activity of 
GPVI (Pierre et al., 2017). 
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Figure 3. 21. Treating Gp6-/- mice with podoplanin-blocking antibody leads to a 
reduction in wound neutrophils and macrophages (but increase in monocytes) 
during the inflammatory phase. (A) Staining of neutrophils (Gr-1; brown) in wound 
area at day 3 post-injury. (B) Quantification of neutrophils (Gr-1+ cells) in wound area at 
day 3 post-injury (n=5). (C) Detection of Ly6C+ cells (brown) in wound at day 3 post-
injury. (D) Quantification of Ly6C+ cells in wound at day 3 post-injury (n=5). (E) 
Detection of macrophages (F4/80 staining; brown) in wound area at day 3 post-injury. (F) 
Quantification of macrophages (F4/80+ cells) in wound area at day 3 post-injury (n=5). 
Data from females (open symbols) and males (closed symbols) are shown in (B, D, F). 
All graphs are presented as mean ± SEM and analysed by Student’s t-test. *p<0.05. Scale 
bar = 20 µm. 
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Figure 3. 22. Wound CXCL-1 and TNF-α are similar between Gp6-/- mice with and 
without anti-podoplanin antibody injection. (A) Detection of CXCL-1 (brown) in 
wound area at day 3 post-injury. Scale bar = 50 µm. (B) Quantification of keratinocyte-
expressed CXCL-1 in wound at day 3 post-injury (n=5). (C) Immunohistochemistry 
staining of TNF-α (brown) in the wound at day 3 post-injury. Scale bar = 20 µm. (D) 
Quantification of TNF-α level in granulation tissue area (n=5). Data from females (open 
symbols) and males (closed symbols) are shown in (B) and (D). All graphs are presented 
as mean ± SEM and analysed by Student’s t-test. NS = non-significant. 
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3.2.12 Platelet depletion results in severe haemorrhage following skin injury 
It has previously been demonstrated that thrombocytopenia does not affect skin wound 
healing in mice (Szpaderska et al., 2003). To assess the haemostatic function of platelets, 
a pilot wound experiment in thrombocytopenic mice was investigated. Platelet depetion 
was performed by intravenous injection of anti-GPIb antibody 24 hours before skin 
biopsy. According to small sample numbers, a subjective interpretation was presented 
here. Immediately after biopsy where the mice were under general anesthesia, wound 
bleeding was minor (Figure 3.23). Once the mice started moving, the wound of severe 
thrombocytopenic mice (platelet count was lower than 70 x 103 cell/mm3) showed 
persistent bleeding and had a severe haemorrhage, accompanied with impaired movement 
at 2 hours post-injury (Figure 3.23) whereas moderate thrombocytopenia had normal 
blood clot formation. The severe phenotype prevented further experimentation in this 
setting. 
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Figure 3. 23. Severe bleeding following skin injury in thrombocytopenic mice. All 
mice were intravenously injected with anti-GPIb antibody at 24 hours prior to skin biopsy. 
Platelet counts were measured before skin biopsy. The severity of platelet depletion 
depended on the extent of antibody that entered systemic circulation. Immediately after 
biopsy, minor bleeding at the wound site was observed in mice with platelet count lower 
than 70 x 103 cells/mm3 (n=2). At 2 hours after biopsy, severe haemorrhage was observed 
in severe thrombocytopenic mice whereas normal blood clot was generated in moderate 
thrombocytopenia, which has platelet count higher than 200 x 103 cells/mm3 (n=1). 
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3.3 Discussion 
In this chapter, the data show that platelet CLEC-2 and GPVI double deficiency facilitates 
skin wound healing in mice, resulting in a smaller wound scar at the end. The accelerated 
wound closure is associated with a temporal and self-limited vascular leakage during the 
inflammatory phase, which promotes the deposition of fibrinogen and fibrin, 
accompanied by a reduced infiltration of leucocytes and enhanced re-epithelialisation and 
angiogenesis. A proposed model for multistep contribution of the accelerated wound 
healing in the absence of CLEC-2 and GPVI is summarised in Figure 3.24. 
Skin wound healing requires multiple cellular and molecular contributions, including 
haemostasis (Drew et al., 2001, Shaw and Martin, 2009), vascular permeability that 
allows extravasation of plasma-derived solutes (Shaterian et al., 2009, Mendonca et al., 
2010), the recruitment of inflammatory cells to remove invading microbes and cellular 
debris (Martin and Leibovich, 2005), the proliferation and migration of skin epithelial 
and stromal cells to regenerate skin tissue (Shaw and Martin, 2009, Pastar et al., 2014), 
and the synthesis of connective tissue to recover skin elasticity (Shaw and Martin, 2009). 
Combined deletion of CLEC-2 and GPVI in platelets does not affect classical haemostasis 
but results in transient bleeding into the wound during the inflammatory phase, which 
reflects the role of GPVI and CLEC-2 in rescuing vascular integrity in the skin at sites of 
inflammation (Gros et al., 2015, Rayes et al., 2018). The presence of collagen and 
podoplanin (i.e. on pericytes, fibroblasts, infiltrating monocytes, and macrophages), in 
contact with platelets, at perivascular area of skin also supports this function of the two 
(hemi)ITAM receptors. 
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A                                                  
Normal wound healing 
 
B 
Accelerated wound healing due to combined loss of GPVI and CLEC-2 
 
Figure 3.24. 
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Figure 3. 24. Proposed model for the multiple regulation of accelerated wound 
healing in the absence of GPVI and CLEC-2. (A) During the inflammatory phase of 
normal wound healing, GPVI binds collagen in subendothelial matrix underneath the 
vessel wall to safeguard vascular integrity following leucocyte diapedesis. CLEC-2 
provides a backup function by binding to podoplanin that expressed on cells in proximity 
to the vessel wall, including pericytes, fibroblasts, infiltrating monocytes, and 
macrophages. (B) A lack of GPVI and CLEC-2 causes local and transient vascular 
leakage (1), which allows increased extravasation of fibrinogen into the wound (2) during 
the inflammatory phase of wound healing. In addition, other plasma-derived 
macromolecules (e.g. clotting factors, growth factors, and cytokines) may also entry into 
the wound. Tissue factor-expressing cells in wound area promote the conversion of 
fibrinogen to fibrin through extrinsic pathway of coagulation, which in turn facilitates 
wound healing. Moreover, a reduction in wound leucocytes during inflammatory phase 
is observed under ITAM-receptors deficiency, likely because of physical obstruction by 
fibrinogen and fibrin (3), which subsequently attenuates inflammation and tissue damage. 
Together, an increased vascular leakage-mediated accumulation of fibrinogen/fibrin 
matrix and a decrease in inflammation contribute to an accelerated skin wound healing, 
at least by promoting re-epithelialisation (4) and angiogenesis (5). 
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Several animal studies have previously demonstrated the benefits of increased vascular 
permeability, a less severe form of vascular leakage, in facilitating cutaneous wound 
healing. For example, histamine released from mast cells enhances vascular permeability 
during the inflammatory phase, which promotes wound healing (Weller et al., 2006). In 
addition, accelerated wound healing is observed in mice directly treated with histamine 
(Numata et al., 2006), VEGF (Howdieshell et al., 2001), and serum fraction of the natural 
latex from rubber tree (Mendonca et al., 2010), all of which increase vascular 
permeability. In contrast, antihistamine delays wound healing (Weller et al., 2006). 
Therefore, impairment of vascular integrity and enhanced vascular permeability caused 
by various mechanisms result in leakage of plasma-derived growth factors, cytokines, and 
proteins into the tissue, which potentially facilitates wound healing.  
It is important to note that the cause of increase in vascular leakage was not due to a defect 
in coagulation. On one hand, continuous intra-tissue bleeding due to a defect in blood 
coagulation impairs wound healing. In hemophilia B mice (lack of FIX) (Hoffman et al., 
2006) or mice expressing low tissue factor (Monroe et al., 2010), persistent subcutaneous 
bleeding arises, in association with a reduction in fibrin generation, which leads to 
haematoma formation within the wound, contributing to delayed wound healing. On the 
other hand, the increased bleeding into the wound in the context of GPVI and CLEC-2 
deficiency arises only at initial stage and it is ceased in later phase of repair when the 
inflammation subsides. In addition, there is an increase in fibrinogen accumulation and 
fibrin generation, in the presence of an intact tissue factor within the wound, under platelet 
CLEC-2 and GPVI double deficient setting. Therefore, it is likely that the mechanism and 
characteristics of bleeding direct its consequences in wound healing. Indeed, the temporal 
and self-limited intra-skin bleeding following GPVI and CLEC-2 deficiency is associated 
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with accelerated wound healing. A similar result of wound healing is observed in Gp6-/- 
mice treated with a podoplanin-blocking antibody, which negates the influences of 
blood/lymphatic mixing and the reduced platelet counts in wound healing of DKO mice. 
By using this antibody, it also demonstrates the contribution of CLEC-2-podoplanin 
interaction, especially in the regulation of vascular integrity during skin wound healing, 
in addition to GPVI. Moreover, it has been already demonstrated that anti-podoplanin 
antibody inhibits CLEC-2 interaction to podoplanin in vivo, including in dermatitis 
(Rayes et al., 2018), deep vein thrombosis (Payne et al., 2017) and sepsis (Rayes et al., 
2017). In a murine model of dermatitis, anti-podoplanin antibody also enhances vascular 
leakage in Gp6-/- mice (Rayes et al., 2018). These results support that treatment of Gp6-/- 
mice with anti-podoplanin antibody blocks CLEC-2 interaction to podoplanin, which 
mimics the GPVI and CLEC-2 double deficient setting during skin wound healing.    
Fibrinogen and fibrin not only function for clot formation, but also act as provisional 
matrix for cell migration, a reservoir for accumulation of growth factors and cytokines, 
and a natural suture/sealant during wound healing (Brown et al., 1992, Drew et al., 2001). 
In DKO setting, deposition of fibrinogen and fibrin in the inflammatory phase may 
enhance migration of keratinocytes (Ronfard and Barrandon, 2001) and endothelial cells 
(Chalupowicz et al., 1995, Sahni and Francis, 2000), contributing to the accelerated 
progression of re-epithelialisation and angiogenesis during wound healing. 
However, fibrinogen/fibrin matrix appears to inhibit neutrophil and monocyte 
recruitment. Fibrinogen (Higazi et al., 1994) and a high concentration of fibrin (Hanson 
and Quinn, 2002) have been reported to inhibit neutrophil chemotaxis, which is similar 
to the results of in vitro neutrophil chemotaxis presented in this chapter. In addition, 
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fibrinogen shows in vitro anti-adhesive effect against monocytes (Lishko et al., 2007). In 
agreement with the finding in DKO animals, wound neutrophils and monocytes are not 
altered at day 1 post-injury where the fibrinogen/fibrin content is identical to WT controls. 
Rather, a decrease in wound neutrophils and M1 macrophages is present in the 
inflammatory phase of wound repair where fibrinogen/fibrin content is increased in DKO 
mice. Moreover, the higher number of wound monocytes is detected, which may further 
suggest a reduction in monocyte-to-M1 macrophage differentiation in DKO animals. 
Previous studies have shown that TNF-α secretion is elevated during monocyte-to-
macrophage differentiation (Francke et al., 2011, Crane et al., 2014, Vasamsetti et al., 
2015). Therefore, a reduction in TNF-α level, in association with increased 
fibrinogen/fibrin deposition, during the inflammatory phase may explain a decrease in 
monocyte-to-M1 macrophage transition in DKO mice.  
It is no doubt that leucocytes are important for pathogen killing during wound healing 
(Kim et al., 2008, Chen et al., 2018). However, several lines of evidence demonstrate that 
inflammatory cells may not be essential in wound healing as long as the wound is kept 
sterile (Hopkinson-Woolley et al., 1994, Dovi et al., 2003, Martin et al., 2003). Indeed, 
improved wound healing is observed in neutrophil-depleted conditions (Dovi et al., 2003, 
Mori et al., 2002, Wong et al., 2015). Neutrophil can cause tissue damage and delay 
wound healing through several mechanisms, including a production of proteases (Dovi et 
al., 2003), inflammatory cytokines and oxidative radicals (Wilgus et al., 2013), and NETs 
(Wong et al., 2015). In addition, macrophage depletion model in mice demonstrates that 
a lack of macrophages within the first five days does not significantly affect wound 
closure during the inflammatory phase (day 1-3) but rather delays the later stages of 
wound closure (Lucas et al., 2010), which is related to a decrease in M2 macrophages. In 
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DKO mice, there was no alteration in M2 macrophages during the course of wound 
healing, but a decrease in M1 macrophages in the early phase may contribute to a 
reduction in scar formation, which is resemble to the finding in previous study (Lucas et 
al., 2010). 
A prolonged/excessive accumulation of extravascular fibrin can induce skin fibrosis (de 
Giorgio-Miller et al., 2005). Therefore, fibrinolysis and fibrin degradation are also 
important for repair process, which have been previously demonstrated to promote wound 
healing (Romer et al., 1996, Chan et al., 2001). Macrophages have also been reported to 
mediate clearance of extravascular fibrin (Motley et al., 2016) and Rbcs (Yin et al., 2015). 
During wound healing in DKO mice, extravascular fibrin and Rbcs were completely 
removed in the later phases, suggesting no risk of skin fibrosis. 
A reduction in leucocyte infiltration might raise the concern of wound contamination. 
However, a recent study has shown that a rapid fibrin film formation over the surface of 
the wound plays a protective function against bacterial invasion (Macrae et al., 2018). 
This mechanism might also limit the need for leucocyte infiltration to eliminate 
pathogens. Although it has previously been reported that Staphylococcus aureus infection 
leads to a two-fold increase in wound neutrophils (Kim et al., 2008), this has not yet been 
investigated in DKO mice. Further studies are required to test whether targeting GPVI 
and CLEC-2 might increase the risk of wound infection. 
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Taken together, this study demonstrates that a local and self-limited intra-skin bleeding 
caused by loss of GPVI and CLEC-2 provides potential benefits in wound healing. Unlike 
the persistent bleeding due to a lack of fibrin generation in coagulation-deficient mice, 
the increased vascular leakage following platelet GPVI and CLEC-2 deficiency results in 
fibrinogen/fibrin deposition and reduced leucocyte infiltration, which promotes wound 
healing. Therefore, these findings may present the potential implication of targeting 
platelet CLEC-2 and GPVI to facilitate wound healing and reduce scar formation. 
 
  Chapter 4: Characterisation of the CRISPR/Cas9-generated Podoplanin Cytoplasmic Tail 
Deficient Mouse Model 
 
143 
 
Chapter 4 Characterisation of the CRISPR/Cas9-
generated Podoplanin Cytoplasmic Tail 
Deficient Mouse Model 
4.1 Introduction 
Podoplanin is the only known endogenous ligand for CLEC-2 (Pan and Xia, 2015). This 
mucin type transmembrane glycoprotein comprises of 172 and 162 amino acids in mice 
and humans, respectively (Pan and Xia, 2015), which is expressed on podocytes, LECs, 
and type I lung epithelial cells, and is upregulated on inflammatory macrophages, 
fibroblasts, T cells and many cancer cells (Kerrigan et al., 2012, Peters et al., 2015, 
Nylander et al., 2017, Retzbach et al., 2018). The extracellular domain of podoplanin 
contains repeat regions known as PLAG domains, a heavily O-glycosylated stalk, and a 
short cytoplasmic tail of 10 amino acids (Figure 4.1). The binding of podoplanin to 
CLEC-2 requires the electrostatic interaction between a conserved EDXXXT/S sequence 
in PLAG and four arginine residues in CLEC-2 to mediate platelet aggregation (Kaneko 
et al., 2006, Nagae et al., 2014). The cytoplasmic tail of podoplanin contains three basic 
residues crucial for the binding of ERM proteins, which further activate downstream 
signals to regulate cell migration and function (Pan and Xia, 2015, Astarita et al., 2012).  
The vast majority of experimental studies demonstrate the role of the extracellular 
domains of podoplanin for the activation of CLEC-2. For example, podoplanin has been 
shown to activate CLEC-2 on platelets and mediate platelet aggregation, preventing 
  Chapter 4: Characterisation of the CRISPR/Cas9-generated Podoplanin Cytoplasmic Tail 
Deficient Mouse Model 
 
144 
 
backfilling of blood into lymphatic (Bertozzi et al., 2010, Hess et al., 2014). Podoplanin 
can also interact with several lateral membrane proteins to mediate cellular function, 
including (1) the binding with CD44 on tumour cells, which promotes cell migration 
(Martin-Villar et al., 2010), (2) the association with galectin-8 on LECs, subsequently 
regulates LEC adhesion to the surrounding ECM during lymphvasculogenesis (Cueni and 
Detmar, 2009), and (3) the interaction with tetraspanin family member CD9 to inhibit 
podoplanin-induced platelet aggregation, attenuating cancer metastasis (Nakazawa et al., 
2008). CLEC-2 is also proposed to inhibit lateral interaction of podoplanin in mediating 
fibroblastic reticular cell (FRC) contraction, leading to lymph node expansion during 
immunisation (Astarita et al., 2015). 
Moreover, soluble factors physically bind to podoplanin and modulate biological 
function. For example, CCL21, a leucocyte chemoattractant found in secondary lymphoid 
organs and tumour microenvironment, has been reported to bind podoplanin on LECs, 
FRCs, and cancer-associated fibroblasts. This interaction promotes the binding of CCL21 
to its receptor, the CCR7, on leucocytes and tumour cells, contributing to leucocyte 
trafficking and tumour cell migration (Astarita et al., 2012, Tejchman et al., 2017). Heat 
shock protein A9 secreted from cancer cells also binds podoplanin, promoting cancer cell 
growth and invasion (Tsuneki et al., 2013). In addition, nerve growth factor has been 
shown to interact with podoplanin on hippocampal neurons, which promotes 
neuritogenesis, facilitating learning and memory (Cicvaric et al., 2016). 
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Figure 4. 1. Schematic representation of murine podoplanin structure. Serine (S) and 
threonine (T) residues in extracellular region of podoplanin are extensively glycosylated. 
The conserved EDXXXT/S sequence within platelet aggregation-stimulating (PLAG) 
domain is a potential binding site for CLEC-2. Three basic residues, comprising lysine 
(K) and arginine (R), in cytoplasmic tail of podoplanin act as binding sites for ERM 
proteins. Podoplanin can signal through ERM phosphorylation, which subsequently 
mediate cellular function (e.g. cell migration). Adapted from (Pan and Xia, 2015, Astarita 
et al., 2012, Kaneko et al., 2006, Nagae et al., 2014). 
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Interestingly, the interaction of CLEC-2 with podoplanin under (patho)physiological 
conditions is primarily associated with the upregulation of podoplanin, although it is 
unclear whether these effects are mediated through podoplanin signalling in the 
intracellular tail or the changes of its interaction with other lateral membrane proteins. A 
previous model of podoplanin cytoplasmic tail deficiency, called ‘∆cyto’, has been 
generated (Astarita et al., 2015) by inserting three STOP codons immediately after the 
sequence encoding lysine-164 (K164) within exon 5 of Pdpn (slightly different locus to 
the model in this thesis). These mice did not show physical abnormalities although it was 
noted that podoplanin expression was reduced in FRCs. In addition, the phosphorylated 
ezrin/radixin/moesin (ERM) level in FRCs of ∆cyto mice was unaltered whereas it was 
reduced in FRCs of constitutive podoplanin knockout (Pdpn-/-) mice. Moreover, there was 
no clear evidence of blood-filled lymphatics in these mice (Astarita et al., 2015), arguing 
against the roles of podoplanin cytoplasmic tail in inhibiting LEC migration during blood-
lymphatic separation (Pollitt et al., 2014).  
During skin wound healing, podoplanin is upregulated in various cell types, including in 
the proliferating/migrating keratinocytes, and it is recovered when the wound is 
completely healed. A previous report has demonstrated that the increased expression of 
keratinocyte podoplanin is related to the progression of re-epithelialisation to resurface 
skin epidermis (Asai et al., 2016). In this model, platelets are present in proximity to 
podoplanin-expressing cells at day 1 post-injury, which may function in limiting 
keratinocyte migration at initial period while waiting the preparation of wound bed. In 
the absence of platelets, podoplanin is speculated to mediate keratinocyte migration in 
later phases of wound healing (Asai et al., 2016). However, keratinocyte-specific 
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podoplanin knockout mice display a normal skin wound closure, suggesting non-essential 
function of keratinocyte-derived podoplanin in skin wound healing (Baars et al., 2015). 
Another aspect of CLEC-2-podoplanin interaction in wound healing is illustrated by a 
significant acceleration in skin wound healing following a single intradermal injection of 
human podoplanin-positive monocytes in combination with platelets around the wound 
edge in mice (Hur et al., 2014). A proposed mechanism of improved wound healing 
underlying this model is the observation of enhanced lymphangiogenesis at day 7 post-
injury, which may help draining the inflammatory component (Hur et al., 2014). 
However, the accelerated wound closure begins at the early phase (day 3 post-injury), 
suggesting other potential mechanisms that may have promoted wound healing in this 
setting. 
The global deletion of podoplanin in mice leads to perinatal death (Uhrin et al., 2010), 
limiting its uses for investigating podoplanin function in adulthood. To examine the 
significance of podoplanin signalling through its cytoplasmic tail in vivo, a novel 
PdpnCyto mouse model was generated and characterised. This model of mutated 
podoplanin was produced by Taconic Biosciences using CRISPR/Cas9 technology, 
which constitutively inserts three stop codons immediately before the nucleotide 
sequence encoding K164 located in exon 5 of Pdpn gene (Figure 4.1 and 4.2 A). Mice 
were monitored for viability and inheritance, haematological parameters, the evidence of 
blood-lymphatic mixing and leucocyte infiltrates within specific organs alongside WT 
and CELC-2 deficient animals. In addition, skin wound experiment was performed to 
examine the contribution of podoplanin cytoplasmic tail in wound repair. 
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4.2 Results 
4.2.1 Identification of the podoplanin cytoplasmic tail deficient mice 
In addition to the insertion of three stop codons, the nucleotide sequence containing A to 
C mutation (A AGATT→A AGCTT) designed as a site for HindIII restriction enzyme 
(Loenen, Dryden et al. 2014) was introduced during CRISPR/Cas9-mediated gene editing 
(Figure 4.2 B). Therefore, mutated Pdpn alleles can be cleaved into two fragments by 
HindIII enzyme. Genotyping using PCR that amplifies the sequences encoding 
cytoplasmic domain of podoplanin, followed by HindIII digestion revealed that in WT 
mice that lack HindIII restriction site, a single PCR product was present at 496 base pair 
(bp) on agarose gel following gel electrophoresis (Figure 4.2 C). The DNA samples 
derived from homozygous podoplanin cytoplasmic tail deficient (PdpnCyto-/-) animals 
was digested by HindIII and gave rise to two bands of nucleotide fragments at the size of 
327 bp and 176 bp (Figure 4.2 C). The heterozygous littermates (PdpnCyto+/-) that had 
both intact and mutated Pdpn alleles demonstrated three PCR bands at 496, 327, and 176 
bp, respectively (Figure 4.2 C). The incomplete HindIII digestion may cause false 
negative results during genotyping, in which three PCR bands might also be detected 
from PdpnCyto-/- samples.  
Moreover, in order to confirm whether the samples are classified in correct genotypes, 
PCR products were further amplified and identified using the Sanger method of DNA 
sequencing. The results showed there was no stop codons detected in the exon 5 of Pdpn 
gene in WT mice (Figure 4.3, upper). In PdpnCyto-/- mice, three stop codons were 
observed, accompanied with the A to C mutation for HindIII restriction site (Figure 4.3, 
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middle). The PdpnCyto+/- mice exhibited a mixed nucleotide sequence that indicated stop 
codons and A to C mutation in overlap with the sequence identical to WT controls (Figure 
4.3, lower). 
4.2.2 Podoplanin cytoplasmic tail deficient colony shows Mendelian inheritance  
To set up the PdpnCyto colony, PdpnCyto-/- females were bred out with WT C57BL/6 
males to generate PdpnCyto+/- offspring. Then, the breeding pairs of PdpnCyto+/- parents 
were set to maintain the colony that was expected to give approximately 25 % of either 
WT or PdpnCyto-/- mice and 50% of PdpnCyto+/- mice, according to Mendelian genetics 
(Figure 4.4). In total, 22 litters were monitored. The analysis showed  that 47 pups (25%) 
died during pre-wean (age less than 3 weeks). The total number of mice that survived was 
138 animals, which comprised of 18% of WT, 57% of PdpnCyto+/-, and 25% of 
PdpnCyto-/- mice, respectively (Figure 4.5 A), suggesting that the PdpnCyto colony was 
born at Mendelian frequency. There was no significant difference between the expected 
numbers and the actual numbers as assessed using Chi-squared test. However, the 
PdpnCyto-/- females were more prevalent than males (Figure 4.5 B). 
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Figure 4. 2. Generation and identification of podoplanin cytoplasmic tail deficient 
mice. (A) Schematic demonstration of CRISPR/Cas9-mediated podoplanin cytoplasmic 
tail deficiency. Three STOP codons are constitutively inserted immediately before the 
sequence encoding lysine-164 located in exon 5 of Pdpn. (B) Representative nucleotide 
sequence within exon 5 of Pdpn in WT mice (upper) and PdpnCyto-/- mice (lower), which 
comprises of three stop codons and A to C mutation for HindIII restriction site. (C) PCR 
bands on agarose gel indicating the genotyping results to identify WT, PdpnCyto+/-, and 
PdpnCyto-/- mice. WT mice show a single PCR band at 496 bp. PdpnCyto+/- mice exhibit 
three bands at 496, 327, and 176 bp whereas there are two PCR bands at 327 and 176 bp 
in PdpnCyto-/- mice.  
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Figure 4. 3. DNA Sequencing of the podoplanin cytoplasmic tail deficient mice. 
Sequence of PCR fragments amplified from DNA of WT mice (upper) shows no stop 
codons in exon 5 of Pdpn. The PdpnCyto-/- mice (middle) have three stop codons and the 
A to C mutation for HindIII restriction site. In PdpnCyto+/- mice (lower), the nucleotide 
sequence consisting stop codons and A to C mutation similar to PdpnCyto-/- mice are 
detected in combination with the normal sequences identical to WT mice.     
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                                                  WT              PdpnCyto+/-          PdpnCyto+/-        PdpnCyto-/- 
                                          
                                                 25%                                   50%                                 25% 
 
 
Figure 4. 4. Generation and maintenance of podoplanin cytoplasmic tail deficient 
colony. Homozygous podoplanin cytoplasmic tail deficient (PdpnCyto-/-) females were 
bred with WT C57BL/6 males to produce the first generation containing all heterozygous 
podoplanin cytoplasmic tail deficient (PdpnCyto+/-) mice. Then, the breeding pairs of 
PdpnCyto+/- parents were set to maintain the colony. The excepted offspring is according 
to Mendelian inheritance, which includes 25% of either WT or PdpnCyto-/- and 50% of 
PdpnCyto+/- mice. 
 
 
 
 
 
 
 
Offspring: 
To set up the colony: 
To maintain the colony: 
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Figure 4. 5. Viability and inheritance of the podoplanin cytoplasmic tail deficient 
mice. (A) Frequency of genotypes observed in podoplanin cytoplasmic tail deficient 
colony suggests Mendelian inheritance. The offspring born from heterozygous 
podoplanin mutant parents (total 138 mice) include 18% of WT, 57% of PdpnCyto+/-, and 
25% of PdpnCyto-/- mice, respectively, which are not significantly different from the 
expected amounts. Data are analysed by Chi-squared test. (B) Numbers of male and 
female mice in each genotype from podoplanin cytoplasmic tail deficient colony.  
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4.2.3 Podoplanin cytoplasmic tail deficient embryos demonstrate an increased 
vasodilation and occasionally develop a mild degree of blood-filled skin 
vessels 
Previous studies have reported that global podoplanin knockout embryos show blood-
filled cutaneous vessels and extravasation of blood, indicating blood-lymphatic 
misconnection and the impairment of vascular integrity, respectively. The severity of the 
phenotype increased with age (E12.5-E16.5) (Bertozzi, Schmaier et al. 2010, Uhrin, 
Zaujec et al. 2010, Lowe, Finney et al. 2015). To examine the contribution of podoplanin 
cytoplasmic tail in the development of blood and lymphatic separation, embryos were 
taken from PdpnCyto+/- mothers at E14.5. Macroscopic observation revealed normal skin 
appearance in WT embryos (Figure 4.6 A). High proportion of both heterozygous (70%) 
and homozygous (90%) podoplanin mutant embryos displayed an increased vasodilation 
without vascular leakage around the head and face areas (Figure 4.6 B). Only a few 
number of PdpnCyto-/- embryos (25%) showed a limited degree of blood-filled cutaneous 
vessels during this stage, compared to WT (Figure 4.6 C). 
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A 
                                   WT                            PdpnCyto+/-                  PdpnCyto-/- 
                                 
 
                                    
B                                                               C 
         
Figure 4. 6. Embryos taken from podoplanin cytoplasmic tail deficient colony at 
E14.5 show minor degree of gross abnormalities. (A) Macroscopic appearance of 
E14.5 embryos. There were no gross abnormalities in WT embryos. The increased 
vasodilation is observed (star) around the head and face areas in PdpnCyto+/- and 
PdpnCyto-/- embryos. The mild form of blood-filled cutaneous vessels (arrow) is also 
detected in a small number of PdpnCyto-/- embryos. The prevalence of increased 
vasodilation and blood-filled cutaneous vessels in embryos are shown in (B) and (C), 
respectively.  
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4.2.4 Normal podoplanin expression is detected at E14.5 in podoplanin 
cytoplasmic tail deficient embryos 
To examine whether the novel model of podoplanin cytoplasmic tail deficiency affects 
global podoplanin expression, immunohistochemistry staining of podoplanin was 
performed in E14.5 embryos. It has previously been reported in mice that podoplanin is 
present at choroid plexus in the brain (Kaji et al., 2012) and the developing alveolar 
epithelial cells (Millien et al., 2006). In PdpnCyto-/- embryos, the result showed no 
apparent alteration in podoplanin expression at choroid plexus and surrounding 
neuroepithelium of the developing brain relative to WT embryos (Figure 4.7 A). In a 
similar manner, podoplanin expression in the developing lung of PdpnCyto-/- embryos 
was equivalent to that of WT controls (Figure 4.7 B), suggesting it is no defect in surface 
expression of the podoplanin extracellular domain during embryonic development in this 
mouse model. 
4.2.5 Homozygous podoplanin cytoplasmic tail deficient mice show a reduction in 
blood monocytes but an increase in lymphocytes 
In contrast to global podoplanin knockout mice that generally die before or immediately 
at birth (Uhrin et al., 2010), the PdpnCyto-/- animals are viable after birth in the absence 
of any detectable gross abnormalities, which allow studying the role of podoplanin, 
especially its cytoplasmic tail, in adulthood. PdpnCyto-/- mice were further characterised 
in comparison to their littermate control alongside with platelet CLEC-2 deficient mice. 
Blood cell counts in adult PdpnCyto-/- mice demonstrated a small increase in red blood 
cells (Figure 4.8 A), and a normal platelets count (Figure 4.8 B), compared to WT mice. 
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Although total white blood cell counts (Figure 4.8 C) and neutrophils (Figure 4.8 D) in 
the blood were not altered, the percentage of monocytes from total leucocytes (Figure 4.8 
E) was significantly reduced in PdpnCyto-/- mice. In contrast, the percentage of circulating 
lymphocytes were increased in PdpnCyto-/- mice relative to WT littermates (Figure 4.8 
F). 
4.2.6 A reduction in cardiac-to-body weight ratio is observed in mice that lack 
podoplanin cytoplasmic tail 
The change in organ-to-body weight ratio is one of an important indicator for organ 
toxicity, such as hypertrophy and hyperplasia (Michael et al., 2007, Mubbunu et al., 
2018). The lack of podoplanin has also been reported to affect cellularity of many internal 
organs, including the lung, liver, and spleen (Peters et al., 2015). In comparison to WT 
littermates, no significant changes in the organ-to-body weight ratio of multiple organs, 
including the liver (Figure 4.9 A), kidney (Figure 4.9 B), spleen (Figure 4.9 C), and lung 
(Figure 4.9 D) were observed in PdpnCyto-/- animals. However, the heart-to-body weight 
ratio was decreased in the PdpnCyto-/- mice compared to WT mice (Figure 4.9 E). 
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Figure 4. 7. Extracellular domain of podoplanin is normally detected in podoplanin 
cytoplamic tail deficient embryos at E14.5. (A) Immunohistochemistry shows 
podoplanin expression (brown) at choroid plexus and surrounding neuroepithelium in the 
developing brain (n=3). Arrow points to choroid plexus. Scale bar = 50 µm. (B) 
Immunohistochemistry of podoplanin (brown) in the developing lung (n=3). Arrow 
indicates developing alveolar epithelial cells. Scale bar = 20 µm. 
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Figure 4. 8. A reduction in circulating monocytes and an increase in lymphocytes 
are observed in homozygous podoplanin cytoplasmic tail deficient mice. Complete 
blood counts of WT (n=13) and PdpnCyto-/- mice (n=10) are presented as mean ± SEM, 
including (A) red blood cells (RBC), (B) platelets, (C) white blood cells (WBC), (D) 
neutrophils, (E) monocytes, and (F) lymphocytes. Data are analysed by Student’s t-test. 
*p<0.05, **p<0.01. 
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Figure 4. 9. Cardiac-to-body weight ratio is reduced in podoplanin cytoplasmic tail 
deficient mice. The mean ± SEM of organ-to-body weight ratios are presented, including 
(A) liver, (B) kidney, (C) spleen, (D) lung, and (E) heart, respectively. Data are analysed 
by Student’s t-test. **p<0.01. 
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4.2.7 Podoplanin expression is downregulated in multiple organs of the adult 
podoplanin cytoplasmic tail deficient mice 
In the previous study using a murine model of podoplanin cytoplasmic tail deficiency, it 
has been stated that podoplanin expression in FRCs is normal. However, the data of both 
surface and total podoplanin expression in FRCs derived from these podoplanin mutated 
mice indicate partial loss of podoplanin expression (Astarita et al., 2015). To determine 
the expression of podoplanin in different organs, an anti-podoplanin antibody that 
recognises the extracellular domain of podoplanin (clone 8.1.1) was used and podoplanin 
expression was assessed using immunohistochemistry (Pan et al., 2014). In WT lung, 
podoplanin was highly expressed, especially on type I alveolar epithelial cells. 
Podoplanin was also detected on LECs and possibly other stromal cells in the lung (Figure 
4.10 A). In PdpnCyto-/- mice, the expression of podoplanin in the lung was decreased, 
accompanied with increased leucocyte infiltrates around the blood vessels and respiratory 
tract (Figure 4.10 A, star). In the kidney, podoplanin was primarily observed on 
glomerulus and LECs in WT mice, and it was significantly decreased in PdpnCyto-/- mice 
(Figure 4.10 B). Podoplanin was mainly located at bile duct and LECs in the liver, which 
was also downregulated in PdpnCyto-/- mice, compared to WT controls (Figure 4.10 C). 
In the heart, podoplanin was only found on LECs, and the level of expression in 
PdpnCyto-/- animals was almost undetectable using this method (Figure 4.10 D). In red 
pulp of the spleen, LECs were the major podoplanin-positive area (Figure 4.10 E, upper) 
whereas there was periarteriolar podoplanin-expressing cells within the splenic white 
pulp (Figure 4.10 E, lower) of WT mice. In a similar fashion, a reduction in podoplanin 
expression was observed in the spleen of PdpnCyto-/- mice (Figure 4.10 E). 
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Figure 4. 10. (A-C) Adult podoplanin cytoplasmic tail deficient mice demonstrate 
downregulation of the basal podoplanin level in multiple organs. 
Immunohistochemistry of podoplanin (brown) is performed in the internal organs (n =3-
4), including (A) lung, (B) kidney, (C) liver, (D) heart, and (E) splenic red pulp (upper) 
and white pulp (lower). Star in (A) indicates leucocyte infiltrates. Arrow in (E) points to 
periarteriolar podoplanin-expressing cells. PDPN = podoplanin, A = arteriole, V = vein, 
L = lymphatic vessel, E = lung epithelium, containing podoplanin-expressing type I lung 
alveolar cells, B = bronchi/bronchiole, G = glomerulus, T = renal tubule, BD = bile duct, 
H = hepatocyte, M = cardiac myocyte. Scale bar = 50 µm. 
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Figure 4.10. (D-E) Adult podoplanin cytoplasmic tail deficient mice demonstrate 
downregulation of the basal podoplanin level in multiple organs. 
Immunohistochemistry of podoplanin (brown) is performed in the internal organs (n =3-
4), including (A) lung, (B) kidney, (C) liver, (D) heart, and (E) splenic red pulp (upper) 
and white pulp (lower). Star in (A) indicates leucocyte infiltrates. Arrow in (E) points to 
periarteriolar podoplanin-expressing cells. PDPN = podoplanin, A = arteriole, V = vein, 
L = lymphatic vessel, E = lung epithelium, containing podoplanin-expressing type I lung 
alveolar cells, B = bronchi/bronchiole, G = glomerulus, T = renal tubule, BD = bile duct, 
H = hepatocyte, M = cardiac myocyte. Scale bar = 50 µm. 
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4.2.8 Absence of significant blood-filled lymphatics in multiple internal organs of 
adult podoplanin cytoplasmic tail deficient mice 
A defect in blood and lymphatic vessel separation during embryonic development is 
speculated to cause blood-filled lymphatic vessels observed in post-natal period in mice 
(Bertozzi et al., 2010). In addition, it has been reported that podoplanin maintains this 
function during late gestation and in adulthood by mediating platelet aggregation to 
prevent backflow of blood through lymphovenous junction into lymphatic vessels (Hess 
et al., 2014). The observation for blood-filled lymphatics in several organs of adult 
PdpnCyto-/- mice revealed that there was no apparent evidence of this phenotype in the 
lung, liver, kidney, heart, and spleen (Figure 4.10) whereas the Clec1bfl/flPf4-cre mice 
clearly demonstrated blood/lymphatic mixing in the lung, heart, and spleen but not in the 
liver and kidney (Figure 4.11). 
4.2.9 Podoplanin cytoplasmic tail deficient and Pf4-cre-driven CLEC-2 knockout 
mice exhibit infiltrates of immune cells in the lung and liver tissues 
Previous study has shown that inflammatory infiltrates are observed in multiple organs 
of transgenic mice with constitutive podoplanin deletion (Peters et al., 2015). The 
histological examination demonstrated that there was inflammatory cell infiltration 
around blood vessels within lung tissue of PdpnCyto-/- and Clec1bfl/flPf4-cre mice (Figure 
4.12, star) but not in WT and Clec1bfl/flGp1ba-cre mice (another platelet-specific CLEC-
2 knockout model). In addition, CLEC-2 deletion on dendritic cells (Clec1bfl/flCd11c-cre) 
did not show this ectopic lymphoid structure within the lung (Figure 4.12). A similar 
fashion of leucocyte infiltration was observed in the liver of PdpnCyto-/- and 
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Clec1bfl/flPf4-cre mice (Figure 4.13). However, it was not detected in the kidney and 
cardiac tissues of PdpnCyto-/- (Figure 4.10) and Clec1bfl/flPf4-cre mice (Figure 4.11). 
4.2.10 CELC-2 is expressed on nucleated cells within the dermis of the skin in Pf4-
cre-driven platelet-specific CLEC-2 knockout mice 
Although CLEC-2 is primarily expressed on platelets, CLEC-2 expression was also 
shown on myeloid cells, especially on dendritic cells (Acton et al., 2012, de Winde et al., 
2018), and contributes to function of dendritic cells (Acton et al., 2014). To examine 
whether the expression of cre recombinase driven by Pf4 promoter (Pf4-cre) could delete 
Clec1bfl/fl on myeloid cells, the immunohistochemistry was performed to detect CLEC-2 
in unchallenged mouse skin. The results showed that CLEC-2 was still present on 
extravascular nucleated cells, indicating the resident myeloid cells rather than anucleated 
platelets within the skin dermis of Clec1bfl/flPf4-cre mice, which was identical to WT and 
PdpnCyto-/- mice (Figure 4.14).  
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Figure 4. 11. Mice with platelet CLEC-2 deficiency display blood/lymphatic mixing 
in the lung, heart, and spleen. Immunohistochemistry of podoplanin (brown) in the 
internal organs of Clec1bfl/flPf4-cre mice (n =3), including (A) lung, (B) kidney, (C) liver, 
(D) heart, and (E, left) spleen. Areas covered by rectangle are magnified to emphasise 
blood-filled lymphatic vessel in the organs. Arrow points to red blood cells. L = lymphatic 
vessel. (E, right) shows H&E staining of spleen that confirms blood-filled lymphatic 
vessels (rectangle) at the same red pulp area observed in podoplanin staining. Red/orange 
colour indicates red blood cells. Scale bar = 50 µm. 
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Figure 4. 12. Infiltration of leucocytes are observed in the lung of podoplanin 
cytoplasmic tail deficient and Pf4-cre-driven platelet-specific CLEC-2 knockout 
mice. H&E staining of lung tissues from WT, PdpnCyto-/-, two platelet-specific CLEC-2 
deficient models (i.e. Clec1bfl/flPf4-cre and Clec1bfl/flGp1ba-cre), and dendritic cell-
specific CLEC-2 knockout (Clec1bfl/flCd11c-cre) mice (n=3). Star indicates leucocyte 
infiltrates. A = arteriole, B = bronchi/bronchiole. Scale bar = 100 µm. 
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Figure 4. 13. Leucocyte infiltrates are present in the liver of podoplanin cytoplasmic 
tail deficient and Pf4-cre-driven platelet-specific CLEC-2 knockout mice. H&E 
staining of liver tissues from WT, PdpnCyto-/-, two platelet-specific CLEC-2 deficient 
models (i.e. Clec1bfl/flPf4-cre and Clec1bfl/flGp1ba-cre), and dendritic cell-specific 
CLEC-2 knockout (Clec1bfl/flCd11c-cre) mice (n=3). Star indicates leucocyte infiltrates. 
BV = Blood vessel. Scale bar = 50 µm. 
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Figure 4. 14. Pf4-cre-driven platelet-specific CLEC-2 knockout strategy does not 
delete CLEC-2 on myeloid cells in murine skin dermis. Immunohistochemistry of 
CLEC-2 (brown) in the unchallenged skin of WT, PdpnCyto-/-, and Clec1bfl/flPf4-cre mice 
(n=3). Scale bar = 50 µm. 
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4.2.11 Lack of podoplanin cytoplasmic tail has no impact on skin wound healing 
As shown in chapter 3, podoplanin was primarily expressed on LECs and cells that 
encircle blood vessels in unchallenged murine skin whereas it was upregulated during 
skin wound healing, including in proliferating/migrating keratinocytes, stromal cells, and 
other infiltrating cells. In PdpnCyto-/- mice, the results showed a reduction in basal 
podoplanin expression in multiple organs. However, it is unknown whether the lack of 
cytoplasmic tail affects podoplanin expression and its physiological function in 
challenged conditions, such as during skin wounding. Following a full-thickness 
excisional skin wound injury, PdpnCyto-/- mice demonstrated a comparable wound 
appearance to that of WT mice throughout the course of wound monitoring for up to nine 
days post-injury (Figure 4.15 A). In addition, there was no difference in wound closure 
between PdpnCyto-/- mice and WT controls at any time points of a daily observation, both 
of which showed complete wound closure at day 9 post-injury (Figure 4.15 B).  
Although podoplanin on LECs was significantly decreased in unchallenged skin of 
PdpnCyto-/- mice relative to WT mice (Figure 4.16 A, B), there was no evidence of blood-
filled lymphatic vessels in the skin of this mouse strain (Figure 4.16 A). Moreover, 
immunohistochemistry using antibody (clone 8.1.1) that recognises the extracellular 
domain of podoplanin (Pan et al., 2014) demonstrated that podoplanin was upregulated 
on the cells within wound area of PdpnCyto-/- mice at day 9 post-injury (Figure 4.16 C) 
and it was not significantly different to that of WT mice (Figure 4.16 D). These data 
suggest that in case of podoplanin upregulation is required, cell surface expression of 
podoplanin is not deficient in the PdpnCyto-/- mice.  
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Figure 4. 15. Podoplanin cytoplasmic tail deficiency does not influence skin wound 
healing. (A) Macroscopic appearance of wound at indicated time points. (B) Changes of 
wound size over 9 days post-injury (n=10). Graphs are presented as mean ± SEM. 
Kinetics of wound closure are analysed by two-way ANOVA with Bonferroni’s multiple 
comparison test.  
 
  Chapter 4: Characterisation of the CRISPR/Cas9-generated Podoplanin Cytoplasmic Tail 
Deficient Mouse Model 
 
172 
 
 
 
 
Figure 4. 16. Expression of podoplanin is upregulated during skin wound healing in 
both WT and podoplanin cytoplasmic tail deficient mice. (A) Detection of podoplanin 
expression (brown) in unchallenged murine skin. PDPN = podoplanin. Scale bar = 50 
µm. (B) Quantification of podoplanin expression in unchallenged skin (n=3). Average 
intensity from five representative lymphatic vessel-containing (podoplanin-positive) HPF 
images per skin sample were taken. (C) Detection of podoplanin expression (brown) in 
wound area at day 9 post-injury. Scale bar = 100 µm. (E) Quantification of podoplanin 
expression within the wound at day 9 post-injury (n=5-6). Data are presented as mean ± 
SEM and analysed by Student’s t-test.*p < 0.05. 
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4.2.12 Normal wound macrophage numbers are observed in the podoplanin 
cytoplasmic tail deficient animals 
Previous evidence has demonstrated an important function of podoplanin in cell 
migration (Martin-Villar et al., 2006, Suchanski et al., 2017). In addition, podoplanin is 
expressed on macrophages (Kerrigan et al., 2012) and it is upregulated during 
inflammatory conditions, including in arthritis, lung injury, and sepsis (Rayes et al., 2017, 
Croft et al., 2016, Lax et al., 2017b). However, the contribution of podoplanin in 
macrophage migration is unknown. Although the time course of macrophage infiltration 
during skin wound healing has not been investigated, the result of immunohistochemistry 
staining at day 9 post-injury revealed that macrophages were present within the wound 
scar of PdpnCyto-/- mice (Figure 4.17 A). In addition, the quantitative analysis 
demonstrated there was no significant difference in macrophage numbers between 
PdpnCyto-/- mice and WT controls at this time (Figure 4.17 B). In support of the intact 
upregulation of podoplanin in PdpnCyto-/- mice at day 9 post-injury (Figure 4.16 C), these 
results may suggest that macrophage turnover during skin wound healing in mice does 
not require podoplanin cytoplasmic tail.  
4.2.13 The absence of podoplanin cytoplasmic tail does not alter scar formation 
during skin wound healing 
The measurement of wound size using callipers showed a similar wound area between 
WT and PdpnCyto-/- mice at the end of experiment (day 9 post-injury) (Figure 4.15 B). 
To ensure this is not due to limitation of the technique used to assess macroscopic wound 
closure, the histological analyses of wound scar were performed. At day 9 post-injury, 
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PdpnCyto-/- mice had complete epithelial regeneration, which was comparable to the WT 
controls (Figure 4.18 A). In addition, these mice exhibited the same length of hyperplastic 
epidermis (Figure 4.18 B) and distance between subcutaneous gaps (Figure 4.18 C) to 
that observed in WT mice at this time.  
The function of podoplanin on skin fibroblasts (Nazari et al., 2016) has also never been 
reported in skin wound healing whereas there is evidence demonstrating its role in 
fibroblast migration in cancers (Suchanski et al., 2017). In the present model of skin 
wound, Martius scarlet blue staining illustrated that in addition to the normal dermis 
around the wound edges, collagen was observed within the scar of both PdpnCyto-/- and 
WT mice at day 9 post-injury (Figure 4.19 A). The results of quantification demonstrated 
an identical collagen content within the scar area between PdpnCyto-/- and WT mice 
(Figure 4.19 B), suggesting there is no defect in fibroblast/myofibroblast function in 
relation to collagen synthesis. 
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Figure 4. 17. Macrophage numbers in the wound of podoplanin cytoplasmic tail 
deficient mice are normal. (A) Detection of macrophages (F4/80 staining; brown) in 
wound area at day 9 post-injury. The areas covered by rectangle are magnified as shown 
in the lower panel. Scale bars = 100 µm (upper panel) and 50 µm (lower panel), 
respectively. (B) Quantification of macrophages (F4/80+ cells) in wound area at day 9 
post-injury (n=5). Graphs are presented as mean ± SEM and analysed by Student’s t-test. 
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Figure 4. 18. Normal scar formation during skin wound healing in podoplanin 
cytoplasmic tail deficient mice. (A) H&E staining of the skin wound tissue at day 9 post-
injury (n=5). a = length of hyperplastic epidermis, b = inter-subcutaneous distance. (B) 
Assessment of the length of hyperplastic epidermis. (C) Measurement of inter-
subcutaneous distance. Scale bar = 200 µm. Data are presented as mean ± SEM and 
analysed by Student’s t-test. 
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Figure 4. 19. Collagen deposition in wound scar is unaltered in podoplanin 
cytoplasmic tail deficient mice. (A) Martius scarlet blue staining of skin wound at day 
9 post-injury. Red = old fibrin, blue = collagen, yellow = red blood cells/fresh fibrin. 
Scale bar = 200 µm. (B) Quantification of collagen content in the wound at day 9 post-
injury (n=5). Data are presented as mean ± SEM and analysed by Student’s t-test. 
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4.3 Discussion 
On one hand, podoplanin contributes to physiological functions through its extracellular 
domain that acts as CLEC-2-activating ligand to induce platelet activation and 
aggregation (Hess et al., 2014, Rayes et al., 2018). On the other hand, the cytoplasmic tail 
of podoplanin modulates downstream signalling in regulating the function of podoplanin-
expressing cells (Astarita et al., 2015). Moreover, podoplanin also interacts with lateral 
integral proteins (e.g. galectin-8) (Martin-Villar et al., 2010, Cueni and Detmar, 2009) 
and some soluble molecules (e.g. CCL21), which subsequently produce biological effects 
(Tejchman et al., 2017, Cicvaric et al., 2016). In this chapter, the (patho)physiological 
contribution of podoplanin cytoplasmic tail is described through the characterisation of 
podoplanin cytoplasmic tail deficient mice, which were generated using CRISPR/Cas9 
technology to knock-in three stop codons before the nucleotide sequence encoding lysine-
164 in exon 5 of Pdpn. These mice are viable, fertile, and have no evidence of severe 
abnormalities. Pre-wean mortality rate of this mouse colony is also normal (Weber et al., 
2013). In support of previous evidences demonstrating the role of podoplanin in various 
settings, the characterisation data suggests that podoplanin cytoplasmic tail might provide 
potential function in (1) the development of cerebral blood vessel and (2) the regulation 
of lymphocyte response. However, the results indicate that cytoplasmic tail of podoplanin 
might not be required for (1) the prevention of blood-filled lymphatics, especially during 
adulthood, (2) safeguarding cerebral vascular integrity, (3) bone marrow-derived platelet 
production, (4) lung development, and (5) the turnover and/or function of various 
podoplanin-expressing cells, including keratinocytes, macrophages, and 
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(myo)fibroblasts, during skin wound healing. The observed physiological settings that 
may or may not require podoplanin cytoplasmic tail are shown in Figure 4.20. 
In the present model of podoplanin cytoplasmic tail deficiency, the expression of 
podoplanin at E14.5 was relatively comparable to that of WT embryos. In adult 
podoplanin cytoplasmic tail deficient animals, the basal podoplanin expression was 
downregulated in several organs. However, the mutated podoplanin was present on cell 
surface at the equivalent amounts observed in WT during skin wound healing, a 
challenged condition that shows the upregulation of podoplanin. Based on these data, it 
is likely that during the initial period of podoplanin expression/upregulation, the 
extracellular domain of mutated podoplanin might be presented normally on cell surface. 
As an abnormal protein, podoplanin that lacks its cytoplasmic region might be degraded 
overtime, leading to the observed downregulation of podoplanin during 
basal/unchallenged setting in adult podoplanin cytoplasmic tail deficient mice. In 
agreement with this, it is well recognised that in eukaryotic cells, several membrane 
proteins are regulated by internalisation followed by lysosomal degradation inside the 
cells (Lecker et al., 2006, Hicke and Dunn, 2003). 
During murine embryonic development, previous studies also suggest that the separation 
of blood and lymphatic vessels via CLEC-2-podoplanin interaction is completed in a short 
period. At E11.5, where podoplanin is initially expressed in cardinal vein and primary 
lymph sac (Schacht et al., 2003), platelet aggregation allows (Bertozzi et al., 2010) to 
separate  lymphatic vessel from cardinal vein. These evidences suggest that podoplanin 
is essential at critical period of blood and lymphatic vessel separation. The persistence of 
podoplanin on LECs until adulthood may be important for other functions, including the 
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migration of dendritic cells, which requires CLEC-2-podoplanin interaction (Acton et al., 
2012). Although in vitro model speculates the contribution of podoplanin cytoplasmic tail 
for the separation of blood and lymphatic vessels via inhibiting LEC migration (Pollitt et 
al., 2014), blood-filled cutaneous vessels rarely occurred (25%) at E14.5 in podoplanin 
cytoplasmic tail deficient embryos and it is entirely mild compared to what has been 
previously reported in the podoplanin null embryos (Bertozzi et al., 2010, Uhrin et al., 
2010). In addition, blood/lymphatic mixing was not detected in all tested organs in adult 
mice that lack podoplanin cytoplasmic tail. A slightly different in vivo model of 
podoplanin cytoplasmic tail deficiency, which inserts three stop codons immediately after 
the sequence encoding lysine-164, also reports no any detectable gross abnormalities in 
adult mice (Astarita et al., 2015). In addition, the phosphorylation of ERM in FRCs from 
these mice is not affected (Astarita et al., 2015). 
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Figure 4. 20. Diagram shows the physiological conditions that may or may not 
require the podoplanin cytoplasmic tail. The known functions of podoplanin are listed 
based on the literatures and further classified in relation to the contribution of its 
cytoplasmic tail according to the present data of characterisation. On one hand, 
podoplanin cytoplasmic tail might be required (green box) for (1) development of cerebral 
blood vessel and (2) the regulation of lymphocyte homeostasis. On the other hand, 
cytoplasmic tail of podoplanin might not be required (red box) for (1) blood/lymphatic 
separation, especially during adulthood, (2) maintaining cerebral vascular integrity, (3) 
bone marrow-derived platelet production, (4) lung development, and (5) cell 
turnover/function during skin wound healing, including keratinocytes, macrophages, and 
(myo)fibroblasts.  
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Upon CLEC-2 interaction, podoplanin on neuroepithelial cells may induce secretion of 
pro-angiogenic factors that contribute to the recruitment of endothelial and mural cells 
for cerebral blood vessel development in mouse embryos, suggesting a functional role of 
the cytoplasmic tail. Simultaneously, podoplanin activates platelet CLEC-2 to maintain 
cerebrovascular integrity (Lowe et al., 2015a). Unlike CLEC-2 null and neuroepithelium-
specific podoplanin knockout embryos (Lowe et al., 2015a), the podoplanin cytoplasmic 
tail deficient embryos have no macroscopic appearance of cerebral haemorrhage at E14.5, 
supporting the role of podoplanin extracellular domain in stimulating CLEC-2 to 
safeguard vascular integrity during brain development. However, embryos that lack 
podoplanin cytoplasmic tail demonstrated an increased vasodilation around head area at 
E14.5, which possibly indicates a certain degree of impairment of cerebrovascular 
development. In CLEC-2 null and neuroepithelium-specific podoplanin knockout 
embryos, a larger vascular lumen relative to WT controls has been observed, in addition 
to a reduction in pericyte recruitment, contributing to tortuous/disorganised vascular 
network within the brain (Lowe et al., 2015a). Therefore, it is likely that podoplanin 
cytoplasmic tail in neuroepithelial cells participates in normal development of cerebral 
blood vessel but not its integrity. 
Previous studies have shown the role of podoplanin for normal development of the lung 
(Ramirez et al., 2003, Tsukiji et al., 2018a) and the heart (Mahtab et al., 2008). Global 
podoplanin deletion leads to death of new-born shortly after birth due to non-inflated lung 
(Ramirez et al., 2003). In addition, CLEC-2 knockout and LEC-specific podoplanin 
deficient mice, but not either lung epithelial cell-specific or mesothelial cell-specific 
podoplanin knockout mice, exhibit this phenotype (Tsukiji et al., 2018a). Thus, it is 
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proposed that extracellular domain of podoplanin on lung LECs activates platelet CLEC-
2 leading to secretion of TGF-β, which regulates differentiation of lung mesothelial cells 
into myofibroblast to synthesise ECM that support alveolar structure (Tsukiji et al., 
2018a). This is in line with the observation of normal viability without any signs of 
breathing difficulty in adult mice that lack podoplanin cytoplasmic tail. In terms of 
cardiac development, it has been shown that murine embryos deficient in podoplanin 
exhibit cardiac malformations, represented by severe hypoplasia in several areas, 
including the myocardium, cardiac conduction system, and coronary artery (Mahtab et 
al., 2008). These defects are due to the absence of podoplanin in epicardium, which leads 
to impaired migration of epicardium-derived cells to the developing heart, contributing 
to embryonic/neonatal death (Mahtab et al., 2008). It is unclear whether a reduction in 
heart-to-body weight ratio in podoplanin cytoplasmic tail deficient mouse strain reflects 
a contribution of podoplanin cytoplasmic tail in normal cardiac development. In addition, 
these mice are alive and develop normally until adulthood.  
In the context of platelet production, it has been demonstrated that megakaryocyte CLEC-
2 activates podoplanin-expressing stromal cells around arterioles within bone marrow to 
secrete CCL5, which regulates megakaryocyte expansion and a subsequent proplatelet 
formation (Tamura et al., 2016). However, a normal platelet count is observed in mice 
with podoplanin cytoplasmic tail deficiency. Moreover, unlike a reduction in circulating 
platelets in Pf4-cre driven CLEC-2 knockout model (Tamura et al., 2016), CLEC-2 
deletion in adult mice using tamoxifen-inducible Cre/loxP strategy does not cause 
thrombocytopenia (Lowe et al., 2015b). Therefore, it is controversial whether CLEC-2-
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podoplanin axis mediates platelet production. Indeed, the present data suggest that 
podoplanin cytoplasmic tail has no role in this physiological process. 
Recently, the role of podoplanin in immune regulation has been described. Podoplanin 
expression is detected in non-pathogenic T cells whereas it is downregulated/absence in 
pathogenic pro-inflammatory Th17 cells (Peters et al., 2015, Nylander et al., 2017). In 
addition, CLEC-2 enhances anti-inflammatory/immunosuppressive regulatory T cell 
population in vitro (Agrawal et al., 2015). These data suggest that CLEC-2-podoplanin 
negatively regulates T cell response. Moreover, transgenic mice with podoplanin 
overexpression demonstrate severe lymphopaenia and this phenotype is rescued by 
crossing with CLEC-2 null mice (Peters et al., 2015). In contrast, the podoplanin 
cytoplasmic tail deficient mice showed increased percentage of circulating lymphocytes. 
In a similar fashion to podoplanin cytoplasmic tail deficient and Pf4-cre driven CLEC-2 
knockout mice, the inflammatory infiltrates comprising macrophages, dendritic cells, B-
cells, and substantial amounts of T-cells, are observed within the lung, liver, and intestine, 
but not in the heart and brain among constitutive podoplanin knockout animals (Peters et 
al., 2015). Therefore, podoplanin cytoplasmic tail (upon platelet CELC-2 interaction) 
may reduce T cell survival and response, which subsequently attenuate tissue 
inflammation (Peters et al., 2015, Nylander et al., 2017, Agrawal et al., 2015). However, 
the effects of lymphatic abnormality on lymphocyte homeostasis cannot be excluded 
since the lymphocyte infiltration is also observed in various organs, accompanied with 
chylothorax, in α9 integrin knockout mice that have defect in lymphatic valve formation 
without blood-lymphatic mixing (Huang et al., 2000, Hess et al., 2014).  
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The absence of inflammatory foci in Gp1ba-cre-driven CLEC-2 knockout mice raises 
concern of non-specific cre recombination under the control of Pf4 promoter (Pertuy et 
al., 2015), which may delete CLEC-2 on immune cells. However, cre recombination does 
not occur in dendritic cells following Pf4 promoter-driven (Pertuy et al., 2015). The result 
of CLEC-2 immunohistochemistry also indicates the presence of CLEC-2 on nucleated 
cells within the skin of Pf4-cre-driven CLEC-2 knockout mice, which is similar to WT 
mice. Further investigations of Gp1ba-cre-driven CLEC-2 knockout colony may provide 
more information whether Pf4-cre or Gp1ba-cre is more specific for deletion of CLEC-2 
on megakaryocyte/platelet lineage. A lack of inflammatory infiltrates in Clec1bfl/flCd11c-
cre animals refuses the association of dendritic CLEC-2 to this phenotype. 
A non-essential function of podoplanin cytoplasmic tail was revealed in many aspects 
during skin wound healing. Firstly, mice that lack podoplanin cytoplasmic tail displayed 
comparable level of podoplanin upregulation during skin wound healing and had normal 
wound closure, accompanied with the complete re-epithelialisation. In agreement with 
this data, previous study has also shown that keratinocyte-specific podoplanin deletion 
does not affect skin wound healing in mice (Baars et al., 2015). Secondly, macrophage 
numbers were not altered in the wound of podoplanin cytoplasmic tail deficient mice, 
suggesting that it is no relevant function of podoplanin cytoplasmic tail in macrophage 
turnover/recruitment, although the upregulation of podoplanin has been reported in 
inflammatory macrophages (Kerrigan et al., 2012, Rayes et al., 2017). Thirdly, the 
absence of podoplanin cytoplasmic tail had no impact on scar formation and collagen 
synthesis during skin wound healing. In agreement with this, podoplanin on lung 
epithelial and mesothelial cells is not required for myofibroblast differentiation during 
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lung development. Rather, the extracellular region of podoplanin on LECs (but not 
fibroblast lineage) activates platelet CLEC-2 to release TGF-β, which promotes 
mesothelial-to-myofibroblast transition. This leads to subsequent synthesis of ECM, 
including collagen, to support alveolar structure and function (Tsukiji et al., 2018a). 
Therefore, it might also imply that podoplanin, especially its cytoplasmic tail, that 
expressed on skin myofibroblasts (Nazari et al., 2016) is not necessary for cell migration 
and collagen synthesis. 
In conclusion, characterisation of podoplanin cytoplasmic tail deficient mice provides the 
evidence that suggests indispensable roles of podoplanin cytoplasmic tail in various 
developmental and biological settings, including the prevention of blood-filled 
lymphatics, cerebrovascular integrity, platelet production, lung development, and skin 
wound healing. However, podoplanin cytoplasmic tail may regulate cerebrovascular 
development and lymphocyte homeostasis. Overall, this novel mouse model of mutated 
podoplanin may serve as a useful tool to discover or to further understand the role of 
podoplanin cytoplasmic tail, particularly in various pathophysiological conditions.
 Chapter 5: The Association of Podoplanin Expression and Metabolic Changes in Macrophages 
187 
 
Chapter 5 The Association of Podoplanin Expression 
and Metabolic Changes in Macrophages 
5.1 Introduction 
5.1.1 An overview of metabolomics 
In systems biology, there are hierarchical links between biomolecules, starting from genes 
that are transcribed into RNAs, subsequently translated into proteins, and finally 
metabolised into a low molecular weight metabolites (Tolstikov, 2016). Metabolomics is 
the study that provides collective information of metabolite expression in a biological 
system (Kim et al., 2016, Rochfort, 2005). This is one of the new “omics” that can support 
other omics data, including genomics, transcriptomics, and proteomics, to understand the 
connection between metabolite profiles and the expression and function of genes, 
proteins, and other biomolecules under certain phenotype (Rochfort, 2005, Kim et al., 
2016). Emerging evidences demonstrate that metabolomics may provide benefits for 
biomedical research in multiple ways, including the finding of metabolite(s) that act as 
biomarkers for disease diagnosis (Zhang et al., 2016, Ussher et al., 2016) or targets for 
drug discovery, development, and monitoring (Tolstikov, 2016). 
Nuclear magnetic resonance (NMR) spectroscopy and MS are commonly used techniques 
in metabolomics (Tolstikov, 2016). In NMR, metabolomics data are generated based on 
atomic nuclei, which differently absorb and re-emit energy following the applied 
magnetic field (Alonso et al., 2015). NMR is highly selective and is beneficial for 
structural determination of metabolites. However, the sensitivity is relatively low 
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(Tolstikov, 2016). MS is generally coupled with a separation technique, such as 
chromatography. Different metabolites take different times to pass through 
chromatographic column, allowing separation of biomolecules to reduce the complexity 
of sample. Chromatography also separates isomers, such as glucose, fructose, mannose, 
and galactose. Following separation, the sample is ionised by mass spectrometer to 
generate peaks that define the fingerprint of metabolite (Alonso et al., 2015, Tolstikov, 
2016). MS provides high specificity and sensitivity, allowing detection of metabolites in 
various classes and concentrations (Tolstikov, 2016). 
Metabolomics can be applied to various types of biological samples (e.g. blood, urine, 
cell or tissue extract, and other biofluids), which is manipulated either by untargeted or 
targeted approach (Schrimpe-Rutledge et al., 2016, Alonso et al., 2015). Untargeted 
metabolomics is a discovery-based study to examine the initial comprehensive 
information of putative metabolites by matching data with reference compounds in 
databases or libraries. A relative quantification can be performed in this approach 
(Schrimpe-Rutledge et al., 2016, Vinayavekhin and Saghatelian, 2010). Targeted 
metabolomics is generally a validation-based analysis to measure well-known 
metabolites. In this approach, the data derived from exact concentrations of standard 
compounds are used as reference for absolute quantification of metabolites from 
biological samples (Schrimpe-Rutledge et al., 2016, Roberts et al., 2012).  
5.1.2 Cellular metabolism of glucose in macrophages 
Glucose metabolism is essential for energy production and cellular function in 
macrophages (Langston et al., 2017, Blagih and Jones, 2012). Glucose can be metabolised 
by a pathway, namely glycolysis with or without a subsequent tricarboxylic acid (TCA) 
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cycle. Glucose undergoes glycolysis to produce pyruvate and two molecules of ATP, and 
in turn, under low oxygen conditions, pyruvate is metabolised into lactate. The rapid 
generation of ATP through glycolysis fuels the inflammatory response and anti-bacterial 
defence (Geeraerts et al., 2017). Under a sufficient oxygen supply, pyruvate is transported 
into mitochondria and further transformed to acetyl coenzyme A, which enters the TCA 
cycle to yield two additional ATPs. The reducing intermediates (electron donors), 
including nicotinamide adenine dinucleotide (NADH) from glycolysis and TCA cycle, 
and flavin adenine dinucleotide (FADH2) generated in the TCA cycle, serve as fuels for 
electron transport chain (also called oxidative phosphorylation (OXPHOS) or 
mitochondrial respiration), which produces the majority of ATP (32-34 ATPs per glucose 
molecule) (Langston et al., 2017, Domblides et al., 2018). In addition, succinate donates 
electrons to complex II of the electron transport chain, which gives rise to fumarate 
(Figure 5.1), demonstrating the link between TCA cycle-derived intermediates and 
OXPHOS (Galvan-Pena and O'Neill, 2014, Diskin and Palsson-McDermott, 2018). The 
OXPHOS provides support for the anti-inflammatory function of macrophages (Geeraerts 
et al., 2017). 
As mentioned previously, macrophages are classified into two main subtypes, including 
M1 pro-inflammatory and M2 anti-inflammatory/reparative phenotypes (Sindrilaru and 
Scharffetter-Kochanek, 2013). Macrophage plasticity is driven by the metabolic profile. 
M1 macrophages primarily rely on glycolysis (Figure 5.1 A). Previous reports have 
shown that in response to M1 activators (LPS and/or IFN-γ), the intracellular levels of 
pyruvate and lactate are elevated in macrophages (Baseler et al., 2016, Jha et al., 2015). 
This is associated with the secretion of pro-inflammatory cytokines and phagocytosis 
(Nishizawa et al., 2014, Rodriguez-Prados et al., 2010, Baseler et al., 2016, Jha et al., 
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2015, Galvan-Pena and O'Neill, 2014, Diskin and Palsson-McDermott, 2018, Ussher et 
al., 2016). Macrophages from patients with coronary artery disease also demonstrate 
increased glycolysis, which contributes to the enhanced secretion of pro-inflammatory 
cytokines and the pathogenesis of vascular inflammation (Watanabe et al., 2018). A 
truncated TCA cycle has been described in M1 macrophages with two major breaks 
occurring at isocitrate dehydrogenase (IDH) and succinate dehydrogenase (SDH) 
enzymes (Figure 5.1 A). A reduced activity of IDH and SDH results in accumulation of 
citrate and succinate, respectively, in macrophages treated with LPS plus IFN-γ (Jha et 
al., 2015). The increase in succinate release from M1 macrophages also acts in an 
autocrine manner by binding to its surface receptor, which promotes inflammatory 
responses (Littlewood-Evans et al., 2016). Moreover, LPS and IFN-γ have been reported 
to inhibit OXPHOS in macrophages (Jha et al., 2015, Van den Bossche et al., 2016).  
M2 macrophages are predominantly dependent on mitochondrial function, including the 
TCA cycle and OXPHOS (Figure 5.1 B) (Van den Bossche et al., 2016, Das et al., 2015, 
Geeraerts et al., 2017, Galvan-Pena and O'Neill, 2014). In contrast to accumulated 
succinate, fumarate is a TCA cycle intermediate that has been shown to promote M2 
polarisation of macrophages, represented by a reduction in pro-inflammatory mediators 
(e.g. iNOS and TNF-α) but an increase in anti-inflammatory mediators (e.g. arginase-1 
and IL-10) (Han et al., 2016, Bomprezzi, 2015). Previous evidence has also illustrated 
that M2 activators (e.g. IL-4 and IL-13) show increased activity of the TCA cycle 
(Rodriguez-Prados et al., 2010) and OXPHOS in macrophages (Jha et al., 2015, Van den 
Bossche et al., 2016, Binger et al., 2015). The glucose metabolism is therefore a key 
regulator of immune cell functions. 
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5.1.3 Arginine metabolism in macrophage polarisation 
In addition to glucose, the amino acid arginine is important for macrophage function 
(Rath et al., 2014, Comalada et al., 2012). M1 macrophage increases uptake of arginine, 
which is metabolised by iNOS to produce nitric oxide and citrulline following activation 
with LPS plus IFN-γ (Figure 5.1 A) (Yeramian et al., 2006a). This metabolic pathway 
involves reactive oxygen species production and pathogen killing (Galvan-Pena and 
O'Neill, 2014, Sosroseno et al., 2004, Comalada et al., 2012). In contrast, arginase-1 
activity and ornithine level are increased in macrophages treated with anti-inflammatory 
cytokines (IL4/IL10) (Figure 5.1 B) (Yeramian et al., 2006a), indicating alternative 
arginine catabolism, which supports tissue repair, characteristic of the M2 phenotype 
(Galvan-Pena and O'Neill, 2014, Comalada et al., 2012). Moreover, amino acid glutamine 
acts as a precursor for glutamate and α-ketoglutarate, which bypasses citrate to replenish 
the TCA cycle. This process can be driven by IL-4 (Langston et al., 2017). 
5.1.4 Macrophage-expressed podoplanin in inflammation 
Podoplanin is expressed at low level or not at all on macrophages and is upregulated 
during inflammatory conditions in vitro (Kerrigan et al., 2012) and in vivo, including in 
lung injury (Lax et al., 2017b), sepsis (Rayes et al., 2017), and skin wound healing. It is 
currently unknown whether the upregulation of podoplanin on inflammatory 
macrophages regulates their function. To study the function of podoplanin in 
macrophages, the haematopoietic cell-specific podoplanin-deficient mouse model 
(Pdpnfl/flVav1-cre) has been generated. Previous evidence has demonstrated that cultured 
alveolar macrophages derived from this model show a 50% reduction in baseline 
podoplanin expression compared to macrophages derived from WT mice (Lax et al., 
 Chapter 5: The Association of Podoplanin Expression and Metabolic Changes in Macrophages 
192 
 
2017a). These Pdpnfl/flVav1-cre macrophages produce increased levels of pro-
inflammatory cytokines in response to low-dose LPS (0.1 µg/ml) without an upregulation 
of podoplanin (Lax et al., 2017a), suggesting that podoplanin-deficient macrophages are 
hypersensitive to LPS/inflammatory challenge. On the other hand, in a sepsis model, a 
reduction in macrophage recruitment is observed in Pdpnfl/flVav1-cre mice relative to 
controls, suggesting a role for podoplanin in macrophage migration (Rayes et al., 2017). 
A recent study also reports that the interaction of platelet CLEC-2 with podoplanin on 
alveolar macrophages stimulates matrix metalloproteinase-12 secretion to inactivate 
chemokines, which reduces inflammation and tissue damage during LPS-induced lung 
injury (Lax et al., 2017b), demonstrating the anti-inflammatory activity of the CLEC-2-
podoplanin axis. However, there is no known association between podoplanin and the 
metabolic profile of macrophages.  
In this chapter, the alteration of macrophage metabolism, focusing on glycolysis, TCA 
cycle coupled to OXPHOS, and arginine catabolism, were investigated in bone marrow-
derived macrophages from WT and Pdpnfl/flVav1-cre mice using HILIC/MS-based 
untargeted metabolomics. In addition, the metabolic changes during stimulation by LPS 
in the absence and presence of rCLEC-2-Fc were examined. 
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Figure 5.1. 
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Figure 5. 1. Immunometabolic profile of M1 and M2 macrophages. (A) Glycolysis is 
the primary pathway of metabolism of M1 macrophages. In addition, arginine is 
metabolised by inducible nitric oxide synthase (iNOS) to produce nitric oxide (NO) that 
promotes M1 pro-inflammatory phenotype. The red arrows represent the metabolic 
pathways that are mainly used by M1 macrophages. Red cross mark indicates breakage 
of the TCA cycle in M1 macrophages. (B) The tricarboxylic acid (TCA) cycle coupled to 
oxidative phosphorylation (OXPHOS) is the major metabolic pathway in M2 
macrophages. In contrast to M1 macrophages, arginase-1 metabolises arginine and gives 
rise to ornithine, which induces the M2 anti-inflammatory/reparative phenotype. The 
green arrows represent the metabolic pathways that are primarily used by M2 
macrophages. I, II, III, and IV = complex I, II, III, and IV of electron transport chain, Co-
A = coenzyme-A, Q = ubiquinone, Cyt C = cytochrome C, α-KG = α-ketoglutarate, OXA 
= oxaloacetate, IDH = isocitrate dehydrogenase, SDH = succinate dehydrogenase, NADH 
= nicotinamide adenine dinucleotide, FADH2 = flavin adenine dinucleotide, ATP = 
adenosine triphosphate (Galvan-Pena and O'Neill, 2014, Geeraerts et al., 2017, Jha et al., 
2015). 
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5.2 Results 
5.2.1 Macrophages deficient in podoplanin show an increase in glycolytic 
metabolites 
In this preliminary study, two metabolites in glycolysis, glucose and pyruvate were 
detected in bone marrow-derived WT macrophages (Figure 5.2 A, B). LPS treatment (1 
µg/ml) of bone marrow-derived macrophages for 24 hours, a concentration known to 
induce the M1 phenotype and upregulation of podoplanin in vitro (Rayes et al., 2017, 
Kerrigan et al., 2012) had no effect on the glucose content (Figure 5.2 A). A 1.7-fold 
increase in pyruvate was observed in LPS-treated WT macrophages, which is in 
agreement with a previous study (Baseler et al., 2016) (Figure 5.2 A); however, a two-
group comparison between LPS-treated and unchallenged WT macrophages 
demonstrated statistical significance for the increase in pyruvate following LPS (Figure 
5.2 B). To examine the influence of the CLEC-2-podoplanin interaction on metabolic 
changes, LPS-treated WT macrophages were also incubated with rCLEC-2-Fc (20 
µg/ml). The results showed that rCLEC-2-Fc did not affect the level of glucose and 
pyruvate in LPS-treated macrophages (Figure 5.2 A).  
A significant increase in glucose and pyruvate levels was observed in Pdpnfl/flVav1-cre 
macrophages relative to WT cells (7-fold and 3-fold respectively, Figure 5.2 A). There 
was no further alteration of glucose and pyruvate upon LPS stimulation in Pdpnfl/flVav1-
cre macrophages (Figure 5.2 A). These preliminary data indicate a negative association 
of podoplanin expression and glycolysis in macrophages. 
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Figure 5. 2. Glycolytic metabolites are increased in podoplanin-deficient 
macrophages. (A) Relative quantification of glucose and pyruvate level in macrophages 
(n=5). Rectangle indicates a certain change of pyruvate in LPS-treated WT macrophages. 
(B) A subsequent two-group analysis of pyruvate level between unchallenged and LPS-
treated WT macrophages revealed statistical significance (n=5). Bone marrow-derived 
macrophages from WT and haematopoietic cell-specific podoplanin deficient 
(Pdpnfl/flVav1-cre) mice were incubated with LPS (1 µg/ml) for 24 hours. In addition, 
macrophages from WT mice were treated with LPS plus recombinant CLEC-2-Fc 
(rCLEC-2-Fc, 20 µg/ml). Cell extracts were collected for LC/MS-based untargeted 
metabolomics analysis. The peak area of individual metabolite was used as arbitrary unit 
of metabolite expression. The metabolite of interest from each sample was presented as 
fold change relative to the mean value in unchallenged WT. Data are presented as mean 
± SEM, and analysed by either one-way ANOVA with Bonferroni’s post-hoc test (A) or 
Student’s t-test (B). *p<0.05. 
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5.2.2 A reduction of podoplanin does not alter the TCA cycle and/or OXPHOS in 
macrophages 
Only a few metabolites related to the TCA cycle and OXPHOS were detected in this 
work. Fumarate was observed in unchallenged WT macrophages and there was no 
alteration following LPS treatment with or without rCLEC-2-Fc (Figure 5.3 A). 
Macrophages derived from Pdpnfl/flVav1-cre mice did not exhibit differences in the 
baseline level of fumarate compared to WT (Figure 5.3 A). In a similar manner, LPS did 
not affect fumarate expression in Pdpnfl/flVav1-cre macrophages (Figure 5.3 A). 
Glutamine was also detected but was not significantly different between all groups 
(Figure 5.3 B). These preliminary results suggest that a decrease in podoplanin does not 
affect the TCA cycle and OXPHOS in macrophages. 
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Figure 5. 3. Expression of fumarate and glutamine are unaltered in podoplanin-
deficient macrophages. (A) Relative quantification of fumarate level in macrophages 
(n=5). (B) Relative quantification of glutamine level in macrophages (n=5). Bone 
marrow-derived macrophages from WT and haematopoietic cell-specific podoplanin 
deficient (Pdpnfl/flVav1-cre) mice were incubated with LPS (1 µg/ml) for 24 hours. In 
addition, macrophages from WT mice were treated with LPS plus recombinant CLEC-2-
Fc (rCLEC-2-Fc, 20 µg/ml). Cell extracts were collected for LC/MS-based untargeted 
metabolomics analysis. The peak area of individual metabolite was used as arbitrary unit 
of metabolite expression. The metabolite of interest from each sample was presented as 
fold change relative to the mean value in unchallenged WT. Data are presented as mean 
± SEM, and analysed by one-way ANOVA with Bonferroni’s post-hoc test. 
Glutamine 
Fumarate 
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5.2.3 Podoplanin deficiency leads to increased expression of metabolites in 
arginine metabolism, particularly iNOS-mediated pathway, in macrophages 
In unchallenged WT macrophages, several metabolites in arginine pathway were 
detected, including arginine, citrulline, and ornithine (Figure 5.4 A). LPS did not cause 
significant changes of these metabolites in WT macrophages (Figure 5.4 A), which is in 
agreement with a previous study (Yeramian et al., 2006b). The metabolites were also 
unaltered in the presence of rCLEC-2-Fc (Figure 5.4 A). The Pdpnfl/flVav1-cre 
macrophages exhibited a 30-fold increase in baseline arginine compared to WT 
macrophages and there was no further alteration following LPS treatment (Figure 5.4 A). 
In addition, citrulline and ornithine were upregulated (25-fold and 13-fold, respectively) 
in Pdpnfl/flVav1-cre macrophages compared to WT, irrespective of LPS challenge (Figure 
5.4 A). Moreover, a sub-analysis of the data revealed that Pdpnfl/flVav1-cre macrophages 
had significantly higher levels of citrulline (approximately 2-fold) than ornithine (Figure 
5.4 B). Together, these results show that arginine catabolism, the iNOS-mediated 
pathway in particular, is enhanced in podoplanin-deficient macrophages. 
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Figure 5. 4. Metabolites in arginine catabolism, especially iNOS-mediated pathway, 
are upregulated in podoplanin-deficient macrophages. (A) Relative quantification of 
arginine, citrulline, and ornithine level in macrophages (n=3-5). (B) Comparison between 
the level of citrulline and ornithine in haematopoietic cell-specific podoplanin deficient 
(Pdpnfl/flVav1-cre) macrophages. Data from unchallenged and LPS-treated Pdpnfl/flVav1-
cre mice are combined (n=6). Bone marrow-derived macrophages from WT and 
Pdpnfl/flVav1-cre mice were incubated with LPS (1 µg/ml) for 24 hours. In addition, 
macrophages from WT mice were treated with LPS plus recombinant CLEC-2-Fc 
(rCLEC-2-Fc, 20 µg/ml). Cell extracts were collected for LC/MS-based untargeted 
metabolomics analysis. The peak area of individual metabolite was used as arbitrary unit 
of metabolite expression. The metabolite of interest from each sample was presented as 
fold change relative to the mean value in unchallenged WT. Data are presented as mean 
± SEM, and analysed by either one-way ANOVA with Bonferroni’s post-hoc test (A) or 
Student’s t-test (B). *p<0.05. 
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5.3 Discussion 
In response to stimuli, macrophages change their metabolic profile to support their 
numerous biological functions (Diskin and Palsson-McDermott, 2018, Galvan-Pena and 
O'Neill, 2014). In this chapter, the alteration of metabolic pathways has been examined 
in cultured bone marrow-derived macrophages from WT and podoplanin-deficient mice 
in order to investigate whether the anti-inflammation action of podoplanin is mediated by 
alteration of metabolism. Although limited numbers of metabolites were detected in this 
work, the preliminary results show that macrophages deficient in podoplanin had a 
significant increase in the expression of key metabolites in glycolysis and arginine 
catabolism but not in TCA cycle and/or OXPHOS, suggesting a negative regulatory role 
of podoplanin in glycolysis and arginine metabolism. Moreover, the metabolic profile in 
LPS-treated WT macrophages was not affected by rCLEC-2-Fc, indicating that the 
alteration of these two metabolic pathways in macrophages is independent of CLEC-2-
podoplanin interaction. Alternatively, this might be due to the limited binding of this 
recombinant protein to macrophage podoplanin in the studied condition (unpublished data 
in Watson laboratory). The summary of metabolic status of podoplanin-deficient 
macrophages is shown in Figure 5.5. 
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Figure 5. 5. An alteration of tested metabolic pathways in podoplanin-deficient 
macrophages. Metabolic intermediates in glycolysis (i.e. glucose and pyruvate), a 
primary pathway used by M1 macrophages, are increased in podoplanin-deficient 
macrophages. Podoplanin deficiency does not affect the TCA cycle and/or OXPHOS-
related metabolites (i.e. fumarate and glutamine), an important metabolism found in M2 
macrophages. Baseline arginine is also increased in podoplanin-deficient macrophages. 
However, the increase in iNOS-mediated metabolite (i.e. citrulline) is greater than 
arginase-1-mediated metabolite (i.e. ornithine) in podoplanin-deficient macrophages. 
Together, these metabolic data support the pro-inflammatory activity of podoplanin-
deficient macrophages. ↑↑ = highly increased level, ↑ = increased level, ↔ = unchanged 
level. Metabolites with no coloured circle are not measured in this study. I, II, III, and IV 
= complex I, II, III, and IV of electron transport chain, Q = Ubiquinone, Cyt C = 
cytochrome C, α-KG = α-ketoglutarate.     
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As previously described, Pdpnfl/flVav1-cre model of podoplanin deficiency does not 
completely delete podoplanin in macrophages. However, an approximately 50% 
reduction in podoplanin is sufficient to produce significant phenotypic changes in 
macrophages (Lax et al., 2017a). Treatment with 0.1 µg/ml LPS causes the upregulation 
of pro-inflammatory cytokines, including TNF-α, IL-6, and CXCL2 in Pdpnfl/flVav1-cre 
macrophages, suggesting they are more sensitive to LPS in mediating inflammation. In 
accordance with this, basal glycolysis was upregulated in podoplanin-deficient bone 
marrow-derived macrophages whereas the TCA cycle and/or OXPHOS-associated 
metabolites (i.e. fumarate and glutamine) were unaltered. In addition, the iNOS-mediated 
metabolite citrulline was increase to a higher degree than the arginase-1-driven metabolite 
ornithine. Although a previous study has reported a normal level of iNOS in Pdpnfl/flVav1-
cre alveolar macrophages (Lax et al., 2017a), the enzymatic activity of either iNOS or 
arginase-1 was not tested. More recently, it has been shown in another model of 
podoplanin-deficient macrophages that mRNA expression of arginase-1 (Arg-1), but not 
iNOS (NOS2), is reduced when co-cultured with cancer cells (i.e. glioma), contributing 
to an increase in inflammation (Eisemann et al., 2019). These in vitro data support the 
negative association between podoplanin expression and M1 pro-inflammatory 
phenotype of macrophages independent of CLEC-2. 
In agreement with the metabolic data, it has been shown in vivo that podoplanin-positive 
macrophages are increased during the resolution phase (72 hours post-injection) of 
zymosan-induced peritonitis (Hou et al., 2010). In addition, enhanced phagocytic activity 
is observed in this macrophage population in vitro. Thus, it is speculated that podoplanin-
positive macrophages facilitate the resolution of inflammation by mediating clearance of 
pro-inflammatory components (e.g. leucocytes) through phagocytosis (Hou et al., 2010). 
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Following intra-tracheal LPS infiltration in mice, macrophages collected from 
bronchoalveolar lavage fluid of Pdpnfl/flVav1-cre mice exhibit a 50% reduction in 
podoplanin expression relative to WT, which contributes to the worsening of lung injury 
(Lax et al., 2017b). In a model of glioma, podoplanin on macrophages has been shown to 
suppress immune response, contributing to cancer progression (Eisemann et al., 2019). 
These observations support the role of podoplanin in limiting macrophage-induced 
inflammation in vivo.  
In conclusion, the results of preliminary metabolomics analysis reveal the potential 
function of podoplanin in limiting glycolysis and arginine metabolism in macrophages, 
which possibly attenuates inflammatory response following activation. This metabolic 
profile provides additional evidence that may explain why podoplanin-deficient 
macrophages are more prone to mediate inflammatory responses during inflammation. 
 
 
 
 
 
 
 
 Chapter 6: General Discussion 
206 
 
Chapter 6 General Discussion 
6.1 Summary of results 
This thesis has shown that inflammatory bleeding caused by deficiency in platelet 
(hemi)ITAM receptors enhances the rate of cutaneous wound healing. During the 
inflammatory phase of repair process, it is postulated that a lack of interaction between 
platelet GPVI and CLEC-2 with their ligands in the injured vessel (i.e. collagen and 
podoplanin, respectively) leading to transient vascular leakage that allows extravasation 
of plasma-derived molecules, including fibrinogen, into the wound. The accumulation of 
fibrinogen and fibrin promotes wound healing in multiple ways as shown by the 
accompanied increase in re-epithelialisation and angiogenesis. Simultaneously, 
fibrinogen and fibrin may physically impede leucocyte infiltration, resulting in a 
reduction in inflammation and tissue damage, which also facilitate wound healing. This 
is the first insight into how a different form of bleeding dictates its beneficial or 
detrimental role in wound repair. 
The (patho)physiological contribution of the podoplanin cytoplasmic tail has also been 
described. The loss of the cytoplasmic region however caused a reduction in basal 
podoplanin expression in various organs making it unclear whether a phenotype was 
mediated by the reduced and/or the loss of the tail. As such, the use of the mouse is 
limited. Nevertheless, in contrast to constitutive loss of podoplanin, the mice are viable 
demonstrating that at least part of the physiological role of podoplanin is independent of 
the tail region possibly because part of action of podoplanin is through activation of 
CLEC-2. The demonstration of normal development of the lymphatics and unchanged 
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wound healing times provides evidence that the cytoplasmic tail is dispensable for these 
two processes. 
In addition, this study has provided preliminary evidence that podoplanin regulates 
macrophage metabolism. Glycolysis and iNOS-mediated arginine catabolism, the 
metabolic pathways that are primarily used in M1 pro-inflammatory macrophages, were 
increased in podoplanin-deficient macrophages. The underlying mechanism is not 
known. 
6.2 The cause of intra-tissue bleeding determines its 
beneficial or detrimental role in wound healing 
The association of platelets and vascular integrity has been known for more than a half 
century (Majno and Palade, 1961, Cotran, 1965). More recently,  the role of platelets in 
preventing vascular leakage during inflammation, including in skin, was shown in 
thrombocytopenic (Goerge et al., 2008) and (hemi)ITAM-deficient animals (Boulaftali et 
al., 2013). Several previous studies have shown devastating effects of inflammation-
induced bleeding, particularly in the major organs (Ho-Tin-Noe et al., 2009, Goerge et 
al., 2008, Hillgruber et al., 2015). For example, in the model of LPS-induced lung 
inflammation, the intra-alveolar bleeding spreads throughout the lung in 
thrombocytopenic mice (Goerge et al., 2008, Hillgruber et al., 2015). These mice 
demonstrate breathing difficulty, anaemia, and restricted activity, indicating severe illness 
(Goerge et al., 2008). Following skin rPA, there are no reports of adverse effects directly 
related to intra-tissue bleeding (Rayes et al., 2018, Gros et al., 2015), but the severity of 
inflammation itself may lead to skin necrosis and systemic immune complex diseases 
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(Movat, 1979). Interestingly, this thesis presents the positive effect of inflammatory 
bleeding for the first time in skin wound healing. The short-term intra-wound bleeding 
due to a lack of platelet (hemi)ITAM receptors, GPVI and CLEC-2, resulted in 
accumulation of fibrinogen and fibrin in the wound and accelerated wound healing at an 
early phase, providing a new paradigm for medical impact of intra-tissue bleeding. This 
is in contrast to the delay in wound healing in haemophilia B mice that lack FIX and 
exhibit reduced fibrin generation in association with leakiness of newly-formed blood 
vessel and dysregulated angiogenesis (Hoffman et al., 2006). This thereby emphasises the 
causal link between bleeding characteristics and its consequences. 
6.3 Targeting vascular integrity and platelet (hemi)ITAM in 
wound healing 
Wounds have a global impact in medical and economical aspects (Lindholm and Searle, 
2016, Meier and Nanney, 2006). Millions of people over the world suffer from various 
types of wound injury (Lindholm and Searle, 2016, Meier and Nanney, 2006). The 
shortened healing duration provides effective wound management by reducing the cost 
of care and the risk of complications (e.g. infections and disabilities) (Lindholm and 
Searle, 2016). However, while current therapeutic interventions partially improve the 
healing process, a single agent/method may not be applicable to all cases (Meier and 
Nanney, 2006, Zielins et al., 2015). Therefore, new therapeutic modalities are emerging 
(Boateng and Catanzano, 2015, Park et al., 2013). Platelet and fibrin preparations, such 
as autologous platelet-rich plasma (Chicharro-Alcantara et al., 2018, Lacci and Dardik, 
2010, Carter et al., 2011) and platelet-rich fibrin (Naik et al., 2013, Pinto et al., 2018) 
demonstrate a promising outcome in facilitating skin wound healing, most likely because 
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of growth factors and cytokines released from activated platelets. However, these 
treatments require blood from patients, which is invasive, and the efficacy may vary 
depending on the preparation techniques (Chicharro-Alcantara et al., 2018, Lacci and 
Dardik, 2010, Carter et al., 2011). Intriguingly, this thesis provides a possible way for 
non-invasive therapeutic intervention that allows self-operated release of plasma 
components, including platelets and fibrinogen, into the wound to promote repair process. 
Indeed, the temporal intra-wound bleeding suggests that the degree of vascular leakage 
in platelet (hemi)ITAM receptor deficiency is greater than the increased vascular 
permeability during inflammation (Ono et al., 2017, Park-Windhol and D'Amore, 2016), 
which also shown to enhance wound healing (Mendonca et al., 2010, Cipriani Frade et 
al., 2004, Shaterian et al., 2009, Seo et al., 2007). However, this inflammatory bleeding 
did not cause discernible adverse effects, thereby paving the way for its potential use in 
wound management. Future studies should investigate the impact of this method on 
wound healing in comparison with platelet/fibrin preparations or enhanced vascular 
permeability.  
It has been previously shown that inhibition of kinases of GPVI and CLEC-2, such as Syk 
(Long et al., 2016) or Src kinases (Apperley et al., 2009) disrupts vascular integrity, but 
there is no formal study conducting the impact of tyrosine kinase inhibitors on wound 
healing (Shah et al., 2014). In the future, it will be interesting to investigate whether 
topical inhibition of the two (hemi)ITAM receptors or their downstream tyrosine kinases 
might provide benefits in skin wound healing. In human, a low level of podoplanin is only 
observed around blood vessel during skin inflammation, such as in eczema and psoriasis, 
but not in normal skin (Groger et al., 2007), raising the question of the clinical 
implications of targeting platelet (hemi)ITAM and vascular integrity in human skin 
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wound. Moreover, the repair process in murine skin does not fully represent wound 
healing in human, partly because of a significant contribution of wound contraction to the 
healing process in loose-skin animals (Davidson et al., 2013, Chen et al., 2015). This 
factor should also be considered in order to apply the findings in animal experiments for 
human studies. 
6.4 Filling the gaps in the multifaceted role of podoplanin 
Podoplanin has diverse patterns of expression, interaction, and biological function 
(Schacht et al., 2005, Astarita et al., 2012, Quintanilla et al., 2019). Until recently, many 
aspects of podoplanin biology were elusive. Firstly, it has never been clearly defined how 
platelet CLEC-2 interacts with podoplanin to aid GPVI in maintaining vascular integrity 
during skin inflammation (Ho-Tin-Noe et al., 2018, Boulaftali et al., 2018). This thesis 
reports that podoplanin-positive cells encircled the microvasculature in unchallenged 
murine skin and that this is preserved during wound healing, thereby providing the 
potential to bind to platelet CLEC-2 during vascular endothelial disruption or activation. 
The podoplanin-expressing cells at the perivascular area of skin were shown to include 
pericytes, fibroblasts, infiltrating monocytes, and inflammatory macrophages (Section 
3.2.1). However, podoplanin was not detected in the vicinity of blood vessels in other 
tissues, such as the lungs, liver, and kidneys (Section 4.2.6), supporting previous evidence 
of organ-specific roles of platelet GPVI and CLEC-2 in maintaining vascular integrity 
(Rayes et al., 2018, Ho-Tin-Noe et al., 2018) Secondly, although podoplanin is 
upregulated on keratinocytes during skin wound healing (Section 3.2.1) (Asai et al., 
2016), it is unlikely to affect the healing process as shown by a normal wound closure in 
mice that lack podoplanin on keratinocytes (Baars et al., 2015), arguing against the role 
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of CLEC-2-podoplanin in keratinocyte migration demonstrated in vitro (Asai et al., 
2016). Thirdly, the significance of signalling through podoplanin cytoplasmic tail is 
controversial. Although it is not conclusive, the work in this thesis hints that certain 
developmental and (patho)physiological functions of podoplanin are unlikely to be 
mediated by its cytoplasmic region. For example, the finding of normal blood-lymphatic 
separation in mice that lack the podoplanin cytoplasmic tail (Section 4.2.7) may 
emphasise the crucial role of its ectodomain in activating CLEC-2, leading to platelet 
aggregation to prevent blood-lymphatic vessel mixing (Bertozzi et al., 2010, Hess et al., 
2014). This also suggests that a small amount of podoplanin ectodomain is required for 
blood-lymphatic separation. Future studies should rule out additional interactions of its 
ectodomain and/or transmembrane region in regulating this function e.g. the lateral 
interaction between podoplanin and galectin-8 on cell surface of LECs has been proposed 
to regulate lymphvasculogenesis (Cueni and Detmar, 2009). Further, podoplanin has been 
shown to produce either pro-inflammatory or anti-inflammatory activity depending on 
pathological conditions (Croft et al., 2016, Takakubo et al., 2017, Peters et al., 2015). The 
present metabolic findings in macrophages reveal a negative association of podoplanin in 
glycolysis and iNOS-mediated arginine metabolism (Section 5.2.1), the two metabolic 
pathways found in M1 pro-inflammatory macrophages (Diskin and Palsson-McDermott, 
2018), providing a metabolic contribution for the anti-inflammatory function of 
podoplanin in macrophages (Lax et al., 2017b, Hou et al., 2010). Future studies should 
examine the connection between these metabolites and the biological/functional 
responses, particularly in vivo, to fully understand the role of podoplanin in inflammation. 
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6.5 Final conclusions 
Many emerging roles of platelet CLEC-2 and podoplanin have been investigated, with 
the urgent need for a viable animal model of podoplanin deficiency that allows an 
understanding of podoplanin biology in health and disease. Overall, the newly discovered 
acceleration of skin wound healing in mice deficient in platelet GPVI and CLEC-2 
provides an important insight into a positive regulatory role of intra-tissue haemorrhage 
in repair process. Although there are detailed differences in skin wound healing between 
mice and humans, which require further studies, this new understanding of the benefit of 
targeting platelet (hemi)ITAM and vascular integrity in wound repair may lead to the 
discovery of novel therapeutic innovations.  
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